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Abstract 
Internalization and trafficking are crucial mechanisms regulating G-protein 
coupled receptors (GPCRs) signaling in which b-arrestins play a central role. Biased 
agonists which selectively activate either G protein or b-arrestin signaling pathway 
were identified. On the other hand, the concept of GPCR signaling being restricted to 
cell membrane has been contested on the basis of data demonstrating GPCR signaling 
from endosomes as well as from the cell surface. 
Glucose insulinotropic polypeptide (GIP) is an incretin hormone essential in 
post-prandial glucose homeostasis. It exerts its functions through binding to a G 
protein-coupled receptor, GIPR which is involved in various physiological and 
pathological processes. To date, GIPR internalization and trafficking and the 
underlying molecular mechanisms have not been investigated in detail. In this 
context, the aim of our work was to study these mechanisms and to characterize the 
internalization profile of N-Acetyl-GIP, a GIP analogue resistant to DPP-IV 
degradation. Finally, we investigated if GIPR signaling can occur from endosomes 
alongside its signaling at the cell membrane. 
In this study, we first report that GIPR internalization involves clatherin, AP-2 
and dynamin but not C-terminal region of the GIPR nor b-arrestin1/2. Moreover, N-
Acetyl-GIP, which fully stimulated cAMP production and insulin secretion from 
MIN-6-B1 cells, did not stimulate internalization of the GIPR. This suggests that N-
Acetyl-GIP could be a biased GIPR agonist preferentially inducing Gs activation 
pathway over directing the receptor to clathrin-coated pits. 
We have also succeeded to witness a sustainability in GIP-induced cAMP 
production. The sustained signal was dependent on GIPR internalization and 
unreversed by GIP removal from the cell membrane. Moreover, we directly detected 
the active form of Gαs in early endosomes containing GIPR using a genetically 
encoded GFP tagged nanobody. Finally, using a FRET sensor of cAMP targeted to 
the surface of early endosomes, we also directly detected cAMP production 
specifically at the surface of endosomes containing internalized GIPR. The latter 
observation is the first of this kind, proving the endosomal signaling concept by a 
direct detection approach. 
This study brings new insights into the pharmacological regulation of GIPR 
internalization and signaling, opening  promising  perspectives in GIP field.
Résumé 
L’internalisation et le trafic intracellulaire sont des mécanismes cruciaux dans la régulation 
de la signalisation des récepteurs couplés aux protéines G (RCPG) dans lesquels les b-arrestines 
jouent un rôle central. Des agonistes biaisés qui sont capables d’activer sélectivement les voies de 
signalisation dépendantes des protéines G ou dépendantes des b-arrestines ont été récemment 
identifiés. D'autre part, le concept selon lequel la signalisation des RCPG serait limitée à la 
membrane cellulaire a été contesté sur la base des données qui démontrent que de nombreux RCPG 
induisent du signal aussi bien à partir d’endosomes qu’au niveau de la surface cellulaire. 
Le glucose-dependent insulinotropic polypeptide (GIP) est une hormone incrétine essentielle 
dans l’homéostasie glucidique postprandiale. Elle exerce ses fonctions en se liant à un récepteur 
couplé aux protéines G, le RGIP qui est impliquée dans divers processus physiologiques et 
physiopathologiques. À ce jour, l’internalisation et le trafic intracellulaire du RGIP ainsi que leurs 
mécanismes moléculaires sous-jacents n’ont pas été étudié en détail. Dans ce contexte, le but de 
notre travail était d'abord d'étudier ces mécanismes et ensuite de caractériser le profil 
d’internalisation du N-acétyl-GIP, un analogue du GIP connu pour être résistant à la dégradation 
par le DPP-IV. Enfin, nous avons étudié si, en plus de sa signalisation à la membrane cellulaire, le 
RGIP est capable d’induire une signalisation à partir d’endosomes. 
Dans cette étude, nous montrons d'abord que l’internalisation du RGIP est un processus 
impliquant la clathrine, le complexe AP-2 et la dynamine, mais pas la région C-terminale du 
récepteur, ni les b-arrestines1/2. Nous avons également montré que le N-acétyl-GIP, qui présente 
une activité agoniste pleine sur la production d’AMPc et sur la sécrétion d'insuline dans les cellules 
MIN-6-B1, n’est pas capable de stimuler l'internalisation du RGIP. Cela suggère que le N-acétyl-
GIP pourrait être un agoniste biaisé du RGIP induisant préférentiellement la voie d'activation de Gs 
comparativement à un adressage du récepteur vers des puits recouverts de clathrine. 
Nous avons également réussi à observer une persistance au cours du temps de la production 
d'AMPc induite par le GIP. Le signal persistant dépend de l’internalisation du RGIP et est 
irréversible après lavage du GIP de la membrane cellulaire. De plus, nous avons détecté d’une 
manière directe la forme active de  Gas au niveau d’endosomes contenant le RGIP en utilisant des 
plasmides codant pour des Nanobodies fusionnés à la GFP. Enfin, en utilisant un biosenseur FRET 
d’AMPc dirigé à la surface des endosomes précoces, nous avons également pu détecter d’une 
manière directe la production d'AMPc spécifiquement à la surface des endosomes contenant le 
RGIP internalisé. À notre connaissance, cette dernière observation est la première de ce genre, 
prouvant le concept de signalisation à partir d’endosomes par une approche de détection directe. 
Les résultats de cette étude apportent des informations quant à la régulation 
pharmacologique de l’internalisation et de la signalisation du RGIP, ouvrant des perspectives 
prometteuses dans le domaine du GIP. 
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Signaling via GPCRs, the largest family of membrane receptors, plays an 
essential role in many physiological functions. Signaling homeostasis is disturbed in 
pathological conditions and can be strongly modified under acute or chronic drug 
treatments. GPCR signaling is a highly controlled process which comprises multiple 
mechanisms of regulation at each step of signaling. Receptor internalization is one of 
the important mechanisms that strongly contributes to signal regulation. 
Internalization opens the way for receptor trafficking which leads to either signal 
downregulation, via lysosomal degradation of the receptor, or contrarily, to signal 
resensitization, after a recycling round of the receptor. Mechanistically, 
internalization is generally preceded by a signal desensitization step at the cell 
membrane, mainly occurring via GRK-dependent phosphorylation of ligand-activated 
receptor. Afterwards, for a large number of GPCRs, receptor endocytosis is mediated 
by the recruitment of b-arrestin and is promoted by clathrin-coated pits.  
 
It has been shown that a second GPCR signaling wave can occur in a G 
protein-independent manner. This phase is mainly orchestrated by the b-arrestin 
which scaffolds and promotes the activation of a plethora of signaling proteins. 
Interestingly, the 2 aforementioned phases don’t seem to be always simultaneously 
triggered. It has been found that specific type of agonists can selectively favors the 
activation of one signaling pathway, they are known as “biased agonists”. An 
additional new aspect of subcellular signaling was identified a few years ago, in 
which several GPCRs are shown to signal via G proteins from internal sites after 
internalization. 
 
GIP is an incretin hormone regulating essentially the glucose homeostasis. It 
exerts its function by stimulating insulin secretion through binding to its receptor the 
GIPR. Insulin secretion signal mediated by GIPR is disturbed in diabetic patient and 
on the other hand, the receptor is overexpressed in Neuroendocrine tumors. These 
aspects made the GIPR a potential therapeutic target and thus, numerous agonist 
molecules have been developed for this purpose.  
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Although developing GIPR-targeting strategies witnessed a stagnant period 
for the argument that the receptor is unresponsive in diabetic patients, a renewed 
interest in developing pharmacological strategies targeting GIPR has emerged. In fact, 
it has been found that glycaemia normalization can improve responsivity to GIP. 
Moreover, very recent and innovative preclinical studies on rodents, monkeys and 
humans show that a single peptide molecule having dual or triple agonist activity 
including GIP, exhibits enhanced insulinotropic and anti-hyperglycemic efficacy 
relative to each of natural peptides administered alone (Finan et al., 2013; Finan et al., 
2015). 
 
Our research team has been interested during the last years in the study of GIP 
receptor. Having the experience from studying other G protein coupled receptors, 
essentially CCK2R which is a member of rhodopsin-like group of GPCRs, our team 
conducted a first study on GIPR in an attempt to understand structure/activity 
relationship in addition to the ligand binding and activation processes. At that time, 
the process of GIPR internalization and trafficking which was not clearly decrypted 
yet, appeared as an important issue.  
 
This context led our group to launch works aimed at understanding molecular 
mechanisms underlying GIPR internalization and trafficking. We also intended to 
analyze the pharmacological properties of a functionally improved GIP peptide which 
preliminarily appeared to be a biased agonist towards receptor internalization. In 
parallel, we also aimed at investigating if GIPR internalization confers an additional 
signaling phase that originates from endosomes. 
 
The current manuscript presents a bibliographic introduction that 
resumes actual knowledge on G protein coupled receptors and general 
mechanisms of signal regulation including receptor internalization. The two 
recently discovered aspects of GPCR signaling as well as the actual research data 
on GIP and GIPR are then described in distinct chapters. Next, the section of 
experimental results obtained is presented as two articles accompanied each by a 
brief introduction and conclusion. Finally, in the concluding section, the results 
are discussed in a global view and perspective openings are given. 
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I- G Protein-Coupled Receptors 
 
Complex organisms rely on communication between their members and with 
the outside world to ensure their diverse physiological functions and maintain 
homeostasis. Cells inter-communicate by sending various signals and receiving 
signals back using surface proteins. Those membrane “Receptors” mediate the 
translation of extracellular stimuli into biological cell responses. They exist in 
different types, mainly ion channels or enzyme-associated receptors. In the latter 
category, the heterotrimeric guanine nucleotide–binding protein (G protein)–coupled 
receptors (GPCRs) represent the most physiologically predominant family. GPCRs 
represent one of the largest protein superfamily in human. They count for 
approximately 800 members (Bjarnadottir et al., 2006) corresponding to about 5% of 
the total number of human genes (Collins, 2004).  
GPCRs recognize a variety of extracellular ligands and sensorial stimuli. These 
ligands include the majority of chemical neurotransmitters, peptide hormones, lipids 
and sensory stimuli (light, taste and odorant molecules) and a large variety of clinical 
drugs (for example, β-blockers and anti-psychotics). GPCRs mediate activation of 
downstream signaling networks and initiate a broad range of physiological and 
pathological processes. These properties make GPCRs important drug targets in the 
pharmaceutical industry. Indeed, >30% of all marketed therapeutics act on GPCRs 
(Hopkins and Groom, 2002), including ~25% of the top 100 selling drugs (Klabunde 
and Hessler, 2002). However, only ~30 GPCRs are targeted by these marketed 
therapeutics highlighting the remaining potential for drug discovery in the field of 
GPCRs. 
 
1- Structure and Classification: 
 
GPCRs share common structural features. The greatest homology is observed in 
the 7 transmembrane (7TM) α-helices each composed of 25-35 residues that show a 
relatively high degree of hydrophobicity. Extracellular amino and intracellular 
carboxyl termini domains border the 7TM helices. In between, and on each side of the 
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plasma membrane, 3 intracellular and 3 extracellular loops link 2 consecutive TM 
domains to each other. Loops and terminal domains are the most variable structures 
among the family of GPCRs. 
 
Based on sequence similarity in 7TM segments and on structural features, 
GPCRs are classified into 5 families: Rhodopsin, Secretin, Glutamate, Adhesion and 
Frizzled/Taste2 (shortened to the acronym GRAFS)(Fredriksson et al., 2003). Of 
these, the rhodopsin family is the largest and most studied. It includes rhodopsin and 
the β2-adrenergic receptor (β2AR). Most of its members contain an NPXXY motif in 
helix VII and a DRY motif at the cytoplasmic border of helix III (Kristiansen, 2004). 
A much larger N terminus compared with the rhodopsin family characterizes each of 
the other GPCR families. Members of the secretin family have an N terminus of ~60–
80 amino acids in length, comprised of multiple conserved disulphide bonds, that bind 
relatively large peptide hormones (Fredriksson et al., 2003). Glutamate family 
receptors have a ‘Venus flytrap’ N terminus that is composed of two lobes that close 
around the ligand (Kunishima et al., 2000). Members of the adhesion family of 
receptors have N termini that contain adhesion-like motifs, such as epidermal growth 
factor (EGF) and mucin-like repeats, which might mediate cell–cell adhesion 
(Kristiansen, 2004; Stacey et al., 2000). Frizzled family receptors have a crucial role 
in development in response to signals from Wnt, a secreted glycoprotein, which binds 
to the N‑terminal Cys-rich domain of these receptors (Dann et al., 2001). Taste‑2 
receptors have a short N terminus but share several consensus sequences with other 
members of the family (Fredriksson et al., 2003). 
 
2- G protein-dependent signal transduction: 
 
The classical role of GPCRs is to detect the presence of an extracellular 
agonist, transmit the information across the plasma membrane, and activate a 
cytoplasmic heterotrimeric G protein, leading to modulation of downstream effector 
proteins. 
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a- Conformational changes in GPCR activation 
 
The multitude of biochemical, biophysical and structural data suggest that 
most GPCRs exist in a dynamic equilibrium between inactive (R, R’) and active (R’’, 
R*) states, which can be further converted to the signaling state (R*G) in the presence 
of heterotrimeric G protein, as illustrated in (Kobilka and Deupi, 2007).  
Binding of agonists shifts the equilibrium towards the active states, which 
 are characterized by large-scale conformational changes at the receptor’s intracellular 
side. The conformational changes in receptor activation were unveiled due to the 
characterization of the structure of numerous GPCRs crystallized at different 
functional states during the last 8-10 years. Comparisons of inactive- and active-state 
structures reveal common activation-related features: rearrangement of 
transmembrane helices and rotamer changes in side chains (microswitches). 
  The most pronounced common rearrangement of helices on the intracellular 
side includes an onward “swinging” motion of helix VI in concert with a movement 
of helix V. As example, the motion of the intracellular tip of helix VI can attend 14Å 
of magnitude in β2AR signaling complex with G protein (R*G) (Rasmussen et al., 
2011b). Helix III and VII movement is another substantial rearrangement than is less 
common between Class A GPCRs. The most pronounced changes in this region is 
observed in A2AR agonist bound structures. The intracellular part of helix VII moves 
inward toward the middle axis of the 7TM helical bindle. Motion of helix III consists 
of an upward shift along its axis and some lateral movement (Xu et al., 2011). 
The transmembrane helices movement during activation is accompanied by a 
common set of local microswitches in the intracellular side of the receptor. They 
consist of rotamer changes of highly conserved side chains. The micro-switches 
stabilize the movement of helices and enable the intracellular side of the GPCR to 
interact with G protein. Effectively, in the most conserved DR[E]Y motif sequence in 
Class A GPCRs, the Arg3.50 residue forms a salt bridge with the neighboring acidic 
chain Asp3.49. Counter to the activated b2AR or A2AR where this bond is intact, the 
salt ridge is broken in G protein associated rhodopsin-nanobody and b2AR where it 
changes its rotamer to interact with Ga, suggesting that the switch in Arg3.50 requires 
the presence of a G alpha subunit.  
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b- G protein Overview 
 
Heterotrimeric G proteins are the molecular switches that initiate intracellular 
signaling cascade in response to GPCR activation by extracellular stimuli. Despite the 
big number and diversity of GPCRs, they interact with a relatively small number of G 
proteins. Heterotrimeric G protein is composed of 3 subunits α, β and γ. In humans, 
there are 21 Gα subunits encoded by 16 genes, 6 Gβ subunits encoded by 5 genes, and 
12 Gγ subunits (Downes and Gautam, 1999). They are typically divided into 4 main 
classes depending on sequence similarity of the Gα subunit: Gαs, Gαi, Gαq and Gα12/13 
(Simon et al., 1991). The switching functional unit of the heterotrimer is the Gα 
subunit. It contains a GTPase domain that hydrolyzes GTP into GDP, thus shifting Gα 
between its active (GTP-bound) and inactive (GDP-bound) conformations. 
 
c- G protein activation 
 
Ligand binding induces conformational modification or stabilization of GPCR 
which leads in turn to G protein activation. GPCR catalyzes the GTP/GDP exchange 
reaction on Gα subunit. This reaction begins first by GDP release caused by different 
receptor-mediated structural changes in Gα. Next step is GTP binding and G protein 
dissociation from the GPCR. 
 
GDP release 
 
Two models have been proposed to explain how the receptor alters the relative 
orientation of the Gα and Gβγ subunits to release GDP from Gα. In the first model, 
the receptor uses the N‑terminal helix of Gα as a lever arm to pull Gβγ away from 
Gα. This could wrench switch II away from the nucleotide-binding pocket, which 
results in GDP release (Iiri et al., 1998). In support of this hypothesis, shortening the 
αN helix by four amino acids at its C terminus to mimic the putative orientation 
induced by the receptor allows Gβγ to act as an exchange factor for Gαs (Rondard et 
al., 2001).  
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The second, ‘gear-shift’ model proposes that the receptor uses the αN helix to 
force Gβγ into Gα, allowing the N terminus of Gγ to engage the helical domain of Gα. 
This interaction may cause the interdomain gap between the helical and GTPase 
domains of Gα to open, leading to GDP release (Azpiazu and Gautam, 2001). Another 
alternative hypothesis suggests that Gβγ rotates around an axis that is perpendicular to 
the plane of the membrane during formation of the receptor-G protein complex. Some 
support for this model is offered by spin-labelling studies realized by integrating 
lateral nitroxide chains in switches I and II of Gα. Followed by EPR spectroscopy 
(Electron Paramagnetic Resonance), it shows a large decrease and a small increase in 
the mobility of the 2 regions, respectively (Oldham et al., 2007; Van Eps et al., 2006). 
 
GTP binding and G protein dissociation 
 
Physiologically, the receptor–G-protein complex is transient owing to rapid 
binding of GTP, the cellular concentration of which exceeds that of GDP several-fold. 
Binding of GTP to the Gα subunit causes a structural rearrangement of Gα(GTP), Gβγ 
and the receptor, which permits dissociation from the receptor and interactions with 
the effector. A comparison between the heterotrimer (Lambright et al., 1996) and Gα-
GTPγS (Noel et al., 1993) crystal structures reveals conformational changes in the 
three switch regions of Gα that eliminate the Gβγ binding surface and therefore  
subunit binding. 
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II- Regulation of G Protein Coupled Receptor 
Signaling 
 
 
The exposure of GPCRs to agonist not only mediates activation or inhibition of 
various effectors in downstream signaling pathways, but also triggers attenuation in 
receptor responsiveness. Short-term loss of receptor sensitivity to the appropriate 
stimuli is referred to as desensitization, whereas long-term loss of sensitivity is called 
downregulation of receptor expression. On the other hand, the impossibility of agonist 
binding (blockade by antagonist, denervation, and impaired release of transmitter) can 
lead to the sensitization and/or to upregulation of receptor number. Desensitization 
and downregulation provide a negative feedback mechanism that protects against both 
acute and chronic overstimulation of the receptor, while resensitization, sensitization 
and upregulation allow a positive feedback mechanism that ensure preservation of 
receptor responsiveness though decreased agonist stimulation. 
 
1- Desensitization 
GPCRs control their own responsiveness by mechanisms leading to their 
desensitization. This consists primarily in dissociation of the receptor/G protein 
complex which is predominantly the consequence of receptor phosphorylation 
mediated by two classes of protein kinases: second messenger-dependent kinases (i.e. 
PKA and PKC) and GPCR kinases (GRKs). The two phosphorylation processes 
mentioned above differ by their mechanisms of action. For both of them, 
phosphorylation takes place on serine and/or threonine residues of GPCRs, but these 
sites are different for each of them. (Claing et al., 2002). Two types of desensitization 
of GPCRs can be distinguished: heterologous desensitization and homologous 
desensitization. 
 
a- Heterologous desensitization - Role of second messenger- 
dependent kinases 
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One of the way by which GPCRs may be desensitized is the heterologous 
desensitization permitting the attenuation of GPCR signaling as a result of the 
activation of another receptor. This type of desensitization can affect  and GPCRs  
which have not been exposed to agonist as well as activated GPCRs (Ferguson, 2007). 
Indeed, second messengers (e.g. AC, PLC) produced by agonist stimulation of one 
GPCR may enhance activation of protein kinases phosphorylating other GPCRs. The 
best studied examples of these second messenger-dependent kinases are protein 
kinase A (PKA) and protein kinase C (PKC). Phosphorylation by PKA and PKC 
occurs on serine and/or threonine residues contained in the third intracellular loop 
and/or the C-terminus of the receptor (Hendriks-Balk et al., 2008). Moreover, the 
phosphorylated sequences are localized near the G protein contact sites. Hence that 
phosphorylation of GPCRs is in direct competition with their G protein coupling 
(Kristiansen, 2004).  
Heterologous mechanism of desensitization does not promote β-arrestin binding 
(Moore et al., 2007b) but is thought to contribute to GPCRs internalization via lipid 
rafts and/or caveolae, as reported for the β1-adrenergic receptor (Rapacciuolo et al., 
2003).  
Another type of heterologous regulation can be heterologous down- or up-
regulation comprising changes in gene expression and/or translation processes (see 
related paragraphs below), often caused by cytoplasmic receptors (Kasahara et al., 
2011).  
 
b- Homologous desensitization – Role of G Protein-Coupled Receptor 
Kinases (GRKs) 
 A major process contributing to attenuation of GPCR signaling is the 
homologous desensitization. In homologous desensitization, phosphorylation of the 
receptor is ensured by G protein-coupled receptor kinases (GRKs) and/or by second 
messenger-dependent kinases (as for heterologous desensitization mentioned above).  
 The GRK protein family consists of seven mammalian serine-threonine protein 
kinases (Yang and Xia, 2006) phosphorylating and so regulating exclusively the 
agonist-occupied receptors (Premont et al., 1995). The GRKs family members can be 
subgrouped according to sequence homology and functional similarities to three 
subfamilies. Members of the first subfamily, GRK1 (rhodopsin kinase) and GRK7 
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(cone opsin kinase,) are only found in retinal cells. Members of the two other sub-
groups are non-visual: GRK2 (β-ARK1) and GRK3 (β-ARK2) composing the 
subfamily with better known characteristics, and GRK 4, GRK5 and GRK6, whose 
roles are studied more profoundly today.  
 GRKs consist of more than 500 amino acid residues. Phosphorylation by GRKs 
occurs at residues contained either in the carboxy-terminal tail of GPCRs (rhodopsin, 
β2AR) or in the third intracellular loop of the receptor (e.g. M2 muscarinic 
acetylcholine receptor), but the serine and/or threonine residues concerned are 
different from those phosphorylated by second messenger-dependent protein kinases 
(Hendriks-Balk et al., 2008). Both visual and non-visual GRKs share a similar 
structure, in particular at the highly conserved central catalytic domain containing D-
L-G sequences, and at the level of N-terminal region. Because of considerable 
homology within the 185-amino acids region, this latter is thought to be implicated in 
receptor recognition and, in addition, it embodies an RGS domain providing a 
phosphorylation-independent mechanism of receptor signaling attenuation (Yang and 
Xia, 2006) (Brinks and Eckhart, 2010). In unstimulated cells, kinases are 
predominantly localized to the cytosol and become associated with the plasma 
membrane after GPCR activation. However GRK4, GRK5 and GRK6 exhibit 
substantial membrane localization in the absence of agonist stimulation (Premont et 
al., 1995).  
 Phosphorylation by GRKs generally promotes β-arrestin binding (Moore et al., 
2007a) and GRKs thus play an important role not only in GPCRs desensitization but 
also in receptor internalization (Figure 1). 
 
c- Arrestins – More than key regulators of GPCR desensitization 
 The arrestin family comprises four members. Visual arrestins, arrestin 1 and 
arrestin 4, are expressed almost exclusively in the retina. Non-visual arrestins, arrestin 
2 (β-arrestin1) and arrestin 3 (β-arrestin2) are expressed ubiquitously in most tissues 
(Patel et al., 2009). Here, we will exclusively focus on β-arrestins. 
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Figure	1	
Role	of	β-arrestins	in	GPCR	trafficking		
(1)	Agonist	binding	to	a	GPCR	results	in	heterotrimeric	G	protein	activation	leading	to	
dissociation	of	Gα	from	Gβγ	subunits.	This	promotes	GRK	association	with	the	agonist-
bound	 GPCR	 which	 mediates	 receptor	 phosphorylation	 and	 (2)	 promotes	 β-arrestin	
recruitment	 to	 the	 receptor.	 (3)	β-arrestin	association	with	 the	phosphorylated	GPCR	
mediates	conformational	changes	in	arrestin	that	promote	association	of	the	GPCR-β-
arrestin	complex	with	the	endocytic	machinery	and	subsequent	endocytosis	(4).	GPCRs	
then	traffic	to	sorting	endosomes	(5)	and	ultimately	either	recycle	back	to	the	plasma	
membrane	 through	 recycling	endosomes	 (6	and	7)	or	are	 sorted	 to	 lysosomes	where	
they	are	degraded	(8	and	9)(Tian	et	al.,	2014).	
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 In unstimulated cells, despite their recruitment in the nucleus as well as on 
plasma membrane, β-arrestins are localized in the cytoplasm. These proteins are long 
ago known by their capacity to desensitize the activated receptor. On agonist 
stimulation of GPCR, they translocate to the cell membrane and bind to the 
cytoplasmic side of the activated receptor (Gurevich and Gurevich, 2006). The 
affinity of the receptor for arrestin proteins is increased by the receptor 
phosphorylation mediated by GRKs (Moore et al., 2007a). The binding of arrestin 
prevents further receptor/G protein interaction thereby reducing or preventing 
receptor signaling (Claing et al., 2002). Indeed, GRK phosphorylation alone, without 
presence of arrestins, has a weak effect on the uncoupling of the receptor/G protein 
complex. 
 Besides their  role in homologous desensitization, β-arrestins  take an important 
part in receptor internalization and its subsequent fate in subcellular trafficking (see 
the related paragraph below). Moreover, β-arrestins interact with several cytoplasmic 
proteins and function as scaffolders, thereby linking GPCRs to various signaling 
pathways entirely independent of G protein activation such as MAPK cascades (see 
section “G protein-independent signaling from endosome”s). Furthermore, recent 
studies have also indicated that in response to activation of certain GPCRs, β-arrestins 
associate with transcription cofactors (in the nucleus) or their regulators (in the 
cytoplasm) and thus play important roles in cell growth, apoptosis and immune 
functions (Ma and Pei, 2007). Finally, increasing evidence demonstrates that non 
visual arrestins may also influence endocytosis of non 7TMRs and thus regulate 
signaling via receptors of different types than the GPCRs like IGF-1R as an example 
(Shenoy and Lefkowitz, 2011). 
 
d- Phosphorylation-Independent Desensitization of G Protein-
Coupled Receptors 
Several publications have implicated GRKs in phosphorylation-independent 
desensitization of various GPCRs. In a study on mGluR1a regulation, Dhami et al. 
(2002) suggest a new twist on the general paradigm of GPCR desensitization 
mediated by GRK phosphorylation and propose that the kinase activity of GRK2 may 
be secondary to its role in attenuating GPCR signal transduction.  
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Phosphorylation-independent desensitization may occur through several possible 
mechanisms, including agonist-promoted receptor trafficking, GRK binding, and 
phosphorylation-independent binding of arrestins (Figure 2). 
 
 
2- Internalization and Post-Endocytic Sorting of GPCRs 
GPCR internalization, also termed receptor sequestration or endocytosis, is an 
important process in attenuation of GPCR signaling in response to agonist 
stimulation. It  also plays a major role in resensitization and downregulation of the 
receptor (Luttrell and Lefkowitz, 2002).  
 
a- Internalization  
Internalization of GPCRs is an agonist dependent process which promotes the 
removal of agonist-activated cell surface receptors from the plasma membrane to a 
membrane-associated intracellular compartment. This process is generally mediated 
by serine and threonine phosphorylation and most often by arrestin binding (Marchese 
et al., 2008). From the biochemical view, GPCR internalization is characterized as a 
decrease of receptor binding sites on the plasma membranes without changes in the 
total number of receptors. The process of internalization may occur via different 
pathways including clathrin-coated pits (CCPs) and lipid rafts or caveolae (Hendriks-
Balk et al., 2008). Herein, for many GPCRs, β-arrestins appear as key regulators 
acting as adaptor-like proteins with the capacity to link activated receptors to the 
components of the internalization machinery – clathrin and AP2 (Gurevich and 
Gurevich, 2006) (Figure 1). Once GPCRs are concentrated in CCPs, β-arrestins also 
facilitate the subsequent intracellular trafficking of the cargo by recruitment of 
dynamin, a large GTPase necessary for the fission of vesicles from the plasma 
membrane (Jean-Alphonse and Hanyaloglu, 2011). Besides this most frequent and 
most studied arrestin and clathrin-dependent mechanism of endocytosis, other 
mechanisms have been reported including arrestin, clathrin and/or dynamin 
independance. 
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Figure	2	
Potential	mechanisms	of	phosphorylation-independent	desensitization	of	GPCRs	
Agonist	 binding	 promotes	 the	 interaction	 of	 three	 classes	 of	 proteins	 to	GPCRs:	G	
proteins,	GRKs,	and	arrestins.	GRK	interaction	mediates	uncoupling	of	receptor	and	
G	protein	(desensitization)	through	GPCR	phosphorylation,	physical	association	with	
the	receptor,	or	direct	association	with	and	inhibition	of	Gαq/11.	Arrestin	interaction	
with	 GPCRs	 also	 directly	 inhibits	 receptor-G	 protein	 uncoupling,	 whereas	 receptor	
trafficking	mediates	various	processes,	including	desensitization,	resensitization,	and	
down-regulation.	A,	agonist	(Pao	and	Benovic,	2002).	
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b- Trafficking 
Following internalization, GPCRs undergo different trafficking fate. They are 
either rapidly targeted to lysosomes for enzymatic degradation (process leading to the 
downregulation of receptors), recycled back to the plasma membrane (process termed	
as resensitization) or retained in endosomes by which means the processes of 
degradation or recycling are much slower (Jean-Alphonse and Hanyaloglu, 2011). β-
arrestins operate as sorting agents deciding between the degradative and the recycling 
fate of the internalized receptors. The final sort of each receptor is dependent on the 
strength of its interaction with β-arrestin during the processes of internalization and/or 
trafficking. One group of receptors, class A receptors, interacts preferentially with β-
arrestin2. This interaction is weak and transient which results in rapid dissociation of 
the internalized receptor-β-arrestin complex in endosomes. This leads to a rapid 
recycling of the receptor to the plasma membrane. β2-adrenergic receptor is the most 
studied example of class A GPCR. Class B receptors binds to both β-arrestin1 and 2 
with near equal affinity. This interaction is strong and sustained over the time. The 
internalized receptor-β-arrestin complexes thus traffic together resulting in retarded 
recycling and preferred lysosomal degradation (Luttrell and Lefkowitz, 2002; Patel et 
al., 2009). Our group, working on the cholecystokinin receptor, CCK2R, showed that 
this GPCR  strongly recruits b-arrestin1 and 2 and thus belongs to Class B GPCRs 
(Magnan et al., 2011).	
 
Herein is also interesting to mention that the endocytic activity of arrestins as 
well as their effect on GPCR trafficking is controlled by posttranslational 
modifications such as arrestin phosphorylation or ubiquitination (Shenoy and 
Lefkowitz, 2003), (Wolfe and Trejo, 2007). In addition, recent studies have revealed a 
possible regulatory role for S-nitrosylation of core mediators of GPCR trafficking 
(Jean-Alphonse and Hanyaloglu, 2011).  
Recent studies have also discovered other types of sorting molecules allowing 
degradation or recycling of internalized receptors. Indeed, short linear peptide 
sequences including tyrosine- and dileucine-based motifs and PDZ ligands mediate an 
endosomal sorting of GPCRs while ubiquitination might have an essential role in their 
lysosomal sorting (Marchese et al., 2008). 
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3- Downregulation  
Down-regulation occurs as a result of long-term or repeated exposure to agonist 
(hours or days). Contrary to the receptor internalization corresponding to intracellular 
redistribution of receptors, down-regulation is slower and characterized by a decrease 
in the total number of receptors present in cells or tissues (Tsao et al., 2001). The 
process of down-regulation first comprises the enhancement of proteasomal and/or 
lysosomal degradation of internalized GPCRs. The degradatory processes are 
enhanced by agonist-induced ubiquitination of GPCRs. Second, the mechanism of 
downregulation consists also in the reduction of GPCRs synthesis. This may be 
mediated at one or more molecular levels (Schmidt and Meyer, 1994): 
 
• Changes at the level of transcription by a decrease in the rate of receptor gene 
transcription  
• Changes at the post-transcriptional level by changes in mRNA stability  
• Changes at the post-translational level by shortening of the receptor protein 
half-life. 
These molecular mechanisms can be mediated by these pathways: the first is the 
direct interaction of regulatory molecule with target gene. For βAR there are at least 
two regulatory molecules which are able to modulate the β-adrenergic receptor 
protein synthesis: CREB, cAMP response element binding protein, or CREM, cAMP 
response element binding modulator. These molecules interact with CRE (cAMP 
response element) located in the promoter region of the β-adrenergic receptor gene 
(Vallejo, 1994) and are able to effectively regulate transcription of βAR gene. This 
regulation can result from activation of the βAR itself or from activation of another 
GPCR regulating cAMP formation (Huang et al., 2010). The second (and 
hypothetical) mechanism is an indirect pathway via “third messengers” (Hughes and 
Dragunow, 1995). Third messengers are proteins synthesized immediately after the 
activation of receptor which can modulate target genes. Because of very fast 
synthesis, their own genes are called immediate early genes. 
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4- Resensitization  
Resensitization process includes endocytosis of desensitized receptor, 
dephosphorylation of receptor in endocytic vesicles by phosphatases, and receptor 
recycling back to the plasma membrane. This process of receptor recycling prevents 
intracellular receptor accumulation and degradation (Kristiansen, 2004) and allows 
initiation of further rounds of signaling. As mentioned previously, short linear peptide 
sequences including tyrosine- and dileucine-based motifs and PDZ ligands play a key 
role in GPCRs recycling rate. GPCRs of group A resensitize faster (are recycled back 
to the plasma membrane more quickly) than GPCRs of group B due to the weaker 
association of the receptor-β-arrestin complex.  
 
5- Sensitization and Up-Regulation  
There are situations when a GPCR is not enough stimulated (denervation, 
receptor blockade by antagonist) and can be sensitized or can be up-regulated. The 
mechanisms of sensitization can include  
a) increase in second messenger level,  
b) increase in the concentration of enzymes catalyzing the second messenger 
synthesis or  
c) changes in sensitivity of receptor to agonist.  
Up-regulation involves similar mechanism as those of downregulation (changes 
at the level of transcription, or changes at the post-transcriptional level, or changes at 
the posttranslational level)(Myslivecek and Trojan, 2000).  
 
6- Role of RGS in regulation of GPCR signaling 
An additional mechanism of GPCR signaling regulation was discovered 
involving the family of proteins called regulators of G protein signaling or RGS. In 
the second half of 1990’s, this new class of proteins emerged (Hollinger and Hepler, 
2002) and 37 genes encoding proteins with RGS or RGS-like domain have since been 
identified within the human genome (Willars, 2006). The members of this family 
share a characteristic RGS-homology domain of 120–130 amino acid residues and are 
classified into six distinct subfamilies (Hendriks-Balk et al., 2008). RGS proteins 
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were first described as GTPase activating proteins (GAPs) by their capacity to 
enhance Gα mediated GTP hydrolysis and thus terminate the G protein activation 
cycle (De Vries et al., 2000; Ross and Wilkie, 2000). Further studies have exposed 
that RGS proteins may also regulate GPCR signaling via mechanisms independent of 
the GAP activity by modulating either protein–protein interactions (the effector 
antagonism of RGS4 in the case of G protein-PLC interaction), subcellular 
localization of signaling molecules or protein translation (Sjogren et al., 2010). In the 
sense of regulation through protein-protein interaction, increasing evidence also 
supports the notion that many RGS proteins directly bind to certain GPCRs to 
modulate the signaling (Bansal et al., 2007). The existence of direct RGS–GPCR 
interaction has also been sustained by the observation that co-expression of both 
proteins results in recruitment of RGS to the membrane (Roy et al., 2003). In the case 
of small RGS, selectivity for the receptor is thought to be carried by N-terminal 
region, while the larger RGS might interact with the receptor directly through one of 
their protein interaction domains (PDZ domain). In addition, series of reports show 
that RGS, especially the larger one, act as integrators of GPCR signaling through 
multi-protein complexes (Hollinger and Hepler, 2002). These complexes are 
multifunctional signaling cores which recruit many scaffolding proteins. Moreover, 
certain scaffolds serve as regulators of RGS function such as spinophilin (Wang et al., 
2007).  
Conclusions 
Signaling via GPCRs plays an essential role in many physiological functions. It is 
a highly controlled process which comprises multiple steps of regulation at each level 
of signaling. At the GPCR level, two processes lead to reduction and/or attenuation of 
signaling: desensitization and down-regulation, while resensitization, sensitization 
and up-regulation increase the potential of agonist stimulation and thus re-enable 
signaling. Besides these mechanisms of regulation, complex receptor trafficking has 
been recently appreciated as an important regulatory mechanism of GPCR signaling. 
In addition, receptor responsiveness to extracellular stimuli is also controlled by 
interactions with many proteins, especially the RGS. In fact, GPCRs function as 
multifunctional platforms where receptors and G proteins are closely colocalised with 
other proteins involved in the specific signal transduction, as well as with regulatory 
proteins, scaffolding proteins and adaptors.  
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III- G protein-independent signaling of GPCRs from 
endosomes 
 
The discovery of b-arrestins was made in the context of studying GPCR 
desensitization. Then their role in endocytosis has been updated revealing a role of 
"connector" for desensitized receptors to the endocytic machinery. A 1999 study 
found that after recruitment of b-arrestins by activated b2-adrenergic receptor, the b-
arrestins interact with src kinase protein (Luttrell et al., 1999). Following this study, 
an “interactome” study (proteomics analysis) reported that b-arrestins may bind to a 
wide range of signaling proteins and recruit them into a GPCR associated complex, 
called signalosome (Xiao et al., 2007). Although these proteins have not yet been all 
associated with a physiological function, it appears  that the binding of b-arrestins to 
GPCRs does stop  the signal but rather initiate  a second wave of G protein-
independent signals. 
 
1- b-arrestins and src kinases  
b-arrestins binds to the src kinases protein family and recruit them to activated 
receptors. Concerning the molecular mechanism of interaction, N-terminal domain of 
b-arrestin 2 is rich in proline and contains 3 PXXP motifs that binds  with the SH3 
(src homology 3 domain) of c-src (Luttrell et al., 1999). b-arrestin1 possesses one 
PXXP motif that interacts with the domain SH2 of c-src (Miller et al., 2000). It seems 
that such interactions between arrestins and src preceeds  internalization of the 
receptor since the complex b2AR/b-arrestin2 associated to src was found on  cell 
membrane after isoproterenol stimulation. On the other hand, the mutation of serine 
412 in the C-terminal domain of b-arrestin2, which abolishes the association of the b-
arrestin2 with the b2AR, also prevents the interaction between arrestin and src 
(Luttrell et al., 1999). 
The b-arrestin-dependent recruitment of Src to GPCRs, appears to be 
important in clathrin-dependent internalization. Src recruited by b-arrestins, 
phosphorylates GRK2 which leads to its destabilization and promotes its entry into 
the proteasome causing the end of GPCR desensitization (Penela et al., 2001). 
 22 
Furthermore, b-arrestin-associated Src phosphorylates tyrosine 597 of the dynamin 1 
thereby regulating the self-assembly of dynamin. The expression of the Y597F mutant 
of dynamin 1 prevents the internalization of b2AR and muscarinic M2 receptor (Ahn 
et al., 1999). Another target of b-arrestin-associated src is the b2-adaptin subunit of 
the AP-2 complex. Indeed, src stabilizes the constitutive association between b-
arrestin 2 and b2-adaptin regardless of its kinase activity. In addition, src 
phosphorylates tyrosine 737 of the b2-adaptin, located in membrane clathrin coated 
pits, in response to stimulation of angiotensin II AT1a, b2-adrenergic, vasopressin V2 
and bradykinin B2 receptors. Phosphorylation of this tyrosine leads to the dissociation 
of AP-2 from receptor/arrestin complex which triggers the internalization of the 
receptor. Inhibition of the phosphorylation of b2-adaptin causes the retention of 
receptor/arrestin complexes in the plasma membrane clathrin-coated pit (Zimmerman 
et al., 2009). 
Beyond its role in GPCR endocytosis, it appears that src is recruited to the 
complexes of GPCR-arrestin-signaling proteins called signalosomes. The recruitment 
of Src to activated b2AR and neurokinin NK1 receptor contributes to the activation of 
the MAPKinase pathway through phosphorylation of ERK1/2 (Luttrell et al., 1999) 
(DeFea et al., 2000a). On the other hand, the LH receptor (Luteinizing hormone) 
activates another protein of the src family, c-Fyn, in a b-arrestin2-dependent manner 
(Galet and Ascoli, 2008).The decrease of the expression of b-arrestin2 using RNA 
interference causes the inhibition of c-Fyn activation by LH receptor. Finally, the D2 
dopamine receptor activates the signaling pathway of the nuclear factor NF-kB, in a 
src-dependent manner and overexpression of b-arrestin1 potentiates this activation 
(Yang et al., 2003).  
 
2- Interaction of b-arrestins with ERK1/2 proteins 
b-arrestins involvement in the regulation of the ERK1/2 activation cascade is 
the mechanism dependent of b-arrestin the most studied to date. ERK1/2 are the 
terminal kinases of the three kinases of MAPKinase cascade. This cascade comprises 
the MAPKKK (MAP kinase kinase kinase) c-Raf1, B-Raf, the MAPKKs (MAP 
kinase kinase) MEK1/2 and the MAPK (MAP kinase) ERK1/2. The activity of 
ERK1/2 is required for the G0/G1 transition of the cell cycle and in general, is 
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necessary in mitosis and meiosis. GPCRs often activate this MAPKinase pathway 
through G protein-dependent pathways, in particular via the PKA and PKC, or also by 
transactivation of EGF receptor. However, it is now known that b-arrestin 1 and 2 can 
simultaneously engage the three components of the MAPKinase cascade and operate 
in a complex regulated by agonist of the considered GPCR, increasing the efficiency 
of the phosphorylation cascade Raf-MEK-ERK and imposing a spatial restriction in 
the cell on this signal. 
Purification of PAR2 receptor reveals that c-Raf1 and ERK1/2 are 
components of a signalosome complex consisting of several proteins which assemble 
around the receptor bound to b-arrestins (DeFea et al., 2000b). Similar results were 
obtained with the angiotensin II receptor AT1a that colocalizes, few minutes after 
stimulation, with b-arrestins and ERK1/2 in the early endosomes (Luttrell et al., 
2001). The interaction between b-arrestin ½ and c-Raf1 is direct, but the one between 
ERK1/2 and MEK seem to be indirect. In overexpression conditions and in the 
absence of receptor activity, the complex b-arrestins / Raf / MEK / ERK exists 
already in the cytoplasm with ERK1/2 in an inactive form. In this case, 
overexpression of c-Raf1 increases the phophorylation of ERK1/2 bound to b-
arrestins. This suggests that the binding of b-arrestin promotes the activation of 
ERK1/2 by increasing the efficiency of the sequential phosphorylation of these three 
components Raf-MEK-ERK (DeFea et al., 2000b). Upon stimulation of the GPCR by 
an agonist, the complex b-arrestin-Raf-MEK-ERK translocates to the membrane 
leading to the activation of ERK1/2 (Shenoy et al., 2007). GPCRs such as PAR2 or 
Angiotensin II receptor AT1a which are classified in Class B receptors regarding 
internalization features, have a stable interaction with b-arrestins and ERK1/2 and 
resulting complexes remain localized on endosomes. 
The mechanisms by which GPCR associated with b-arrestin activate ERK1/2 
remain unclear. Mutants of Angiotensin II AT1a and PAR2 receptors unable to bind 
G-proteins and ligands and specifically recruit b-arrestins without activating the G 
protein, have shown that the activation of ERK1/2 by the arrestin/receptor complex is 
independent from G proteins (DeFea et al., 2000b). The expression of a chimeric 
receptor NK1-visual arrestin not coupled to the G protein causes constitutive 
activation of a reservoir of ERK1/2 that remains bound, with c-Raf1 and MEK1/2, to 
the internalized  receptor-arrestin chimer confirming that G proteins are not required 
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(Jafri et al., 2006). The addressing of c-Raf1 to the plasma membrane as well as the 
translocation of the b-arrestin2 to the membrane are sufficient to activate the ERK1/2, 
independently, suggesting that the arrestin protein functions as a passive scaffold by 
recruiting cytosolic c-Raf1 to the membrane. The ERK1/2 related to signalosome are 
also relatively protected from dephosphorylation by MAP kinase phosphatases, which 
is favorable to sustained activation of ERK1/2 (DeFea et al., 2000b). On the other 
hand, PP2A phosphatase protein is found associated with arrestins. This phosphatase 
is known for its activator role of ERK1/2 because it dephosphorylates serine 259 of c-
Raf1, in its inactive state. Thus the presence of PP2A in the signalosome probably 
provides an additional control element in the activation of ERK1/2. 
Signalosomes formation has significant effects on the spatial, temporal and 
functional characteristics of ERK1/2. When the ERK1/2 are recruited by a class B 
receptor, activated ERK1/2 follows the complex towards early endosomes, and are 
unable to migrate into the cell nucleus to activate gene transcription. In contrast, class 
A receptors, such as b2AR or the LPA receptor, also use b-arrestin 2 to activate 
ERK1/2, however, the transient nature of the interaction with arrestin prevents the 
addressing of ERK1/2 to endosomes (Gesty-Palmer et al., 2005). The PAR2 receptor 
activates ERK1/2 preferably via b-arrestins, resulting in the formation of signalosome 
in the cytoplasm, sequestering thereby activated ERK1/2, and preventing cell 
proliferation. A PAR2 mutant, incapable of being phosphorylated, unable to bind b-
arrestins and to internalize, activates ERK1/2 by a G protein-dependent mechanism 
allowing the nuclear translocation of activated ERK1/2 and cell proliferation (DeFea 
et al., 2000b). AT1a and V2 receptors activate ERK1/2 by b-arrestins and G protein-
dependent pathways leading to the increase of activated ERK1/2 both in the 
cytoplasm and the cell nucleus. An AT1a mutant receptor not coupled to G protein, 
activates only cytoplasmic ERK1/2, not allowing genes transcription in the nucleus. 
Conversely a chimeric V2 receptor with the C-terminal end of b2AR, increases the 
proportion of ERK1/2 entering the nucleus and allow to stimulate cell proliferation 
(Lee et al., 2008; Tohgo et al., 2003). 
For class B receptors, the cytoplasmic localization imposed by b-arrestins on 
activated ERK1/2 dictates their function by preferentially targeting membrane or 
cytoplasmic substrates. During PAR2 induced chemotaxis, ERK1/2-arrestin-PAR2 
complexes are located very close to the plasma membrane where the activation of 
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ERK1/2 is required for the reorganization of the actin cytoskeleton (Ge et al., 2003). 
The cytosolic substrates of ERK1/2 include b-arrestin2 and the ribosomal S6 kinase, 
p90RSK. The role of phosphorylation of b-arrestin 2 by ERK1/2 is not known 
precisely, it is assumed that this is either a downregulation of receptor internalization 
or an aid for the internalization of the receptor by promoting dissociation between 
arrestin and clathrin. P90RSK phosphorylation by the ERK1/2 is carried out 
downstream of the stimulation of the AT1a receptor by b-arrestin-dependent pathway 
and leads to the phosphorylation of Mnk1 and eIF4E thus increasing the rate of 
mRNA translation (DeWire et al., 2008). 
The dual role of b-arrestins is also organized on the temporal level. The 
contribution of the G protein and the b-arrestin2 in activating the MAPKinase 
pathway by the AT1a receptor was deeply investigated using RNA interference 
techniques against the b-arrestin2 isoform, pharmacological inhibitors, mutant 
receptors uncoupled to G proteins and b-arrestins pathways selective ligands. When 
b-arrestin 2 expression is inhibited, the activation of ERK1/2 by the AT1a receptor 
becomes transitory and sensitive to PKC inhibitors indicating that the transient 
activation signal of ERK is insured by a Gq protein / PLC / PKC pathway. 
Conversely, the inhibition of PKC in the presence of the b-arrestin 2 blocks the initial 
activity peak of ERK1/2 but does not inhibit the sustained phase of the activation of 
ERK1/2. The Stimulation of the AT1a mutant receptor that is not coupled to the Gq 
protein, or the stimulation of the wild-type receptor with a b-arrestins pathway 
selective ligand, generates a sustained signal of ERK activation, insensitive to the 
inhibition of PKC and abolished by RNA interference of the b-arrestin 2 (Ahn et al., 
2004). 
 
3- Biased agonism 
The concept of functional selectivity proposes that each agonist of a given 
GPCR, preferentially stabilizes one of the active conformations of the receptor, 
leading to the activation of a cellular signal specific of this agonist. 
An agonist is said "biased" when it is selective to a GPCR conformation that 
leads to the activation of only one part of the cellular pathways of a receptor by the 
intermediary of one single specific effector protein (G proteins, b-arrestin) without 
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activating other effectors of the same receptor, thus producing a distortion in the 
signaling. For example, for a GPCR which is coupled to several G proteins, a biased 
ligand will activate an intracellular signal dependent on a single G protein while a 
non- biased ligand will activate all G proteins. In the same way with the b-arrestins, a 
biased ligand can specifically activate pathways that are dependent of one G protein 
without activating the arrestins and vice versa. Since the discovery of the role of the 
b-arrestins in the signaling, a growing number of biased ligands for the arrestins 
signal have been identified. 
 
b2-adrénergic receptor. In a study of sixteen clinical antagonists of b2-
adrenergic receptor, carvedilol (b-blocker) has been shown to have inverse agonist 
activity towards Gs protein-dependent pathway, but activate of b-arrestine 2- 
dependent MAPKinase pathway. In another study, specifically examining the 
transactivation of EGF receptor by the b1-adrenergic receptor via b-arrestin-
dependent channels, carvedilol and alprenolol, two b-blockers, were identified as 
inducers of this phenomenon. Indeed, carvedilol and alprenolol stimulate the 
transactivation of EGF receptor by a mechanism dependent of receptor b1-adrenergic 
receptor and b-arrestines 1/2 phosphorylation.  
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IV- G protein-dependent signaling of GPCRs 
from endosomes 
 
Until very recently, it was considered that GPCR signaling mediated by G 
proteins is generated exclusively from the plasma membrane in which the receptors 
are activated by their ligand and the receptor internalization ends this signaling. 
Recently, this classic concept that G-protein dependent signaling of GPCRs is limited 
to the plasma membrane has been questioned. 
 
The first demonstration of the existence of a G protein-dependent GPCR 
signaling from endosomes has been made in the yeast.  
Fertilization in Saccharomyces cerevisiae requires a G protein-dependent 
signaling pathway. This signaling pathway is initiated by the binding of the 
fertilization pheromone ste2 receptor coupled to Gs. By performing a screening of 
mutated strains of yeast, the authors of the study identified two effector proteins 
necessary for GPA1 protein-induced signaling, the Gα homolog in yeast. The two 
proteins, Vps34 and Vps15, are the main components of the one and only 
phosphatidylinositol 3-kinase (PI3K) in yeast. In contrast to other effector proteins 
identified in other GPCRs’ signaling pathways, both Vps34 and Vps15 proteins are 
localized on the membrane of endosomes and not in the plasma	 membrane. 
Specifically, the authors have shown that the signaling induced by GPA1 is generated 
at the endosomal membrane where the two partner proteins Vps34 and Vps15 are 
located. Indeed, the authors showed by immunoprecipitation that the catalytic subunit 
Vps34 of the endosomal PI3K interacts directly with the activated GPA1. On the 
other hand, this interaction stimulates the kinase activity of the Vps34 and results in a 
high production of PI3P that was sufficient to recruit low affinity PI3P binding 
protein, Bem1, to the endosomes (Slessareva et al., 2006).   
 
This study is the first direct demonstration that a G protein-dependent signaling 
can also emanate from an intracellular membrane. 
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1- Persistence of the G protein- dependent signal from 
the endosomes 
 
In mammals, the first evidence of the existence of a G protein-dependent signaling 
from endosomes was shown with the receptor of the sphingosine-1-phosphate (S1P). 
In addition to its natural ligand S1P, the S1P1 receptor can be targeted therapeutically 
by the immunomodulatory drug FTY720 (fingolimod) administered orally in the 
treatment of multiple sclerosis (Cyster,	2005).	The S1P1R is coupled to Gi protein and 
its activation induces the inhibition of the production of cAMP by the adenylate 
cyclase. 
Mullershausen et al. (2009) have shown, by measuring the inhibition of cAMP 
production triggered by forskolin, that a short stimulation by the FTY720P agonist of 
CHO cells overexpressing the S1P1 receptor induces a Gi-dependent signal that 
persists during the time. This signal lasts for several hours after washout removal of 
the ligand. During the sustaining signaling period, the receptor is internalized and 
substantially absent from the plasma membrane. This phenomenon was not observed 
in case of stimulation with S1P where the receptor is recycled to the plasma 
membrane few hours after washing out the ligand. Furthermore, Calcium signal 
(Ca2+), produced via the Gq-dependent pathway, the second G protein coupled to 
S1P1, is abolished 5h after washing out the FTY270P. This result shows a specificity 
of the Gi-dependent pathway which, unlike Gq protein-dependent PLC-Ca2+ pathway, 
could be activated at the intracellular compartment. 
Next, in order to identify the structural domain of FTY720P responsible for the 
persistence of the signal, the authors tested several modified analogues of this ligand. 
Analogs with a reduced hydrophobicity, with the same power and efficiency than the 
FTY720P but not capable of promoting a continuous signal, have been identified. On 
the other hand, a short stimulation by FTY720P did not induce a Gi-dependent 
persistent signal in CHO cells that over-express the homologous receptor S1P3. These 
results led the authors to conclude that effects of FTY720P observed on the S1P1 are 
specific to ligand-receptor couple and not to the ligand or to the receiver each alone. 
The persistent signaling process induced by the complex FTY720P / S1P1 was 
confirmed in cells that express endogenously the S1P1 receptor, HUVEC cells and in 
rat primary astrocytes, reinforcing its physiological relevance. 
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The team proposed as an explanation to the observed phenomenon that the 
persistent signal could be due to a long association between ligand and receptor at the 
membrane and during S1P1 receptor internalization. Indeed, the addition of W146, a 
competitive antagonist of S1P1, during wash out of CHO-S1P1 cells preincubated 
with FTY720, inhibits internalization and the Gi-dependent persistent signal. In 
addition, FTY720P competition by W146 was associated with the recovery of the 
S1P1 receptor recycling to the plasma membrane as well as the restoration of the 
calcium response. Based on these results, the authors conclude that FTY720P binding 
to the S1P1 is persistent over time and maintains the internalized receptors in an 
activated conformation that is difficult to direct to membrane recycling pathway. 
The authors observed co-localization of the complex S1P1-FTY720P 
internalized with markers of the Golgi / trans-Golgi network, but little or no with 
markers of early and late endosomes and lysosomes. Even after 8 hours of 
stimulation, the S1P1 receptors are predominantly found in the Golgi and very little in 
the lysosomes. The authors conclude that the FTY720P-activated S1P1 endocytosis 
follows a retrograde unusual pathway towards the Golgi network / trans-Golgi. 
S1P has been shown previously to stimulate chemotaxis of endothelial cells via 
the S1P1 (Lee et al., 2006; Lee et al., 2001; Wang et al., 1999). Thus, in terms of 
functional consequences of the persistent signal, experimenters have shown that the 
migration ability of HUVEC cells was increased during 24 hours, even after only 1 
hour of pre-incubation with FTY720 (Mullershausen et al., 2009). 
 
A second study strongly supports the concept of signaling from endosomes; it 
concerns a Gs protein-dependent signaling initiated by the stimulatory thyroid 
hormone (TSH). Calebiro et al. (2009) generated transgenic mice that express 
ubiquitously inert fluorescent biosensor of cAMP (YFP-EPAC1-MFF), the first 
messenger generated upon activation of the Gs pathway. The authors indicate that 
their animal model enables to conduct studies under physiological conditions, unlike 
the transfected cells where transfection may alter the spatial and temporal 
characteristics of the signaling pathways. Mice were used to study the dynamics of a 
GPCR-cAMP signaling cascade activated by TSH, within the intact multicellular 
functional unit that constitutes the thyroid. The production of cAMP in real time was 
traced by FRET microscopy (Förster resonance energy transfer) by measuring the 
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fluorescence ratio YFP / CFP (acceptor / donor) (see Appendix describing the 
method). 
Indeed, the binding of cAMP to EPAC induces a conformational change in the 
probe, resulting in a change of the distance between the fluorophores YFP and CFP 
positioned at both ends of the biosensor binding domain. The thyroid cells were 
selected in this study for several reasons: they are strictly dependent, for all their 
functions, on activation of a GPCR, the TSH receptor. TSHR is expressed on the 
baso-lateral membrane of the cells and it mainly induces its effects via stimulation of 
cAMP production. In addition, thyroid cells form supra-cellular structures: the thyroid 
follicles. These follicles are a suitable model for studying the spatiotemporal 
dynamics of GPCR-cAMP signaling, particularly because of their polarization and 
their 3D structure in culture. 
The authors of the study show that following the follicle stimulating by TSH, 
immediate and rapid decrease in the YFP / CFP intensity ratio is observed, reflecting 
an increase in the level of cAMP. Surprisingly, in contrast to the other cell types 
tested (embryonic fibroblasts or cortical neurons), for which the kinetics of cAMP 
production show a decrease in cAMP levels over time, a production of prolonged 
cAMP was observed in thyroid follicles in response to TSH. In addition, this 
persistent cAMP production is only slightly reversible after removal of the ligand by 
continuously washing the follicles and is concomitant with the internalization of TSH 
and its receptor (TSHR). 
In a test to determine the origin of intracellular signal, the experimenters found 
that the effectors of Gs-dependent pathway are still in the same compartment as the 
TSH-TSHR internalized complex. In terms of sub-cellular localization, the receptor-
ligand complexes co-localize partially with the Gs protein and adenylate cyclase in 
endosomes or in the pre-Golgi compartments associated to endosomes. 
Remarkably, inhibition of TSH / TSHR endocytosis, by sucrose or dynasore, 
reverses the fraction of cAMP signal that is induced by TSH resistant to ligand 
removal. These various observations lead the investigators to conclude that the 
activated TSHR induces a transient cAMP production from the cell membrane, 
similar to other Gs-linked GPCRs, and also a Gs-dependent persistent cAMP 
production originating from internalized TSHR. 
The authors finally observed that the inhibition of endocytosis reduces the 
ability of TSHR to control actin organization. This led them to suggest that the 
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specific form of endosomal activation of the G protein directs the signaling towards 
qualitatively different effectors (Calebiro et al., 2009). 
These findings are contradicted by Gershengorn team who showed that the TSH 
persistent signal is independent of the internalization. Indeed, in the latter study, the 
inhibition or stimulation of internalization by overexpressing dominant negative of 
dynamin, K44A, or β-arrestin2 respectively, does not alter the persistent cAMP signal 
production (Boutin et al., 2011; Neumann et al., 2010). 
 
Another study on the signaling of the TSH receptor confirms the existence of a 
signaling from endosomes by showing that the duration of the cAMP signal greatly 
exceeds the fast dissociation duration (~ 3min) of the TSH / TSHR couple at the 
membrane, thus refuting the hypothesis that the persistence of the signal is due to a 
prolonged binding to membrane receptors. In addition, this study showed the 
specificity of the signal by showing that it is not persistent in embryonic kidney cells 
HEK293 (Werthmann et al., 2012). 
 
In the same year, another study on the PTH receptor (PTHR) strongly supported 
the hypothesis of signaling from endosomes (Ferrandon et al., 2009).  
In fact, earlier observations showed that PTHR has two response types, a long 
and a short one, induced by two different ligands, PTH1-34 or PTHrP1-36 respectively 
(Dean et al., 2008) ; (Horwitz et al., 2003; Horwitz et al., 2005; Okazaki et al., 2008). 
In order to understand the molecular mechanisms responsible for the difference in 
PTHR signaling in response to the two ligands, Ferrandon et al. (2009) conducted a 
study based on FRET constructions in the HEK cell model. The kinetics of the key 
biochemical reactions involved in PTHR signaling, beginning from the initial step of 
binding till the cAMP production, were recorded. 
Experimenters have shown that the two ligands associate with PTHR by the same 
process but dissociate by two different mechanisms: PTHrP dissociates slowly and 
completely from the receiver while the PTH1-34 form a more stable and persistent 
complex with the receptor. The stable ligand / receptor couple formed after 
stimulation with PTH1-34 keeps the receptor in an active and stable state and persists 
long after washing the ligand. 
The stimulation of HEK293 cells overexpressing the PTHR by the PTH1-34 
induced receptor internalization. At the subcellular level, the PTHR stays colocalized 
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with its ligand, with Gs and with adenylate cyclase, and the complex is directed 
towards early endosomes marked by Rab5 and EEA-1.  
Surprisingly, stimulation by the PTH1-34 results in persistent cAMP production 
that correlates perfectly with the internalization kinetics of the complex. Finally, the 
inhibition of internalization by overexpression of dynamin dominant negative, the 
K44A mutant, greatly shortened the duration of cAMP production, even in the 
continued presence of ligand. The authors conclude that the persistent part of signal 
comes from the ligand-receptor-G protein complex in endosomes and not at the 
plasma membrane (Figure 3,4)(Ferrandon et al., 2009). 
 
2- Regulation of the persistence of G protein-dependent 
signal from the endosomes 
 
The study of the mechanism that controls the cAMP production from endosomes 
was mainly conducted by a team working on PTH and vasopressin receptors. An 
unexpected and different new role has been ascribed to β-arrestins. Indeed, blocking 
the expression of β-arrestin by SiRNA shortens the production of cAMP signal. 
Conversely, overexpression of β-arrestin 1 extends the cAMP signal. Consistent with 
these results, it was found that the β-arrestin1 remains associated with the signaling 
complex during its internalization and activation but in a discontinuous manner, 
between the cytosol and the endosomal complex (half-life ~ 30s)(Feinstein et al., 
2011). 
 
 These results obtained in HEK cells are also found in the line ROS17 / 2.8 
(osteoclast-like) that naturally expresses the PTHR. In addition, the inhibition of 
phosphodiesterase 4, cAMP specific (PDE4) by a pharmacological inhibitor prolongs 
the cAMP production duration in response to the PTH1-34 whereas the inhibition of 
MEK activation reduces the cAMP signal. These observations added to the fact that 
arrestin is known to activate ERK via a signaling complex (see section: G protein 
independent GPCR signalling), suggest that the persistence of cAMP signal from the 
endosomes involves β-arrestin that, via stimulation of ERK1/2, inhibit the action of 
PDE4 (Feinstein et al., 2011). 
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Figure	3	
Mode	of	activation	of	the	PTHR	by	long-acting	and	short-acting	signaling	ligands	
	
	(a)	 The	 action	 of	 a	 short-acting	 signaling	 ligand	 is	 represented	 by	 the	 classical	
model	 for	G	protein	 signaling.	 The	 ligand	 interacts	 first	with	 the	 receptor	 (1).	 The	
receptor	is	then	switched	on	to	lead	to	G	protein	recruitment	(2)	and	activation	(3),	
which	in	turn	initiates	adenylyl	cyclase	activation.	In	the	classical	model—that	is,	the	
PTHrP-like	hormone	model—the	ligand	rapidly	dissociates	from	the	receptor,	which	
deactivates	 and	 ultimately	 terminates	 the	 signaling.	 Receptor	 and	 ligand	 traffic	
through	 distinct	 compartments	 and	 pathways.	 (b)	 In	 the	 model	 of	 long-acting	
signaling	 ligand,	 the	 hormone	 interacts	 tightly	 with	 the	 receptor	 in	 a	
conformationally	dependent	manner.	The	 receptor	 is	 then	 locked	 into	a	prolonged	
active	state	inducing	sustained	receptor–G	protein	coupling	and	sustained	G	protein	
activation.	 The	 ternary	 ligand–receptor–	 G	 protein	 heterocomplex	 is	 preserved	
during	 its	 internalization	 in	 Rab5-containing	 endosomes	 and	 persists	 over	 time	 to	
appear	 as	 a	 key	 structure	 in	 the	 prolonged	 downstream	 signaling	 of	 PTH-like	
hormone	(Ferrandon	et	al.,	2009).	
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Figure	4	
	
Altered	modes	of	cAMP	signalling	at	PTHR1	
	
Structurally	distinct	PTH	and	PTHrP	ligands	can	bind	preferentially	to	two	different	high	
affinity	receptor	conformations,	R0	and	RG,	and	thereby	 induce	different	modes	of	GαS-
mediated	cAMP	signaling	(inset,	 lower	panel).	RG-selective	 ligands	(for	example	PTHrP)	
induce	transient	cAMP	responses	that	are	derived	from	signaling	complexes	localized	at	
the	 plasma	 membrane,	 whereas	 R0-selective	 ligands	 (for	 example	 certain	 PTH	
analogues)	can	also	induce	prolonged	cAMP	responses	that	are	derived	from	complexes	
associated	within	 endosomes.	 The	 internalized	 signaling	 complexes	 contain	 β-arrestin,	
which	promotes,	rather	than	terminates	cAMP	signaling	by	activating	ERK1/2,	leading	to	
the	 inhibition	of	PDE4	enzymes.	Termination	of	endosomal	signaling	correlates	with	an	
exchange	at	the	complex	of	β-arrestin	for	retromer	sorting	proteins,	and	is	promoted	by	
vATPase-mediated	vesicle	acidification.	The	vATPases	are	activated	by	cAMP-dependent	
PKA,	 and	 thereby	 establish	 a	 negative	 feedback	 loop.	 PTHR1	 activation	 of	 cAMP	
signaling	 that	 differs	 in	 duration	 and	 location	 of	 origin	 within	 the	 cell	 provides	 a	
potential	 mechanism	 for	 ligand-directed	 diversification	 of	 cellular	 responses.	
Abbreviations:	 ERK1/2,	 extracellular	 signal-regulated	 protein	 kinase	 1/2;	 PDE4,	
phosphodiesterase	 4;	 PKA,	 protein	 kinase	 A;	 PTH,	 parathyroid	 hormone;	 PTHR1,	
PTH/PTHrP	type	1	receptor;	PTHrP,	parathyroid	hormone-related	protein;	R0,	G-protein-
independent	 conformational	 state;	 RG,	 G-protein-dependent	 conformational	 state;	
vATPase,	vacuolar	H+-ATPase	(Cheloha	et	al.,	2015).	
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Figure	5	
Mode	of	regulation	of	PTHR	signaling	by	retromer	and	arrestin	
	
PTH-activated	 PTHR	 (green)	 generating	 cAMP	 (gray)	 by	 activation	 of	 adenylyl	 cyclases	
internalizes	to	endosomes	in	a	process	that	involves	binding	of	β-arrestin	(red).	Activated	
PTHR	 is	 then	maintained	 in	 the	 early	 endosome	 bulk	 compartment	 by	 arrestin	 binding,	
where	 arrestin-mediated	 activation	 of	 ERK1/2	 signaling	 inhibits	 phosphodiesterases	 and	
permits	sustained	cAMP	signaling.	Binding	of	PTHR	and	retromer	(blue)	causes	sorting	of	
the	receptor	to	retrograde	trafficking	domains.	Generation	of	cAMP	is	stopped	after	either	
retromer	binding	in	the	retrograde	domain	or	upon	retromer-mediated	traffic	to	the	Golgi	
(Feinstein	et	al.,	2011).	
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The same team was also interested in the mechanism causing the turn-off of 
cAMP production from endosomes. Previous work had shown that the internalized 
PTHR can be directed to the Golgi (Feinstein and Linstedt, 2008) by retrograde 
transport from endosomes to the trans-Golgi network. The authors showed that the 
retromer, multimeric complex of endosome/Golgi transfer (Bonifacino and Rojas, 
2006; Collins, 2008; Collins et al., 2008) has a role in the traffic of internalized 
PTHR. 
Using spectral deconvolution imaging (resolution of 40 nm/pixel), the 
experimenters found that the PTHR undergoes a gradual transfer in the endosomes 
from a compartment labeled by β-arrestin1 to a compartment marked by VPS29, a 
subunit of the retromer. This transfer begins approximately at the same time with the 
desensitization of the cAMP response (~ 20min). An inverse correlation was observed 
between the expression level of the retromer and the cAMP production by the PTHR. 
Contrarly, the involvement of the retromer is not observed in the β2AR receptor 
leading the authors to conclude that the turn-off of the endosomal signal of cAMP 
production is due to a direct interaction between PTHR and the retromer at the 
endosome and not to a specific role of this retromer in cAMP signaling (Figure 4,5). 
 
The fact that the persistence of the cAMP endosomal signal requires continuous 
activation of Gs leads to the following question: how Gs can remain linked to PTHR 
and activated while the latter is always associated with the β-arrestin? 
Two hypotheses have been proposed and tested by the authors (Wehbi et al., 
2013): The complex PTH-PTHR-arrestin could contribute to the cAMP persistent 
signaling by stabilizing an interaction with active Gs. Alternatively, the dimer formed 
βγ subunits of the G protein, known to recruit signaling complexes, could be involved 
by interacting with β-arrestin (Laporte et al., 2002; Luttrell et al., 2001; Yang et al., 
2009). This second hypothesis was validated experimentally. First, the binding of 
arrestin simultaneously with Gβγ and the receptor has been demonstrated by FRET 
and by immunoprecipitation. Then, the possibility that a stable PTHR-arrestin 
connection can still allow an interaction with Gβγ was tested. For this, the PTHR was 
artificially immobilized on the cell membrane and a mutated form of β-arrestin1 (IV-
AA), having a strongly stabilized binding to the receptor, was overexpressed. Using 
the FRAP technique on cells stimulated with the PTH1-34, the recovery of the 
fluorescence of the β-arrestin1 [IV-AA]Tom was not observed confirming a stable 
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bond between β-arrestin1 [IV-AA ]Tom and activated PTHR. In a second series of 
experiments, M-PTH1-14, a PTH analog that does not induce a persistent cAMP signal, 
was used. Under the conditions of β-arrestin1 or 2 or IV-AA overexpression, the 
combination of activated PTHR with Gβγ is prolonged and, in addition, the 
knockdown of β-arrestin1/2 by siRNAs reduces the signal. These results support a 
role of β-arrestin in prolongating the association of Gβγ with activated PTHR. 
The authors also identified PTHR signaling steps in the presence of arrestins by 
studying the activation of Gs using two approaches. First, they followed the binding 
of [35S]GTPγS, a nonhydrolysable GTP analogue, to Gαs on membranes from 
HEK293 cells overexpressing the PTHR in the presence or not of purified β-
arrestin1/2. Second, a FRET biosensor measuring the activation of Gs was used under 
the same conditions. Overall, the results suggest that Gβγ remains associated with the 
PTHR, which is associated with the arrestin during the Gs activation cycle. This 
association results in accelerated and intense activation of Gs.  
Finally, even by stimulating PTHR with the M-PTH1-14 peptide which yet does 
not induce a persistent cAMP signal, stabilization of the complex PTHR-arrestin, by 
overexpressing the mutant β-arrestin1 (IV-AA), leads to the extension of the cAMP 
signal. This confirms the role of the arrestin in stabilizing the activated PTHR-Gβγ 
complex. 
These data highlight a new mechanism for regulating the signaling of GPCRs, 
in which the β-arrestin contribute to the stabilization and not to inhibition of Gs signal 
allowing several cycles of coupling and activating of the Gαs subunit or stabilizing 
the persistent coupling of active Gαs to receptor-arrestin complex (Figure 6)(Wehbi 
et al., 2013). They contradict the general view that arrestin and Gs cannot bind 
to a GPCR at the same time.  
 
3- Direct detection of G protein activation in 
endosomes using conformational biosensors 
 
A fundamental problem in the interpretation of all of the above summarized 
studies is the use of temporal correlations and possible artifacts associated with non-
specific or pleiotropic effects of inhibitors of endocytosis. This led to launch studies 
aiming to detect direct activation of the GPCR or G protein in endosomes. 
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Figure	6	
Signaling	models	of	GPCR	
	
(a)	Classical	model.	The	ligand	(L)	binds	the	inactive	state	of	a	GPCR	(R)	and	stabilizes	its	
active	 form	 (R*),	 which	 then	 couples	 with	 heterotrimeric	 G	 proteins	 (Gabg)	 through	 a	
diffusion-controlled	 process	 (step	 1).	 The	 L–R*–G	 complex,	 in	 turn,	 catalyzes	 GDP-GTP	
exchange	on	Ga,	leading	to	dissociation	the	GTP-bound	Ga	(Ga-GTP)	along	with	the	Gbg	
dimer	 from	the	receptor	 (step	2).	 In	 the	case	of	Gs,	Gas-GTP	activates	ACs	that	catalyze	
the	 synthesis	 of	 cAMP	 from	 ATP	 (step	 3).	 The	 hydrolysis	 of	 GTP	 to	 GDP	 causes	 the	
reassociation	of	Gas	to	Gbg	subunits	and	the	termination	of	the	cAMP	production.	In	this	
model,	the	recruitment	of	b-arrestins	mediate	desensitization	of	G-protein	signaling	(step	
4).	(b)	Noncanonical	model,	using	PTHR	as	an	example.	(i)	A	long-lived	PTH–PTHR–arrestin	
complex	 could	 contribute	 to	 sustained	 cAMP	 signaling	 by	 stabilizing	 an	 interaction	with	
the	 active	 state	 of	Gs	 (i.e.,	 the	GTP-bound	 form	of	Gs);	 (ii)	 alternatively,	 the	 interaction	
between	the	activated	PTHR	and	Gbg	 is	 stabilized	by	b-arrestins.	After	 the	 first	 round	of	
activation,	 the	 initial	 interaction	 between	 PTHR	 and	 Gs	 is	 bypassed	 such	 that,	 after	
hydrolysis	of	 the	GTP-bound	 form	of	Gas,	 free	Ga-GDP	directly	 reassociates	with	PTHR–
Gbg	 complexes	 to	 initiate	 a	 new	 cycle	 of	 G-protein	 activation.	 Arrestin	 stabilizes	 the	 G-
protein	cycle,	resulting	in	prolonged	cAMP	production	(Vilardaga	et	al.,	2014).	
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A single domain antibody fragments (Nanobodies), originally developed as 
tools for structural investigations (Steyaert and Kobilka, 2011), have been developed 
to operate as " Conformational Biosensors ". These are genetically encoded by 
plasmids and they detect the GPCR or G protein activation states in living cells 
(Figure 7 A-C) (Irannejad et al., 2013). 
The first conformational biosensor was developed from a nano-antibodies 
(Nanobody) against the purified β2AR linked to an irreversible agonist. This 
nanobody, Nb80, appears to selectively bind to activated receptors because it mimics 
the α subunit of the Gs protein in its form free from nucleotide (Rasmussen et al., 
2011a; Rasmussen et al., 2011b). The same nanobody, when present at a much lower 
concentration than in structural studies, can effectively detect the activated receptor 
conformation without forcing its activation in the absence of the agonist. The fusion 
of Nb80 to the green fluorescent protein (GFP-Nb80), and its expression by 
transfection, to allow a low concentration in the cytoplasm, enabled to successfully 
detect the ligand-dependent and reversible conformational activation of the β2AR in 
living cells (Irannejad et al., 2013)( Figure 7 B).  
Real-time fluorescence imaging of the location of Nb80-GFP in living cells 
revealed an interesting sequence of events. First, the addition of the agonist 
(isoproterenol) to the cells caused Nb80-GFP recruitment to the plasma membrane, 
then the β2AR apparently non-associated to Nb80-GFP were grouped into clathrin- 
coated pits, and afterwards Nb80-GFP was recruited to endosomes. The recruitment 
of Nb80-GFP to the endosomes was visible several minutes after the recruitment to 
the plasma membrane and appeared as a second discrete phase triggered after the the 
addressing of nanobody non-associated receptors to endosomes (Irannejad et al., 
2013).  
Another biosensor was then generated, it is based on a distinct nanobody 
(Nb37) recognizing a helical region of the of Gs α subunit that is not accessible under 
the nucleotide binding conformation, but which becomes mobile and exposed when 
its nucleotide binding pocket is empty (Irannejad et al., 2013). This free conformation 
is characteristic of the α subunit present in the active ternary complex agonist-GPCR-
G protein, and appears to be the key catalytic intermediate in the G protein activation 
process (Westfield et al., 2011). This conformational biosensor was fused to the green 
fluorescent protein giving Nb37-GFP (Figure 7 C).  
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Figure	7	
Conformational	biosensors	in	b2AR	signaling	
	
A,	 The	 main	 events	 in	 b2-AR	 cAMP	 signaling	 include	 agonist	 binding	 (step	 1),	
conformational	 activation	 of	 the	 receptor	 (step	 2)	 that	 is	 coupled	 to	
conformational	 activation	 of	 Gs	 (step	 3)	 that	 produces	 guanine	 nucleotide	
exchange	 on	 Gs	 and	 subsequent	 activation	 of	 adenylyl	 cyclase	 (AC)	 (step	 4).	 B,	
Scheme	 for	 detecting	 conformational	 activation	 of	 b2-AR	 with	 Nb80–GFP. C,	
Scheme	for	detecting	conformational	activation	of	Gs	with	Nb37–GFP	(Irannejad	et	
al.,	2013).	
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When this nanobody is expressed at a sufficiently low level, it homogeneously 
diffuses into the cytoplasm in the absence of stimulation by the agonist of β2AR. The 
administration of the agonist triggers two phases of recruitment of Nb37-GFP, first a 
recruitment to the plasma membrane, and then a recruitment to endosomes 1 minute 
after the arrival of the receptor. The two phases of recruitment of Nb37-GFP, 
similarly to those of the Nb80-GFP, are reversed quickly and completely after 
washing the ligand. In addition, in terms of cellular response, the two phases of 
activation of Gαs correlate temporally with two phases of by β2AR mediated cAMP 
accumulation, with the second endosomal phase characterized by its specific 
sensitivity to inhibitors of endocytosis (the dyngo-4a: specific inhibitor of dynamin) 
(Irannejad et al., 2013). 
 
4- Spatial effects of endosomal signaling 
 
In the above studies, activation of the G protein in the endosomes has been 
consistently observed to extend the duration of response and, in some studies, was 
responsible for maintaining the response after ligand removal. Data suggest that 
endosomal activation can confer a dimension of spatial control to the cellular 
response. Indeed, it has been found that inhibitors of endocytosis reduce the β2AR 
induced expression of a large repertoire of cAMP dependent genes, including for 
example Pck1, the gene encoding the phosphoenolpyruvate carboxykinase 1 involved 
in the regulation of gluconeogenesis. 
This effect was not correlated with changes in the overall level of accumulation of 
cytoplasmic cAMP but was associated with a decrease in the level of phosphorylation 
of CREB (cAMP-response element-binding protein), the factor that induces global 
cAMP-dependent transcriptional activity. These results suggest that activation of the 
G protein by GPCRs in endosomes confers a spatial control character which is added 
to the specificity of downstream signaling, presumably by increasing the effectiveness 
of cAMP-dependent CREB phosphorylation because of the physical proximity of 
actors (Tsvetanova and von Zastrow, 2014). 
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To test spatial importance of cAMP signaling from endosomes, a 
photoswitchable bacterial adenylate cyclase (bPAC) (Stierl et al., 2011) was designed 
to be expressed either at the plasma membrane (Figure 8 A) or the membrane of 
endosomes (Figure 8 B) by fusing it with suitable targeting sequences for each 
location. In illumination conditions, adjusted to produce equivalent increases in the 
overall concentration of cytoplasmic cAMP from each location, the recombinant 
adenylate cyclase activated on endosomes induced the cAMP-dependent transcription 
much more efficiently than the adenylate cyclase activated on the plasma membrane. 
However, when the cells were exposed to rolipram, a chemical inhibitor of the 
enzyme phosphodiesterase-4 concentrated in the periphery of the cytoplasm and 
associated with the plasma membrane (Conti and Beavo, 2007), adenylate cyclase 
localized on the plasma membrane strongly induces transcription (Tsvetanova and 
von Zastrow, 2014).  
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Figure	8	
New	 genetically	 encoded	 tool	 for	 manipulating	 spatiotemporal	 signaling	 in	 living	
cells	
	
A,	 design	 of	 bPAC-PM	 for	 optogenetic	 activation	 of	 adenylyl	 cyclase	 activity	 on	 the	
plasma	membrane	 (PM).	B,	 design	 of	 bPAC-Endosome	 for	 optogenetic	 activation	 of	
adenylyl	 cyclase	 activity	 on	 the	 endosome	 limiting	 membrane	 (Tsvetanova	 et	 al.,	
2015).	
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V- Glucose-Dependent Insulinotropic Polypeptide 
(GIP) and GIP Receptor (GIPR) 
 
1- GIP 
a- Introduction 
 
In 1971 Brown et al. purified a hormone that inhibited gastric acid secretion from 
hog upper small intestinal mucosa and named it gastric inhibitory polypeptide (GIP) 
(Brown, 1971; Brown and Dryburgh, 1971). In 1973 Dupré et al. demonstrated that a 
purified preparation of porcine GIP, infused intravenously in humans with glucose, 
stimulated the secretion of significantly greater amounts of insulin than when the 
same dose of glucose was administered without GIP (Dupre et al., 1973). “Incretin” is 
the term attributed to hormones that stimulate insulin secretion in a glucose-dependant 
manner (Creutzfeldt, 1979). In the light of this important function of GIP as an 
incretin hormone, an altenative definition of the acronym GIP was introduced: 
Glucose-dependent Insulinotropic Polypeptide (Brown and Pederson, 1976). 
 
b- GIP gene, precursor and transcriptional control 
 
The human GIP gene spans approximatively 10kb and is linked to a gene cluster 
on chromosome 17q. The gene consists of six exons plus five introns, with the 
precursor, preproGIP, encoded by exons 2-5 and the 5’-untranslated region and 3’- 
polyadenosine tail in exons 1 and 6, respectively. The GIP1-42 sequence is encoded by 
exons 3 and 4 (Inagaki et al., 1989)(Figure 9). Analyses of human cDNA clones 
identified a 459 base pair open reading frame that encodes the 153 amino acid 
preproGIP (Takeda et al., 1987), and it was predicted that the precursor consists of a 
21 amino acid signal peptide, a 30 residue NH2-terminal peptide, GIP1–42, and a 60 
residue C-terminal peptide (Figure 9). The GIP sequence in proGIP is flanked by 
single arginine residues, sites for cleavage by prohormone convertase (PC) enzymes. 
GIP and PC1/3 are co-localized in K-cells (GIP secreting cells) and PC1/3 has been 
shown to be sufficient for precursor processing (Ugleholdt et al., 2006). 
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Figure	9	
	
Structure	 of	 the	 human	 GIP	 Gene,	 mRNA,	 precursor	 protein	 and	 peptide	
products	(McIntosh	et	al.,	2009).	
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The first intron of human GIP gene contains essential cis-acting elements for its 
cell-specific expression (Hoo et al., 2010). The activity of the human GIP promoter is 
regulated by Pdx1 along with Pax6 (Fujita et al., 2008). Moreover, the human GIP 
promoter contains a TATA motif, consensus Sp1, Ap-1, and Ap-2 sites, as well as 
two CRE elements (Inagaki et al., 1989; Someya et al., 1993), thus suggesting 
regulation by protein kinase A (PKA) and protein kinaseC (PKC) (McIntosh et al., 
2009). Basal promoter activity was found to require the DNA sequence -180 to +14 
(relative to the transcriptional initiation site), whereas inducible transcription was 
primarily mediated by one of the two CRE elements in the regions -164 to -149, and 
c-Jun was capable of repressing transcription Someya (Someya et al., 1993). 
 
 
c- Peptide 
 
In humans, GIP molecule is a 42 amino acid polypeptide (Moody et al., 1984) 
(Figure 10) and there is >90% amino acid homology among human, porcine, bovine, 
mouse, and rat GIP (McIntosh et al., 2009). GIP belongs to the secretin/glucagon 
superfamily of peptides that share strong N-terminal regional homology (Sherwood et 
al., 2000). In humans, identified members of the family include GIP, secretin, 
glucagon, GLP-1, GLP-2, growth hormone-releasing hormone (GHRH), vasoactive 
intestinal polypeptide (VIP), peptide histidine methionine (PHM) and pituitary 
adenylate cyclase-activating polypeptide (PACAP). 
Structure-activity studies on GIP and GIP analogs have identified the N-terminus 
and central region of the GIP molecule as being critical for biological activity. 
Truncated forms of GIP, including GIP1-39 (Sandberg et al., 1986) and GIP1-30 
(Wheeler et al., 1995) retain a high degree of biological activity. However, fairly 
modest changes to Tyr1-Ala2 at the N-terminus can drastically reduce bioactivity 
(Hinke et al., 2003). The high affinity binding region of GIP1-42 resides within the 
region Phe6-Lys30 (Gelling et al., 1997a) that is structured as an a helix in solution 
(Alana et al., 2007). 
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Figure	10	
	
Amino	acid	sequence	of	human	GIP	(Moody	et	al.,	1984).	
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d- Production and regulation 
 
Immunocytochemical (ICC) (Buffa et al., 1975) and electron microscopic 
(Buchan et al., 1978) studies on human and dog tissues demonstrated that GIP is 
produced by enteroendocrine K-cells, mainly located within the crypts and mid-zones 
of glands in the duodenum and upper jejunum. 
In human studies, total GIP levels increase up to sixfold in response to a meal  
with carbohydrates and fats being the most potent stimuli for release. Glucose, 
administered either orally or intraduodenally to humans results in rapid release of 
GIP, with levels reaching a peak within 15 to 30 minutes and returning to fasting 
values with a similar time course to circulating glucose and insulin (3 h) (Creutzfeldt 
and Ebert, 1977; Krarup et al., 1985). More specifically, it is the rate of nutrient 
absorption rather than the mere presence of nutrients in the intestine that stimulates 
GIP release, since GIP secretion is reduced in individuals with intestinal 
malabsorption syndrome or after the administration of pharmacologic agents that 
reduce nutrient absorption (Fushiki et al., 1992). Alongside the main control of GIP 
secretion by nutrient ingestion, various additional studies suggests that GIP secretion 
may be under hormonal input or also under the autonomic nervous system regulation 
(McIntosh et al., 2009). 
 
e- Secretion 
 
The intracellular mechanisms controlling GIP secretion from K-cells are poorly 
understood, but may have some similarities with that of pancreatic b-cells (Baggio 
and Drucker, 2007). Carbohydrate detection by K-cells involves the sodium-
dependent sugar uptake pathway through the intestinal Na+-coupled glucose 
transporters, particularly sodium-dependent glucose transporter 1 (SGLT1). Like b-
cells, K-cells express the glucose sensor glucokinase and purified K-cells also express 
high levels of mRNA for subunits of KATP channels (Kir6.2 and Sur1 genes) (Parker 
et al., 2009)(Figure 11). In cultured canine endocrine cells, GIP secretion was 
stimulated by glucose, potassium depolarization, a calcium ionophore, forskolin (an 
adenylyl cyclase activator to increase cAMP levels), and gastrin-releasing peptide 
(GRP) (Kieffer et al., 1994). 
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Figure	11	
	
A	 schematic	 representation	 of	 the	GIP	 secretion	machinery	 of	 the	 K-cell	 (Cho	
and	Kieffer,	2010).	
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In the study using primary intestinal crypt cultures, GIP release was potentiated by 
forskolin plus 3-isobutyl-1-methylxanthine (IBMX), which inhibits phosphodiesterase 
to increase cAMP levels, and the presence of functional KATP channels in K-cells was 
demonstrated by the findings that GIP release was triggered by tolbutamide, a 
potassium channel blocker, under basal conditions and attenuated by diazoxide, a 
potassium channel activator, in the presence of forskolin/IBMX. In that study, glucose 
(10 mmol/l) triggered GIP secretion 1.3-fold under basal conditions, but three-fold in 
the presence of forskolin/IBMX, indicating a synergistic interaction between these  
stimulatory signals. Since tolbutamide responsiveness was lost but diazoxide still 
inhibited GIP secretion in the presence of forskolin/IBMX, it appears that elevated 
cAMP brings about the closure of KATP channels in K-cells. In addition, a PKC 
activator, phorbol 12-myristate 13-acetate (PMA), increased GIP secretion from 
cultured intestinal crypt cells (Parker et al., 2009). 
 
f- Degradation and elimination 
Once released, GIP is rapidly subjected to degradation by the enzyme dipeptidyl 
peptidase IV, DPP4, which is bound to endothelial cells of blood vessels of gut and 
liver and lymphocytes (where it is designated as CD-26) or present as a soluble form 
in the circulation. The half-life of intact biologically active GIP is approximately 5 
and 7 min in type 2 diabetes patients or healthy subjects, respectively. The first two 
amino acids (Tyr and Ala) at the amino terminus of GIP are cleaved to produce N-
terminally truncated GIP, which functions as a weak antagonist of the GIPR in vitro at 
a pharmacologic concentration but does not antagonize the insulinotropic effects of 
GIP in vivo at a physiological concentration. Studies with both healthy and diabetic 
humans indicate that DPP4 is the primary enzyme responsible for inactivating GIP in 
vivo (Deacon et al., 2000). 
In terms of plasma GIP elimination, the measurement of arteriovenous differences 
in GIP levels across various organs has identified the kidney as the major site of GIP 
elimination (Deacon et al., 2001). It was shown that GIP1-42 levels are not different 
between patients with chronic renal insufficiency and normal subjects (Meier et al., 
2004). However, the concentration of the degradation product, GIP3-42, is higher in 
patients with renal insufficiency, which indicates that the kidney plays an important 
role in final elimination of GIP degradation products (Deacon, 2004). 
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2- Biological Actions of GIP 
 
a- The endocrine pancreas 
 
One of the  main  physiological roles of GIP is to increase insulin secretion from 
the pancreatic b-cells in response to intestinally absorbed nutrients. Dupré et al. 
(1973) first demonstrated that administration of GIP to normal human subjects 
resulted in a potentiation of insulin secretion and more rapid disposal of an 
intravenous glucose load. Several later studies using intravenous administration of 
antibodies against the GIP receptor (Lewis et al., 2000) or GIP receptor antagonist 
(Gault et al., 2002) have provided estimates of 50–70% for the contribution of GIP to 
the overall incretin response. 
 
Another role of GIP in the endocrine pancreas concerns the regulation of b-cell 
mass where it exerts a positive effect. GIP (and GLP-1) have been shown to protect 
rodent islets against glucolipotoxicity-induced apoptosis (Kim et al., 2005b)(The 
mechanisms involved are developed in Section of Signal transduction). 
Furthermore, GIP has also been shown to regulate the secretion of other islet 
hormones, acting on pancreatic alpha-cell function. GIP has been shown to increase 
glucagon secretion from the isolated perfused rat pancreas at glucose concentrations 
less than 5.5mM, while it increases insulin secretion at glucose levels greater than 5.5 
mM (Pederson and Brown, 1978). In addition, at supraphysiological concentrations, 
GIP increases glucagon secretion in human subjects with type 2 diabetes, which 
offsets its insulinotropic effect (Chia et al., 2009). 
	
GIP-activated pathways of signal-transduction 
 
Glucose is the primary stimulator of insulin secretion. Following its entry into the 
b-cell, glucose is metabolized by glycolysis and mitochondrial oxidation. The 
resulting increase in the ATP/ADP ratio causes closure of ATP-sensitive K+(KATP) 
channels, membrane depolarization, activation of voltage-dependent Ca2+ channels 
(VDCCs) and increases in intracellular Ca2+, followed by insulin-granule exocytosis 
(Ashcroft and Rorsman, 2004). This is followed by membrane repolarization 
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mediated by voltage-dependent K+ (KV) (MacDonald and Wheeler, 2003) and Ca2+-
sensitive K (KCa) channels. The incretin hormones act by potentiating membrane 
depolarization and increases in intracellular Ca2+ levels, in addition to exerting direct 
effects on the exocytotic machinery (MacDonald et al., 2002)(Figure 12). 
 
GIP has been shown to stimulate adenylate cyclase (AC) resulting in localized 
increases in cAMP. Increased b-cell cyclic AMP activates both protein kinase A 
(PKA)-dependent and -independent events involving the cAMP-specific guanine 
nucleotide exchange factor (GEF) II/exchange protein directly activated by cAMP 
(EPAC) 2 (Seino and Shibasaki, 2005)( Figure 12). 
 
Other GIP-activated signaling pathways contribute to the stimulation of 
insulin secretion. GIP receptors couple functionally to an islet Ca2+-independent 
phospholipase A2 (iPLA2) both through Gbg  dimer activated and cAMP-mediated 
pathways, resulting in increased arachidonic acid production (Ehses et al., 2001) 
(Figure 12). The importance of such pathways in b-cell function is supported by 
studies showing that inhibition (Song et al., 2005) or siRNA suppression (Bao et al., 
2006a) of iPLA2 in INS-1 b-cells reduced insulin secretion. Additionally, iPLA2 
knockout mice exhibit greater glucose intolerance than wild type mice on a high fat 
diet (Bao et al., 2006b).  
 
Alongside its role in insulin secretion, GIP stimulates insulin gene 
transcription and proinsulin biosynthesis (Drucker, 2007) and also increases 
expression of enzymes involved in glucose uptake and metabolism (Doyle and Egan, 
2007). GIP potentiated glucose-induced INS-1 cell proliferation and it activates the 
MAP kinase or ERK kinase-Extracellular signal-Regulated Kinase 1/2 (MEK1/2 
ERK1/2) and MKK3/6-p38 mitogen-activated protein kinase (MAPK) modules, as 
well as the PI3Kinase/PKB pathway associated with mitogenesis. In INS-1 b-cells 
and CHO-K1 cells expressing the GIP-R, GIP activated Mek1/2 and ERK1/2, through 
phosphorylation (Ehses et al., 2003; Ehses et al., 2002; Trumper et al., 2002; Trumper 
et al., 2001). 
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Figure	12	
	
Representation	of	the	main	signaling	pathways	by	which	glucose	and	GIP	
are	proposed	to	stimulate	insulin	secretion	
	
cAMP	=	Cyclic	AMP;	PKA	=	Protein	kinase	A;	GEFII	=	Guanine	nucleotide	exchange	factor	II;	
Pic	 =	 Piccolo;	 Rim2	 =	 Regulating	 synaptic	 membrane	 exocytosis	 2;	 Rab2	 (member	 RAS	
oncogene	 family);	 PLA2	 =	 Ca2+-independent	 phospholipase	 A2;	 KATP	 =	 ATP-dependent	 K+	
channel;	 CaV	 =	 Voltage-dependent	 Ca2+	 channel;	 KV	 =	 Voltage-dependent	 K+	 channel	
(McIntosh	et	al.,	2009).	
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Downstream, GIP-activation results in increased phosphorylation of substrates 
of ERK1/2 (Elk-1; p90 RSK), p38 MAPK (ATF-2) (Ehses et al., 2002) and PKB 
(p70S6K, Foxo1, glycogen synthase kinase (GSK) 3b) (Kim et al., 2005b).  
 
As already mentioned in the biological actions section, GIP exerts powerful 
pro-survival effects on b-cells. Under apoptotic conditions, GIP reduces activation of 
caspase-3 and DNA fragmentation. These anti-apoptotic effects are associated with 
activation of the Mek1/2-Erk1/2 module, although this pathway may make a 
relatively small contribution to the overall response, and a cAMP-dependent reduction 
in p38 MAPK phosphorylation may be more important (Ehses et al., 2003; Trumper 
et al., 2002).  
 
Regulation of apoptosis by GIP also occurs at the level of gene expression. 
GIP stimulates expression of the anti-apoptotic bcl-2 gene in b-cells through a PKA-
mediated pathway involving dephosphorylation of AMP-activated protein kinase 
(AMPK), increased nuclear entry of cAMP-responsive CREB coactivator 2 (TORC2) 
and phosphorylation of cAMP response element binding protein (CREB) (Kim et al., 
2008). It is likely that expression of the bclXL and bclW genes are also increased. 
PKB/Akt is also a major target of GIP (Kim et al., 2005a; Kim et al., 2005b) 
(Trumper et al., 2002; Trumper et al., 2001) and its activation induces 
phosphorylation and nuclear exclusion of the transcription factor Foxo1. Since 
unphosphorylated Foxo1 is required for expression of the pro-apoptotic protein bax, 
this results in a reduction in Bax levels. In vivo, administration of GIP over 4 weeks 
to the VDF Zucker rat resulted in reduced islet apoptosis and similar reciprocal effects 
on Bcl-2 and Bax to those observed in vitro (Kim et al., 2005b).  
 
b- Adipose tissue 
 
An initial clue regarding the effect of GIP on adipocytes came in the early 1980s 
from an experiment showing that GIP, in the presence of insulin, induces fatty acid 
(FA) incorporation into rat epididymal fats (Beck and Max, 1983). Later GIPR was 
shown to be expressed in adipose tissues (Yip et al., 1998).   
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GIP was shown to stimulate fatty acid synthesis from acetate in adipose tissue 
explants (Oben et al., 1991), as well as increasing uptake and incorporation of glucose 
into lipids (Hauner et al., 1988). In humans, triglycerides originating from ingested fat 
are the main source of accumulated adipose-tissue triglycerides. Lipoprotein lipase 
(LPL) mediates the hydrolysis of circulating triglycerides into free fatty acids (FFA) 
ready for uptake and storage in adipocytes. GIP enhanced the activity of LPL in pre-
adipocytes and mature adipocytes (Kim et al., 2007; Knapper et al., 1995) in addition 
to enhancing FA incorporation into adipose tissue via insulin-dependent pathway 
(Beck and Max, 1983). 
 
GIP also stimulates lipolysis. This opposite function is supposed to be active in 
fasting conditions. The pancreatic b cell is sensitive to circulating FFA. In their 
absence, b cells become insensitive to glucose stimulation (McGarry, 2002). In vitro 
studies showed that, in the absence of insulin, GIP stimulates adipocyte TG 
hydrolysis through PKA activation. GIP’s lipolytic action on differentiated 3T3-L1 
cells is inhibited by insulin (McIntosh et al., 1999). These results suggest that GIP 
primes b cells during fasting by releasing adipocytes FFA into the circulation. 
Following nutrient ingestion, GIP stimulates insulin secretion and the elevated insulin 
levels inhibit GIP’s lipolytic action; the two hormones act in synergy to stimulate 
lipogenesis. An alternative interpretation is that the increased FFAs produced in 
response to GIP-induced lipolysis are re-esterified, thus contributing to lipogenesis. 
Getty-Kaushik et al. (2006) showed that GIP-stimulated increases in glycerol were 
accompanied by decreased FFA in perifused adipocytes. They interpreted these 
responses as reflecting GIP-induced re-esterification from exess FFA. A similar 
response was recently reported in humans, with GIP infusion resulting in small 
increases in adipose tissue FFA re-esterification (Asmar et al., 2010). 
 
GIP might also have long-term effects on lipid metabolism, as synthesis of 
pancreatic lipase and colipase were both stimulated by GIP (Duan and Erlanson-
Albertsson, 1992), an effect that should increase efficiency of lipid uptake. 
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3- Glucose-dependant Insulinotropic Polypeptide 
Receptor (GIPR) 
 
a- GIPR gene and protein sequence 
 
The GIPR belongs to the Secretin, B-family of the seven transmembrane G-
protein-coupled receptor family that includes, among others, the receptors for 
secretin, glucagon, GLP-1, GLP-2, VIP, GRH, and PACAP. Two forms of this 
receptor have been found, which differ by the insertion of a 27 amino acid segment in 
the juxta-membrane domain of the cytoplasmic tail. The shortest form consists of 446 
amino acids (Figure 13). The longest form of the receptor may represent a cDNA 
generated from a partially spliced pre-mRNA since the extra 81 bp sequence is 
flanked by canonical splicing signals. Whether the longer form is actually expressed 
as a functional receptor in human cells is not known. However, authors’ data on GIPR 
binding indicate that both forms are indistinguishable in binding affinity and coupling 
to intracellular second messengers (Gremlich et al., 1995). 
 
The human receptor gene is located on chromosome 19q13.3 (Gremlich et al., 
1995) and contains 14 exons and 12 introns, with a protein coding region of 12.5 kb 
(Yamada et al., 1995). The promoter regions of GIP-R genes have been partially 
characterized. Human promoter lacks TATA boxes and is rich in GC. Analysis of a 
350 bp region upstream of the human GIPR gene revealed six consensus sequences 
for Sp1 transcription factors, that can functionally bind Sp1 and Sp3 (Baldacchino et 
al., 2005).  
 
	
b- Expression on cell surface 
 
Like many family B GPCRs, GIP-R possess a large extracellular N-terminus (NT) 
with multiple consensus sites for Asn-linked (N)-glycosylation. N-glycosylation and 
receptor oligomerization are co-translational processes that are thought to regulate the 
exit of functional GPCRs from the ER and their maintenance at the plasma 
membrane. Whitaker et al. (2012) showed that each of these Asn residues is 
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glycosylated when human receptor is expressed in Chinese hamster ovary cells N-
glycosylation enhanced cell surface expression and function. It mainly enhances 
receptor half-life by reducing degradation in the endoplasmic reticulum. 
N-glycosylation is also required for expression of the GIP receptor at the 
plasma membrane and efficient GIP potentiation of glucose-induced insulin secretion 
from the INS-1 pancreatic b-cell line. Functional expression of a GIP receptor mutant 
lacking N-glycosylation is rescued by co-expressed wild type GLP1 receptor, which, 
together with data obtained using Bioluminescence Resonance Energy Transfer, 
suggests formation of a GIP-GLP1 receptor heteromer (Whitaker et al., 2012). 
.  
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Figure	13	
	
serpentine	representation	of	GIP	receptor	(Yaqub	et	al.,	2010)	
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c- Ligand binding 
 
Chimeric GIP–GLP-1 receptor studies demonstrated that the NT of the GIP 
receptor constitutes a major part of the ligand-binding domain, and the first 
transmembrane (TM) domain is important for receptor activation (Gelling et al., 
1997b). The crystal structure of a complex of the human GIP receptor extracellular 
domain bound to GIP1–42 has been reported (Parthier et al., 2007). GIP binds in an 
a-helical conformation, with the C-terminal region binding in a surface groove of the 
receptor, largely through hydrophobic interactions. The N-terminus of GIP remains 
free to interact with other parts of the receptor. Site-directed mutagenesis data of 
transmembrane domain amino acids of the GIPR together with three-dimensional 
modeling strongly suggest that N-terminal part of GIP binds to a binding cavity and 
activation cavity located within transmembrane domains of the GIPR (Yaqub et al., 
2010). Mutation of threonine to proline at position 340 in the sixth TM domain was 
reported to produce a constitutively active receptor with respect to cAMP production 
(Tseng and Lin, 1997). 
 
d- GIPR desensitization and internalization 
 
In an attempt to identify C-terminal residues implicated in the down regulation 
and the homologues desensitization process of GIP-R, a research group constructed 
five truncated GIP-Rs (T395, T399, T420, T431, T455) to delete consecutive serines 
from the carboxyl end. Down-regulation and desensitization was assessed by 
measuring the receptor number and the ability of agonist-induced cAMP or [Ca2+] 
generation after pre-exposure to 10-7 M GIP for 24 h. The wild-type (WT) and T421, 
T431, T455 mutant GIP-Rs are maximally down-regulated by GIP pre-incubation, 
whereas T399 mutant does not, indicating that the sequence between amino acids 399 
and 420 is critical for this process. Mutation analysis of this area by alanine scanning 
mutagenesis reveals two critical residues: serine 406 and cysteine 411. Replacement 
of serine 406 with arginine (S406R) or alanine (S406A) partly attenuates agonist-
induced down-regulation and desensitization. In contrast, mutation of the cysteine 411 
to glycine (C411G) or alanine (C411A) markedly attenuates both processes. Mutant 
SCRG, in which both serine 406 and cysteine 411 are mutated, behaves similar to 
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C411G or C4111A. The data suggest that chronic desensitization and down-regulation 
of the GIPR may be mediated by similar mechanisms involving C-terminal Ser and 
Thr and that the cysteine in the carboxyl terminus plays an essential role in regulating 
both processes (Tseng and Zhang, 1998). 
 
In a similar approach, site-directed mutagenesis was used to construct truncated 
GIP receptors to study the importance of the carboxyl-terminal tail (CT) in receptor 
internalization, especially serine residues that are usually phosphorylated prior GPCR 
internalization (see GPCR regulation section). Internalization rates were determined 
by measuring cell associated radioactivity using 125I-GIP added on cells stimulated for 
different times with cold GIP. Truncation by 30 or more amino acids, mutation of 
serines 426/427, singly or combined, or complete CT serine knockout all reduced 
receptor internalization rate. Therefore, serines 426 and 427 are important for 
regulating rate of GIP-R internalization (Wheeler et al., 1999). 
 
The implication of 2 important factors in GPCR internalization was also 
investigated in the GIP-R internalization: b-arrestin and GRK-2.  
To determine whether GRK-2 or b-arrestin-1 influence GIP-R internalization, 
agonist-induced receptor internalization was evaluated in L293-GIPR cells 
overexpressing GRK-2 or b-arrestin-1. This time, GIPR internalization was measured 
as the percentage of 125I-GIP resistant to an acid wash after a determined time of 
stimulation. The extent of internalization was not affected by co-expression of GRK-2 
or b-arrestin-1. However, the overexpression of one or both of these proteins 
significantly attenuated GIP induced cAMP and insulin release from L293-GIPR cells 
(Tseng and Zhang, 2000). 
More recently, contradictory results were reported about interaction of GRK-2 
with GIPR. Indeed, recruitment assay using FRET could not detect any binding of 
GRK2 to the GIPR in HEK-293 cells transiently transfected with the receptor. This 
observation was also witnessed for the recruitment of the b-arrestin-2. Results are 
done in comparison to HEK-293 cells transiently expression the GLP-1 receptor that 
shows a plausible interaction with each of the co-expressed proteins (Al-Sabah et al., 
2014). 
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4- Pathophysiology of GIP 
 
a- Diabetes 
 
Studies on the relative insulin responses to oral and intravenous glucose in normal 
subjects and Type 2 Diabetes Mellitus (T2DM) patients shows that the incretin effect 
is greatly reduced in the diabetic group (Nauck et al., 1986). The decrease in incretin 
effect has subsequently been attributed to two major defects:  
1- reduced circulating levels of intact GLP-1 (Toft-Nielsen et al., 2001) and  
2- defective b-cell responsiveness to GIP (Jones et al., 1987), whereas 
responsiveness to GLP-1 is relatively intact (Nauck et al., 1986).  
The underlying causes of GIP resistance are unknown, but could include reduced 
receptor cell surface expression resulting from altered gene transcription/translation or 
receptor down-regulation, faulty GIP-R processing or receptor trafficking, reduced 
hormone-receptor interaction due to mutations, or defective intracellular signaling 
(Holst et al., 1997). 
 
In humans, the defective response to GIP appears to involve largely the late phase 
of insulin secretion (Vilsboll et al., 2002). In rats, the VDF model (Vancouver 
diabetic fatty Zucker rats, pre-obese (fa/fa)) demonstrates a loss of normal glucose 
threshold for GIP action, resulting in potentiation of insulin secretion under fasting 
conditions and subsequently the obese rats become insulin resistant (Chan et al., 
1985). In this VDF rat, that exhibits hyperglycemia, it has been found that GIP-R 
mRNA and protein levels are reduced (Lynn et al., 2001). The reduction in GIP-R 
expression was also observed in a 90% pancreatectomized Sprague Dawley rat model, 
that also exhibits chronic hyperglycemia (Xu et al., 2007). Elevating glucose was 
found to induce down-regulation of the GIP-R in vivo (Lynn et al., 2003) (Zhou et al., 
2007), as well as expression in b-cell lines, by a pathway that involved down-
regulation of the transcription factor PPARa  (Lynn et al., 2003). Inversely, 
normalization of glycaemia with phlorizin treatment reversed GIP-R down-regulation 
in VDF (Piteau et al., 2007) and 90% pancreatectomized rats (Xu et al., 2007), 
suggesting that hyperglycemia was a major factor involved. 
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b- Obesity 
 
Continuously with the actions of GIP in adipose tissue, studies on knock-out mice 
point even further to a role of GIP in fat accumulation and obesity. Although mice 
chronically fed on high-fat diets show an increase in bodyweight as well as visceral 
and subcutaneous fat mass, such bodyweight gain and fat accumulation was not 
observed in GIPR-deficient mice fed the same high-fat diet. GIPR-/- mice fed on high-
fat diets showed higher energy expenditure with a reduction of oxygen consumption 
and respiratory quotient during the light phase, the latter indicating that fat is utilized 
as the preferred energy substrate (Miyawaki et al., 2002). In addition, GIPR deficient 
mice show increased adiponectin secretion, which promotes fat oxidation in muscle 
and increases the respirator quotient (Naitoh et al., 2008). Genetic ablation of GIPR in 
diabetic ob/ob mice prevents obesity by increasing energy expenditure, and improves 
insulin sensitivity and glucose tolerance without seriously affecting insulin secretion 
(Miyawaki et al., 2002).  
 
These observations were reproduced in high-fat fed mice and obese ob/ob mice 
treated with a GIPR antagonist, (Pro3)GIP (Gault et al., 2007; Irwin et al., 2007), and 
in mice lacking GIP-secreting K cells (Althage et al., 2008), establishing the critical 
role of GIP in fat accumulation. Transgenic rescue of GIPR in GIPR-deficient mice 
suggested that, in collaboration with insulin, GIP facilitates fat accumulation 
(Ugleholdt et al., 2011). 
 
A recent report appeared to be inconsistent with these lines of evidence. It showed 
that GIP-overexpressing mice resulted in reduced diet-induced obesity while they 
showed enhanced b cell function and improved glucose tolerance (Kim et al., 2012). 
As interpretation of this result, it was speculated that overexpression of hypothalamic 
GIP decreased energy intake, resulting in reduced adiposity. Another study performed 
on larger mammals also contradicts the implication of GIP in weight gain. It showed 
that transgenic pigs expressing dominant-negative GIPR in pancreatic islets, while 
exhibiting diabetes characteristic symptoms like significantly reduced GIP 
insluinotropic activity and b cell proliferation, did not present any deviation in body-
weight gain compared with controls (Renner et al., 2010).  
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c- GIP analogues: therapeutic potential 
 
Until recently, and based on the lack of GIP effect in some patients with type 2 
diabetes and presumed obesogenic effect of GIP observed in animal models, the use 
of GIPR agonists was avoided in the treatment of type 2 diabetes. Instead, current 
therapeutic strategies have been focused on the use of agonists of the receptor of 
GLP-1, which has analogous actions on the pancreatic b cell as GIP. 
 
A collection of evidences has appeared and supports the attempts to use GIP in 
treatment strategies of metabolic diseases. 
 
Although GIP insulinotropic effect is markedly decreased, its secretion is normal 
or higher in patients with type 2 diabetes compared with healthy control subjects. 
Therefore, alleviating GIP resistance of pancreatic b cells may be a therapeutic option 
to treat type 2 diabetes. In this regard, it is important to mention that GIP resistance 
associated with type 2 diabetes might be reversible by decreasing hyperglycemia. 
Indeed, in the VDF Zucker rat, a model of type 2 diabetes, reducing hyperglycemia 
with phloridzin or injection of a DPP-4 inhibitor, restored GIP sensitivity of 
pancreatic b cells (Piteau et al., 2007). In addition, in patients with type 2 diabetes, 1-
month glyburide (a sulfonylurea) treatment reduced blood glucose levels and 
increased GIP sensitivity  (Meneilly et al., 1993).  
 
On the other hand, DPP-IV inhibitors increase endogenous levels of both GLP-1 
and GIP and serve to improve glucose control and insulin sensitivity without weight 
gain. More recent evidence shows that overexpression of GIP leads to improved body 
weight and glycemic control, contradicting the notion that GIP is obesogenic (Kim et 
al., 2012). Furthermore, genetic impairment of GIP signaling at pancreatic b cells in 
pigs demonstrated a biological alteration comparable to diabetes in humans, without 
any apparent change in body weight (Renner et al., 2010). 
 
Altogether, these results encouraged re-using GIPR as a therapeutic target. 
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d- GIP receptor agonists use in therapy 
 
Cleavage of GIP by DPP-IV ablates b-cell effects of GIP by removal of the N-
terminal dipeptide Tyr1-Ala2. Several different approaches to rendering GIP resistant 
to DPP-IV and improving its stability have been taken. Among these are:  
 
1. Chemical modification of the N-terminus, as in N-Glucitol-, N-acetyl- and 
N-Pyroglutamyl-GIP (Green et al., 2004) (O'Harte et al., 2002; O'Harte et al., 1999).  
2. Substitutions at amino acid position 2 with D-Ala (Hinke et al., 2002), 
Phospho-Ser (Hinke et al., 2004) Gly (Gault et al., 2003) at position 3 with Glu or Pro 
(Gault et al., 2002).  
3. Acetylation with long-chain or short-chain fatty acids (Green et al., 2004; 
Irwin et al., 2005).  
4. Introduction of palmitate residues attached to intrinsic lysine residues at 
positions 16 or 37 (Irwin et al., 2005).  
5. Peptides containing linkers that enhance helix formation in the C-terminal 
(19–30) portion of GIP (Manhart et al., 2003).  
 
Although many modifications have resulted in inactive peptides, DPP-IV 
resistant forms, including D-Ala2-GIP and N-acetyl-GIP have enhanced biological 
activity and are effective in improving glucose tolerance in diabetic rodents. Analogs 
with extended half-lives, resulting from the insertion of albumin-binding palmitate 
residues may also demonstrate extended actions. However, despite their potential, 
none of these analogs have been shown to improve glucose tolerance in humans. 
 
Two recent innovative discoveries pushed even further towards the interest of 
using GIP in treating metabolic diseases. 
One strategy to enhance the efficacy of GLP-1 agonists relies on its co-
administration with other endogenous hormones (Muller et al., 2012). By trying this 
concept, acute co-infusion of GLP-1 and GIP in diabetic patients resulted in an 
enhanced first phase insulin secretory response (Mentis et al., 2011). Due to the 
complexity of developing a medicine based on co-administrating two hormones, 
Finan et al. (2013) tried a combination approach that consists in using a single 
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molecule with balanced mixed agonism towards the receptors of the two incretin 
hormones GLP-1 and GIP in the aim of maximizing glycemic outcomes. 
The group of scientists reported the discovery of a synthetic peptide with dual 
incretin GLP-1/GIP co-agonists with balanced activity at each constitutive receptor 
and optimized pharmacokinetics. The co-agonists potently reversed metabolic 
syndrome through synergistic pharmacology, including an enhanced effect on 
adiposity, hyperglycemia and dyslipidemia in rodent models of obesity, insulin 
resistance, and type 2 diabetes, compared to best-in-class selective GLP-1 agonists. 
GLP-1/GIP co-agonists improved glucose homeostasis through a potent effect on 
acute glucose-stimulated insulin release in rodents. The group also showed that this 
insulinotropic effect translates to cynomolgus monkeys and humans, significantly 
resulting in improved levels of glycosylated hemoglobin A1c (HbA1c) in type 2 
diabetic patients. Moreover, unlike GLP-1 mono-agonist therapy, the co-agonists did 
not induce adverse gastrointestinal effects in humans. 
 
Very recently, the same crew reported the discovery of a peptide with 
balanced high potency at the three different metabolically relevant receptor targets: 
GIPR, GLP-1R and GcgR (glucagon receptor). The tri-agonist showed greater 
metabolic efficacy in rodent models of obesity, insulin resistance, and type 2 diabetes, 
than the dual incretin co-agonist previously obtained. Moreover, a similar effect on 
body weight loss was achieved with the tri-agonist compared to results with the co-
agonist GLP-1/GIP, but at a much lower dose of the tri-agonist (Finan et al., 2015).  
 
Collectively, the discovery and validation of these incretin peptides provide a 
fresh perspective on GIP pharmacology for treating metabolic diseases and offers a 
new direction for enhancing the efficacy of selective incretin agonists to generate 
better drug candidates for the treatment of type 2 diabetes, obesity, and related 
metabolic disorders. 
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Introduction to Article I 
 
GIPR signaling is involved in many physiological and pathological organism 
functions. Although a restricted amount of data is available on GIPR internalization 
and trafficking, decrypting the molecular mechanisms underlying these processes is 
crucial to clarify our understanding of GIPR regulation. For this context, our group 
launched a work aimed at studying these mechanisms and also to analyze the 
pharmacological properties of a functionally improved GIP peptide which 
preliminarily appeared to be a biased agonist towards receptor internalization.  
 
We conducted our study in HEK-293T cells, the most widely used cellular 
model in GPCR experimental biology. The specific cell line variant adapted to our 
study, FlpInTM HEK-GIPR, was established by permanently overexpressing the GIPR 
in HEK-293T cells.  
 
Triggered on the cell surface towards the intracellular compartment, GIPR 
internalization is visually traced by confocal microscopic observations which allow 
live time scanning as well as high resolution and precise imaging. This technique 
requires the use of appropriate tools. Therefore, fluorescently tagged GIP and GIPR, 
AlexaF647-GIP and GIPR-GFP respectively, were used. On the other hand, many 
other fluorescently tagged molecules, known to be engaged in the general process of 
GPCR internalization, or fluorescent dyes that specifically stain intracellular 
compartments were also used. 
 
On the receptor side, to test the involvement of the C terminal region of GIPR, 
we constructed receptors truncated at different residues that could be potential 
phosphorylation candidates. Furthermore, the plausible recruitment of the b-arrestin 
adaptor protein was tested by BRET as well as by confocal microscopy. BRET is a 
biophysical technique that enables the detection of protein proximity in a more 
precise scale (Appendix contains detailed information). 
 
In a second time, we intended to characterize N-Acetyl-GIP behavior towards 
internalization. A work in which our team previously contributed, N-terminal region 
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of GIP was demonstrated to be essential for its biological activity. On the other hand, 
being more resistant to enzymatic degradation, the N-Acetyl-GIP analogue possesses 
a longer life time, thus is functionally improved compared to GIP. Therefore, before 
proceeding to the characterization of the internalization profile, pharmacological 
properties of N-Acetyl- GIP were first verified. GIP-mediated cAMP production was 
evaluated by BRET technique which can be adjusted to detect meaningful 
conformational changes of second messenger biosensors. Finally, the potential to 
stimulate insulin release was compared between GIP and N-Acetyl-GIP in the 
cultured b-cell line MIN-6-B1. 
 
The results of this work are presented and discussed in the article below, 
published in “Molecular and Cellular Endocrinology” journal under the title: 
“Internalization and Desensitization of the Human Glucose-Dependent 
Insulinotropic Receptor is Affected by N-terminal Acetylation of the Agonist”. 
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a b s t r a c t
How incretins regulate presence of their receptors at the cell surface and their activity is of paramount
importance for the development of therapeutic strategies targeting these receptors. We have studied
internalization of the human Glucose-Insulinotropic Polypeptide receptor (GIPR). GIP stimulated rapid
robust internalization of the GIPR, the major part being directed to lysosomes. GIPR internalization
involved mainly clathrin-coated pits, AP-2 and dynamin. However, neither GIPR C-terminal region nor b-
arrestin1/2 was required. Finally, N-acetyl-GIP recognized as a dipeptidyl-IV resistant analogue, fully
stimulated cAMP production with a ~15-fold lower potency than GIP and weakly stimulated GIPR
internalization and desensitization of cAMP response. Furthermore, docking N-acetyl-GIP in the binding
site of modeled GIPR showed slighter interactions with residues of helices 6 and 7 of GIPR compared to
GIP. Therefore, incomplete or partial activity of N-acetyl-GIP on signaling involved in GIPR desensitiza-
tion and internalization contributes to the enhanced incretin activity of this peptide.
© 2015 Published by Elsevier Ireland Ltd.
1. Introduction
Glucose-dependent insulinotropic polypeptide (GIP) is released
by the entero-endocrine K cells from the proximal duodenum
(Jornvall et al., 1981; Moody et al., 1984). GIP stimulates insulin
secretion from pancreatic b-cells after ingestion of nutrients. GIP,
together with Glucagon-like peptide 1 (GLP1), contributes for 50 to
70 percent to post-prandial insulin secretion (Baggio and Drucker,
2007). GIP further enhances its glucose-lowering effects by the
inhibition of hepatic glucose production and the stimulation of
proinsulin gene transcription and translation. Moreover, GIP is
known to play a role in lipid metabolism and fat deposition. Indeed,
GIP increases lipoprotein lipase activity, stimulates lipogenesis,
enhances fatty acid and glucose uptake in adipocytes (Baggio and
Drucker, 2007). GIP exerts its physiological functions through
binding to GIP receptor (GIPR) which belongs to subfamily-2 of G-
protein-coupled receptors (GPCR) (Gremlich et al., 1995; Bockaert
and Pin, 1999). GIPR triggers Gs-mediated cAMP production and
subsequent signaling cascades (Baggio and Drucker, 2007).
Until very recently, one major argument against the develop-
ment of a therapeutic strategy using GIP analogues to treat diabetes
2 was raised by the impairment of GIP-dependent insulin secretion
in diabetic type II patients, with an almost complete loss of
ampliﬁcation of the second phase of insulin secretion (Nauck et al.,
1993; Younan and Rashed, 2007; Kieffer et al., 1995; Vilsboll et al.,
2002; Lynn et al., 2001). This detrimental effect was found to result
Abbreviations: GIP, glucose-dependent insulinotropic polypeptide; GIPR,
glucose-dependent insulinotropic polypeptide receptor; BRET, Bioluminescence
Resonance Energy Transfer.
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from down-regulation of GIPR presence in pancreatic b-cells
exposed to diabetic milieu. Conversely, recent reports indicated
that glycemia normalization in diabetic animals and humans
signiﬁcantly improves GIP-stimulated insulin secretion (Piteau
et al., 2007; Hojberg et al., 2009). Moreover, very promising pre-
clinical data were obtained in rodents, monkeys and humans
showing that a single peptidic molecule having dual agonist ac-
tivity at GIP and GLP1 receptors exhibits enhanced insulinotropic
and anti-hyperglycemic efﬁcacy relative to GLP1 alone (Finan et al.,
2013). As a consequence, a renewed interest in developing phar-
macological strategies to target GIPR has emerged (Finan et al.,
2013; Irwin et al., 2010; Tatarkiewicz et al., 2013).
So far, regulation of GIPR presence at the cell surface remains
poorly understood. First, although exposure of pancreatic islet cells
to GIP has been shown to produce homologous desensitization of
the GIP receptor, the impact of GIPR internalization and trafﬁcking
on GIPR-dependent response and the underlying molecular
mechanisms have not been investigated in detail yet (Tseng et al.,
1996; Hinke et al., 2000). Recently, it has been reported that in
3T3-L1 adipocytes, GIPR constitutively internalizes and recycles to
the cell surface and that GIP induces a down-regulation of plasma
membrane GIPR by slowing GIPR recycling without affecting ki-
netics of GIPR internalization (Mohammad et al., 2014). Accord-
ingly, GIPR does not conform to the typical behavior of G-protein
coupled receptors which has been essentially studied for members
of rhodopsin-related GPCRs (sub-family 1) and much less
frequently for members of sub-family 2 of GPCRs such as the GIPR
(Marchese et al., 2008; Ferguson, 2001).
In most cases, agonist-induced internalization of GPCRs starts
with the action of GPCRs kinases (GRKs) that selectively phos-
phorylate agonist-activated receptors. Phosphorylation of the re-
ceptors and subsequent binding of arrestins terminate the G-
protein-mediated signal of the membrane receptors. Arrestin-
bound membrane receptors are then rapidly targeted to the
clathrin-coated pits, thereby promoting their internalization
(Ferguson, 2001; Traub, 2009). Furthermore, it has been recognized
that in addition to its role in desensitization of G-protein mediated
signal and cell responsiveness, b-arrestins trigger signaling path-
ways independently of G-protein coupling (Sorkin and von
Zastrow, 2009). Importantly, pharmacological agents, named
“biased ligands”, have been discovered, which activate differen-
tially G-protein-dependent and arrestin-dependent signaling
pathways (Rajagopal et al., 2010).
In this context, the aim of this study was to investigate inter-
nalization of GIPR following agonist exposure, as well as cellular
and molecular underlying mechanisms. Besides, this study enabled
the identiﬁcation of a GIP analogue, N-acetyl-GIP, so far recognized
as a dipeptidyl-IV resistant GIP analogue, which fully stimulated
cAMP production but with a ~15-fold lower potency than GIP.
Furthermore, N-acetyl-GIP only weakly induced internalization of
the GIPR and desensitization of GIPR-dependent cAMP response.
2. Materials and methods
2.1. Materials
Fragment 1e30 of human GIP (termed GIP) was synthesized as
previously described (Yaqub et al., 2010). N-acetyl-GIP(1e30)
(termed N-acetyl-GIP) was from Millegen (Toulouse, France). Alexa
Fluor 647 labeled-GIP (termed AlexaF647-GIP) and Alexa Fluor 647
labeled-acetyl-GIP(1e30) (termed AlexaF647-N-acetyl-GIP) were
obtained according to the procedure described (Yaqub et al., 2010).
In both peptides, Alexa Fluor 647 moiety was coupled to the pep-
tide and coupling products were HPLC puriﬁed. Peak corresponding
to peptide in which Alexa Fluor 647 was attached to Lysine 30, as
determined by Maldi Tof analysis, was selected (Yaqub et al., 2010).
Both ﬂuorescent probes were highly speciﬁc of GIPR (less than 5%
nonspeciﬁc labeling in the present of 100-fold excess of unlabeled
peptide). Radio-labeled GIP was obtained by radio-iodination of
Phe1-GIP(1e30) with 125I-Na (Perkin Elmer, France) in the presence
of chloramine T and was HPLC puriﬁed on a C-18 column. 125I-Phe1-
GIP bound to a single class of GIPR binding sites from HEK 293T or
Flp-InTMGIPR-293 cells with a dissociation constant, Kd of
75.7 ± 8.4 nM. Sequence encoding short variant of the human GIPR
was derived from a plasmid kindly given by Professor Bernard
Thorens (Lausanne, Switzerland). Chemicals were from the
following sources: dynasore from Calbiochem, Pitstop2 from
Abcam, Filipin and H89 from SigmaeAldrich, LysoTracker® Red
from Invitrogen.
The cDNAs encoding GIPR, green ﬂuorescent protein (GFP)
tagged GIPRs and Renilla luciferase (Rluc) fused GIPR were gener-
ated by subcloning respectively the GIPR cDNA in pcDNA5/FTR
(Invitrogen), pEGFP-N1 (BD biosciences clontech), pRluc-N1(h)
(Perkin Elmer). DsRed tagged Rab5, DsRed tagged Rab11, DsRed
tagged Rab7, Clathrin-LCa-eYFP and Caveoline1-GFP were obtained
from Addgene (www.addgene.org). Plasmids encoding green ﬂuo-
rescent protein (GFP) tagged b-arrestin1 (b-arrestin1 ¼ arrestin2),
yellow ﬂuorescent protein (YFP) tagged b-arrestin1, yellow ﬂuo-
rescent protein (YFP) tagged b-arrestin2 (b-arrestin2 ¼ arrestin3),
Rluc-EPAC-YFP and D44A-dynamin were generous gifts from Marc
Caron (Duke University Medical Center, Durham, USA). Green
ﬂuorescent protein (GFP) tagged b-arrestin2, kindly given by Robert
Lefkowitz (Duke University Medical Center, Durham, USA), was
subcloned in pcDNA5/FRT. Plasmid encoding YFP tagged b-adaptin2
was given by Professor Michel Bouvier (Montreal University, Can-
ada). All truncated receptor cDNAs at C-terminal tail (TR414, TR432
and TR452) and the GFP tagged GIPR constructs were obtained by
insertion of a stop codon or linker sequence, respectively. All con-
structs were sequenced before use.
2.2. Cell lines and transfections
HEK 293 cells stably expressing the GIPR (Flp-lnTM HEK-GIPR)
and the CCK2R (Flp-lnTM HEK-CCK2R) were obtained using the
Flp-InTM system (Invitrogen). Alternatively, HEK293T transiently
expressing the GIPR were used. All HEK293 derived cell lines cells
were maintained in Dulbecco's Modiﬁed Eagle's medium supple-
mented with 10% of fetal bovine serum (FBS), in a humidiﬁed at-
mosphere at 95% air and 5% CO2. MIN-6-B1clone (kindly given by
Doctor Jun-Ichi Miyazaki) was maintained in culture in Dulbecco's
Modiﬁed Eagle's medium 25 mM glucose supplemented with 15%
of FBS, 71 mM 2-mercaptoethenol. Transfections were performed
using polyethylenimine (PEI) transfection reagent (1 mg/mL, pH
7.4) (Polyplus). Plasmids were diluted in DMEM without FBS (ratio
DNA (mg)/PEI (mL) 1:3). The mixture was mixed for 15 s on a vortex,
incubated for 15 min at room temperature and then deposited on
the cells.
2.3. Confocal ﬂuorescence microscopy
Cells were plated onto poly-L-lysine (SigmaeAldrich) coated 4-
wells Lab-Tek chambered coverglass (Nunc). After an overnight
growth, cells were transfected either with 1 mg/well of pcDNA5/FRT
containing cDNAs of interest. 24 h later, the culture medium was
replaced by D-PBS (Dulbecco's PBS1X, 1 mg/L glucose, 36 mg/L
sodium pyruvate, pH 7.4, calcium and magnesium free). Cells were
stimulated with appropriate ligands and confocal microscopy im-
ages of GFP, DsRed or Alexa Fluor 647 ﬂuorescence, were collected
by using single- or double-line excitation (respectively 488 nm,
543 nm, 633 nm) on a Zeiss Laser Scanning Microscope LSM-510 or
S. Ismail et al. / Molecular and Cellular Endocrinology 414 (2015) 202e215 203
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Zeiss Laser Scanning Microscope LSM-780 at 37 !C. Concentrations
of ﬂuorescent GIP analogues equal or above 10 nM were used in
internalization and trafﬁcking studies because confocal microscopy
and FACS did not enable detection of cell-associated ﬂuorescence at
lower concentrations. For b-arrestin1-GFP and b-arrestin2-GFP
membrane recruitment assays, time series over a 5 min period
were performed (pictures were taken every 30 s) and the decrease
of cytoplasmic ﬂuorescence was measured using the Region of in-
terest (ROI) function of LSM-510 software.
2.4. Quantiﬁcation of internalization and recycling by ﬂow
cytometry
Flp-InTMGIPR-293 cells or HEK293Tcells were plated onto poly-
L-lysine coated 24-wells plates. After an overnight growth, cells
were incubated with AlexaF647-GIP (100 nM) in PBS 0.2% for
various times (from 5 to 60min). Cells werewashed twicewith cold
PBS 0.2% BSA and acid washed (0.2 M acetic acid, 0.5 M NaCl, pH
2.5) for 10 min on ice. Cells were then washed twice with PBS 0.2%
BSA and detached for transfer to FACS tubes. Cell-associated ﬂuo-
rescence was determined using a BD FACSCalibur™ ﬂow cytometer,
with Flp-InTM 293 that do not express GIPR as a negative control.
For recycling assay, cells were incubated with 100 nM GIP in
DMEM/HEPES (20 mM) for 1 h at 37 !C to enable GIPR internali-
zation. Cells were washed 3 times with DMEM/HEPES and incu-
bated without ligand for increasing times in order to enable GIPR
recycling. GIPR at the cell surface were identiﬁed with AlexaF647-
GIP (1 mM) for 45 min at 37 !C in the presence of the internaliza-
tion inhibitor, dynasore (100 mM) added 5 min before the ligand.
2.5. BRET assays of b-arrestin recruitment and cAMP production
HEK 293T or Flp-InTMGIPR-293 cells were plated onto 10-cm
culture dishes and overnight grown. For b-arrestin recruitment
assays, cells were transfected with 0.2 mg of Rluc tagged GIPR and
10 mg of either b-arrestin1-YFP or b-arrestin2- YFP. For cAMP
measurements, Flp-InTMGIPR-293 cells were transfected with 5 mg
of Epac biosensor. Alternatively, HEK 293Tcells were co-transfected
with 5 mg of Epac biosensor and 1 mg of GIP receptors. 24 h after
transfection, cells were plated in 96-wells clear bottom plates
(Corning) at a density of 100.000 cells per well in phenol red free
DMEM 2% FBS. After an overnight incubation, the medium was
removed and replaced by calcium and magnesium free PBS. BRET
assay was initiated by adding 10 mL of coelenterazine h to the wells
(ﬁnal concentration 5 mM). After 5 min of incubation with coe-
lenterazine h, GIP, N-acetyl-GIP or Forskolin was added. Readings
started 5 min after the addition of GIP or N-acetyl-GIP. A Mithras
LB940 instrument (Berthold) that allows the sequential integration
of signals at 465e505 nm and 515e555 nmwindows andMicroWin
2000 software were used.
2.6. Receptor binding assays
Flp-InTMGIPR-293 cells grown overnight were onto 10-cm
culture dishes. 24 h later, cells were transferred to 24-well plates.
Approximately 24 h later, binding assays were performed using
125I-Phe1-GIP according to the protocol previously described in
detail (Foucaud et al., 2008). Ki for competitors were calculated
according to the equation Ki ¼ IC50/1þ[125I-Phe1-GIP]/Kd (125I-
Phe1-GIP) in which IC50 (concentration inhibiting half of speciﬁc
binding) and Kd of 125I-Phe1-GIP were calculated using the non-
linear curve ﬁtting software GraphPad Prism (San Diego, CA).
2.7. cAMP-desensitization assay
Flp-InTMGIPR-293 cells transfected with Epac biosensor and
plated in 96-well clear bottom plates were pre-stimulated at 37 !C
for increasing times by GIP (0.1 mM) or N-acetyl-GIP (1 mM) with or
without H89 (10 mM). Then, pre-stimulation was stopped by
removing the medium. GIP peptides were washed out from cells
(two times) with PBS buffer containing 0.5% BSA. cAMP production
in response to a second challenge with 1 mMGIP or 10 mMN-acetyl-
GIP was measured by BRET as indicated above. cAMP levels were
expressed as the percent of cAMP in cells which were not pre-
stimulated with peptides.
2.8. Insulin secretion from MIN-6-B1cells
Insulinoma cells were seeded on 24-wells plates (3.105 cells/
well) and let to grow for 48 h. Cells were thenwashed 3-times with
500 mL KRBH buffer pH: 7.4 (125 mM NaCl, 4.74 KCl, 1 mM CaCl2,
1.2 mM KH2PO4, 1.2 mMMgSO4, 5 mMNaHCO3, 10 mM, Hepes, 0.1%
BSA). Cells were incubated for 2 h at 37 !C in KRH buffer supple-
mented with 2.8 mM glucose. The incubation medium was dis-
carded and replaced with 500 mL buffer containing 11 mM glucose
with or without GIP or N-acetyl-GIP. Cells were let to secrete insulin
during 2 h. Supernatants were centrifuged for 5 min at 2000 rpm to
eliminate detached cells, and secreted insulin contained in super-
natants was determined using Ultrasensitive Insulin Elisa Kit
(Alpco) according to manufacturer instructions. Insulin secretion
was expressed as -fold basal value obtained in the absence of GIP
analogue.
2.9. Molecular modeling
The crystal structure of the human glucagon receptor (GCGR)
with PDB code of 4L6R was used to build the homology model of
the GIPR helical bundle using Prime 3.8 with the energy-based
method (Siu et al., 2013). The N-terminal domain of GIPR bound
to GIP with PDB code of 2QKH was docked to the helical bundle
taking into account the previously identiﬁed interactions between
the N terminal domain of GIP and the residues of the GIPR helical
bundle (Yaqub et al., 2010; Parthier et al., 2007). The docking was
done in two steps. Firstly, the ﬁrst ﬁve amino acid residues of the N
terminal domain was docked with the Induced Fit protocol, where
docking was constrained around residues known to be important
for binding from mutagenesis. Next, the remaining part of GIP
together with the N terminal domain of GIPR was assembled
manually and subjected to 500 ps minimization followed by
1000 ps of molecular simulations in implicit environment. Macro-
Model 9.9 was used for all minimizations and simulations. Images
with the molecular models were prepared with Maestro 9.9.
2.10. Statistics
All values are expressed as the mean ± standard error of the
mean (SEM). Statistical analyses of data using One- or two-way
ANOVA with Dunnett's or Turkeys's comparison test were per-
formed using GraphPad Prism version 6.0. In ﬁgures and Table 1,
signiﬁcance degrees were given as following: *0.01 < p < 0.05;
**0.001 < p < 0.01; ***p < 0.001 or ✹0.01 < p < 0.05;
✹✹0.001 < p < 0.01; ✹✹✹p < 0.001.
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3. Results
3.1. GIP receptors rapidly and abundantly internalize following GIP
stimulation
Flp-lnTM HEK-GIPR and HEK293T-GIPR cells used for studies of
internalization and trafﬁcking of GIPR were characterized prior to
their use as biological tools. As shown on Supplemental Fig. 1S,
cAMP levels measured by BRET using EPAC sensor were dose-
dependently increased upon stimulation by GIP, with half-
maximal stimulation (EC50) in the nanomolar range. Therefore,
GIPR appeared correctly coupled to adenylyl cyclase in the two cell
lines. Moreover, cAMP production measured with EPAC sensor was
in agreement with that measured using a radio-immunoassay
(Yaqub et al., 2010) thus validating BRET assay to measure cAMP.
We also characterized pharmacologically AlexaF647-GIP whichwas
used to study internalization and intracellular trafﬁcking of GIPR.
As shown on Supplemental Fig. 1S and Table 1, alexaF647-GIP
bound to Flp-lnTM HEK-GIPR cells and stimulated production of
cAMP similarly to GIP. Moreover, ﬂuorescence labeling of GIPR by
alexaF647-GIP was highly speciﬁc since FACS analysis of Flp-lnTM
HEK-GIPR cells incubated with alexaF647-GIP in the presence
1 mM unlabeled GIP revealed less than 5% of nonsaturable labeling
(not illustrated).
Confocal microscopy observations of Flp-lnTM HEK-GIPR cells
showed intense labeling of the plasma membrane immediately
after addition of AlexaF647-GIP (Fig. 1A). Then, ﬂuorescence was
relocated in numerous membrane clusters and progressively
penetrated into the cells as punctuate vesicles which formed
clusters over the incubation time. Moreover, in HEKT293 tran-
siently expressing GFP tagged GIPR, AlexaF647-GIP and GFP tagged
GIPR co-localized during internalization and intracellular traf-
ﬁcking for at least 2 h (Fig. 1B). This result establishes that inter-
nalized AlexaF647-GIP truly accounted for GIPR internalization. On
the other hand, most of AlexaF647 and GFP ﬂuorescence remained
co-localized at time 5 h, although some labeling appeared sepa-
rately and GFP ﬂuorescence intensity decreased likely because of
degradation of GFP (Fig. 1B). Therefore, based on these controls and
potential risks that GFP tag could hinder interactions between the
intracellular region of GIPR and proteins of the endocytosis ma-
chinery, next experiments aimed at characterizing molecular
mechanisms of GIPR internalization were carried out using
AlexaF647-GIP to trace GIPR intracellular trafﬁcking following
internalization. It is worthy to mention that due to detection limits
of confocal microscope and FACS, internalization and trafﬁcking of
the GIPR were investigated with concentrations of ﬂuorescent
probes equal or above 10 nM. Previous studies investigating GIPR
targeting in vivo demonstrated GIPR internalization in response to
picomolar concentrations of radio-labeled GIP (Gourni et al., 2014).
Quantiﬁcation of the amount of internalized ligand resistant to
acid-washing which efﬁciently removed membrane-bound ligand
(Supplemental Fig. 2S) indicated that 60% and near 100% of bound
AlexaF647-GIP became resistant to acid-washing after 5 and 30min
of incubation, respectively, demonstrating rapid and abundant
trapping of GIPR in endocytosis structures (Fig. 1C).
3.2. Internalized GIP receptors poorly recycle and are mainly
directed to lysosomes
The trafﬁcking and fate of internalized GIPR was investigated in
Flp-lnTMHEK-GIPR. Results from experiments designed to examine
possible recycling of internalized GIPR at the cell surface showed a
slight increase of GIPR density through recycling which however
did not exceed 10e15% of initial GIPR population after 1 h (Fig. 2A).
Trafﬁcking was examined in Flp-lnTM HEK transiently expressing
both GFP tagged GIPR and ﬂuorescent Rab proteins which are
GTPases regulating intracellular trafﬁcking between functionally
distinct compartments in the cells (Stenmark, 2009). Results
showed early co-localization of internalized GIPR in Rab-5-positive
early endosomes (Fig. 2B) and rare late co-localization in Rab-11
containing vesicles (Fig. 1C). On the other hand, transport to lyso-
somes was evaluated using LysoTracker, an acidic organelle-
selective ﬂuorescent probes. Confocal microscopy images indicate
that a part of AlexaF647-GIP labeled GIPR and GIPR-GFP co-local-
ized in lysoTracker-labeled lysosomes at 30min and that almost the
totality of internalized labeled GIP receptors were found in lyso-
somes at times 2 and 3 h (Fig. 2C). Together, these data demonstrate
that GIPR receptors rapidly internalize upon GIP stimulation and
are mostly directed to lysosomal degradation pathway, with only a
minority of receptors recycling to the cell surface.
3.3. Internalization of GIP receptor involves clathrin-coated pits and
dynamin
Internalization of GPCRs can occur through two main mem-
brane structures, caveolae and clathrin-coated pits (Traub, 2009;
Mayor and Pagano, 2007). The role of clathrin in GIPR internaliza-
tion was investigated by expressing a GFP tagged fragment of cla-
thrin in the cells or by treating Flp-lnTM HEK-GIPR cells with
chlorpromazine, an inhibitor of clathrin-coated pit formation. As
shown on Fig. 3A, in cells expressing GFP tagged fragment of cla-
thrin, abundant punctuated co-localization with labeled GIPR was
observed both at the cell surface and in endocytosis vesicles.
Furthermore, Pitstop2 blocked AlexaF647- and GFP-labeled GIPR at
the cell surface (Fig. 3B). Together, these results support that GIPR
internalization occurred through clathrin-coated pits. The possi-
bility that GIPR internalized through caveolaewas also evaluated by
expressing GFP tagged caveolin-1 in the cells or by treating Flp-
lnTM HEK-GIPR cells with ﬁlipin, a caveole inhibitor. GFP tagged
caveolin-1 mostly remained at the cell membrane following stim-
ulation with AlexaF647-GIP. Presence of GFP tagged caveolin-1
could be observed in some endocytosis vesicles containing
AlexaF647-GIP (Supplemental Fig. 3S). On the other hand, the
caveole inhibitor did not signiﬁcantly affect GIPR internalization
(Supplemental Fig. 3S). All together, these experiments support
that internalization of GIPR likely occurs mainly through clathrin-
coated pits in HEK cells.
The contribution of dynamin, a GTPase involved in the separa-
tion of endocytosis vesicles from the plasma membrane was
assessed. As illustrated on Fig. 3C, in the presence dominant
negative dynamin, DN-K44A, AlexaF 647-GIP labeled GIPR
Table 1
Summary of the pharmacological parameters of GIPR ligands.
GIP N-acetyl-GIP AlexaF647-GIP AlexaF647-N-acetyl-GIP
cAMP (EC50 ± SEM, nM) 1.1 ± 0.2 14.8 ± 1.9***(a) 0.47 ± 0.10 7.3 ± 0.9✹✹(b)
Binding
(Ki ± SEM, nM)
11.3 ± 3.1 28.6 ± 4.3*(c) 25.5 ± 5.7 49.5 ± 5.8✹(d)
(a) and (c): Comparison EC50 and Ki of N-acetyl-GIP versus EC50 and Ki of GIP; ***p < 0.001; *0.01 < p < 0.05.
(b) and (d): Comparison EC50 and Ki of AlexaF647-N-acetyl-GIP versus EC50 and Ki of AlexaF647-GIP; ✹✹0.001 < p < 0.01; ✹0.01 < p < 0.05.
S. Ismail et al. / Molecular and Cellular Endocrinology 414 (2015) 202e215 205
 74 
 
remained at the cell surface for a long period as labeled clusters and
internalization was clearly delayed relative to control transfected
cells. The delay of internalization was more pronounced in the
presence of dynasore. Indeed, even after times of incubation as long
as 1 h, most of the AlexaF647-labeled GIPR remained at the cell
surface and a minority of labeled GIPR was internalized (Fig. 3C).
These images clearly indicate that dynamin is required for the
internalization of GIPR.
3.4. Internalization of the GIP receptor does not require b-arrestins
nor C-terminal region of the receptor but involves AP-2
Most often, the cascade of molecular events in the process of
GPCR internalization through clathrin-coated pits involves the
phosphorylation by GRK of Ser/Thr residues located on extreme C-
terminal region and/or intracellular loops of receptors and subse-
quent binding of b-arrestins which play a role of adaptor for re-
ceptor binding to both b2-subunit of AP-2 complex and clathrin
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Fig. 1. Internalization of human GIP receptor. A: GIPR internalization was traced using AlexaF647-GIP (z100 nM) incubated for indicated times with Flp-InTM HEK-GIPR cells.
Images show a cell representative of the population in a single experiment. Cells expressing lower levels of GIPR (as shown by AlexaF647-GIP binding) presented an identical proﬁle
of internalization. B: GIPR internalization was traced using GFP-tagged GIP receptor. HEK 293T cells transiently expressing GFP-tagged GIP (green) were incubated with AlexaF647-
GIP (100 nM, red) for indicated times. Merged confocal microscopy images show AlexaF647-GIP co-localization with GFP tagged GIPR during intracellular trafﬁcking. Images at
different times correspond to distinct ﬁeld from the same cell population. C: Quantiﬁcation of GIPR internalization. AlexaF647-GIP (z100 nM) was incubated with Flp-InTM HEK-
GIPR cells for indicated times. Cells were directly assayed for ﬂuorescence by FACS to measure amount of both bound and internalized AlexaF647-GIP (black bars) or were acid-
washed before measuring cell-associated ﬂuorescence (white bars), which according to confocal experiment control (Fig. 2S), corresponded to GIPR-mediated trapped and
internalized AlexaF647-GIP. Values are expressed as % of maximum ﬂuorescent labeling and are mean ± SEM of 3 experiments. Statistical signiﬁcance of resistant acid-washing
uptake versus total uptake: * 0.01 < p < 0.05. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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(Ferguson, 2001).
The possible involvement of b-arrestins in GIPR internalization
was examined. We ﬁrst determined whether GIPR recruited b-
arrestins using confocal microscopy and BRET, the later being
recognized as a highly sensitive biophysical assay for detection of
protein proximity (Hamdan et al., 2006). Results showed no change
in the concentration of cytoplasmic GFP tagged b-arrestin1 or 2
following GIP stimulations (Fig. 4A and Supplemental Fig. 4S). In
contrast, stimulation of CCK2R (used here as a receptor recruiting
b-arrestins) caused rapid translocation of cytosolic GFP tagged b-
arrestin1 or 2 to the cell plasma membrane upon activation.
Moreover, no BRET signal between RLuc tagged GIPR and YFP tag-
ged b-arrestin1 or 2 could be detected (illustrated only with YFP
tagged b-arrestin2, Fig. 4S), whereas BRET signal was seen with
CCK2R, as previously documented (Magnan et al., 2011). Absence of
b-arrestin1/2 recruitment by GIPR was observed in confocal mi-
croscopy and BRET experiments with ratio of transfected plasmids
ranging from 1:10 to 10:1. Collectively, these results indicate that
GIPR most likely internalizes without requiring b-arrestin1 or 2
recruitment.
We then evaluated the involvement of the C-terminal region of
GIPR by constructing truncated GIPR. The GIPR constructs were ﬁrst
tested for their ability to stimulate adenylyl cyclase in response to
GIP. As shown on Supplemental Fig. 5S, A, truncated GIPR at resi-
dues 414, 432 or 452 responded to GIP stimulations by increasing
cAMP levels to the samemaximum as thewild-type GIPR. However,
Fig. 2. Analysis of recycling and trafﬁcking of internalized human GIP receptor. A: Graph shows results from quantiﬁcation of GIPR recycling. Cells were treated with GIP
(100 nM) for 1 h, washed several times and incubated without ligand for indicated times to enable GIPR recycling at the cell surface. Then, cells were incubated with AlexaF647-GIP
(1 mM) for 45 min and presence of GIPR was assayed using FACS. Values are the mean ± SEM of at least 3 separate experiments. The value 100 corresponds to cell-associated
ﬂuorescence at time 0 of recycling. Statistical signiﬁcance of recycling values in reference to initial value: *0.01 < p < 0.05; **0.001 < p < 0.01; ***p < 0.001. B1 and B2: Intra-
cellular trafﬁcking was traced by co-transfecting HEK 293T cells with cDNA encoding GIPR or GIPR-GFP and Rab5-DsRed or Rab11-DsRed. Images were captured at times 3, 6 and
24 min in B1, and at 4 h in B2 after stimulation by AlexaF647-GIP (100 nM). Images in B1 show examples of co-localization of AlexaF647-GIP labeled GIPR (in red) with Rab5-DsRed
(in green) in early endosomes at initial steps of trafﬁcking (3e24 min). Images B2 show rare triple co-localization between AlexaF647-GIP (shown in red), GIPR-GFP (shown in blue)
and Rab11-DsRed in slow recycling endosomes at long times of incubation (between 2 and 5.5 h, illustrated for time 4 h). These images are representative of 3 microcopy ﬁelds from
2 distinct experiments. C: Flp-InTM HEK cells transfected with GFP-tagged GIP receptor were incubated with LysoTracker (75 nM, displayed in green) for 15 min AlexaF647-GIP
(100 nM) was added to the cells and incubated for 30 min. At this time, incubation medium was withdrawn, cells were washed once with PBS and new buffer without
AlexaF647-GIP was added. Trafﬁcking of internalized GIPR was let to proceed at 37 !C. Images show that only a part of AlexaF647-GIP labeled GIPR (shown in red) and GIPR-GFP
(shown in blue) co-localized in lysoTracker-labeled lysosomes at 30 min (shown in green, the arrow indicates an example of absence of co-localization). Co-localization in lysosomes
increased over the time of incubation, as displayed at 2 h and 3 h. These images are representative of 4e5 microcopy ﬁelds from 2 distinct experiments. (For interpretation of the
references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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half-maximal stimulation of GIPR-TR414 or GIPR-TR432 required
higher GIP concentrations than did the wild-type GIPR (EC50:
5.2 ± 0.1 nM or 5.8 ± 0.1 nM versus 0.27 ± 0.21 nM, respectively)
suggesting importance of the eliminated part of the receptor C-
terminal tail for Gs coupling. Confocal microscopy observations
indicate that abundant internalization could be seen in cells
expressing the different truncated GIPR (Supplemental Fig. 5S, B).
Quantiﬁcation of internalization of these truncated GIPR using
acid-washing showed no signiﬁcant differences (Supplemental
Fig. 5S, C). Therefore, none of the amino acids from C-terminal
tail of GIPR seems to be essential for internalization, thus con-
ﬁrming previous data with rat GIPR (Wheeler et al., 1999).
Finally, the involvement of AP-2 in GIPR internalization was
investigated by co-expressing YFP tagged b2-subunit of AP-2 in Flp-
lnTM HEK-GIPR cells. Imaging results show abundant co-
localization between b2-subunit of AP-2 and AlexaF647-labeled
GIPR strongly suggesting participation of AP-2 complex to the
internalization machinery of the GIPR (Fig. 4B).
3.5. N-acetylation of GIP affects activity of the peptide on cAMP
production, GIPR internalization and GIPR desensitization
Structure-activity relationship data with GIP as well as mapping
of GIP binding site in GIPR demonstrated that N-terminal region of
Fig. 3. Human GIP receptor internalization involves clathrin coated-pits and dynamin. A: HEK 293T cells co-transfected with cDNA encoding GIPR and Clathrin-LCa-eYFP were
stimulated with AlexaF647-GIP for indicated times. Merge images show co-localization of eYFP-tagged chlathin with AlexaF647-labeled GIPR both at the cell surface and in
endocytosis vesicles. Images at different times correspond to different microcopy ﬁelds representative of several others. B: HEK 293 cells transfected with cDNA encoding GIPR-GFP
were incubated with AlexaF647-GIP alone or in the presence of the clathrin inhibitor, Pitstop2 (25 mM). For each condition, images correspond to a single microscopy ﬁeld
representative of 2 others. They show that AlexaF647-labeled GIPR-GFP is maintained at the cell surface in the presence of Pitstop2. It was observed that Pitstop2 decreased in-
tensity of AlexaF647 ﬂuorescence over the time. Therefore, in order to ensure visualization of the GIPR, the experiment was performed on cells expressing GIPR-GFP and not on Flp-
InTM HEK-GIPR cells. C: Flp-InTM HEK-GIPR cells were incubated with AlexaF647-GIP alone (left panels) or HEK 293T cells co-transfected with cDNA encoding GIPR and dominant
negative DN-K44A of dynamin were stimulated with AlexaF647-GIP for indicated times (middle panels) or Flp-InTM HEK-GIPR cells were incubated with AlexaF647-GIP in the
presence of dynasore (50 mM) (right panels). Images showing different microscopy ﬁelds representative of several others indicate that both the dominant negative of dynamin and
the chemical inhibitor strongly delay the process of GIPR internalization.
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GIP is essential for its biological activity (Yaqub et al., 2010; Gault
et al., 2003a; Hinke et al., 2001). On the other hand, N-terminal
modiﬁcations of GIP were reported to increase resistance of GIP to
degradation by DPP IV and/or its efﬁcacy as an incretin (Gault et al.,
2003a; Irwin et al., 2005). We therefore tested whether N-acetyl
modiﬁcation of GIP affects ability of the peptide to trigger inter-
nalization and desensitization of the GIPR.
We ﬁrst determined afﬁnity of N-acetyl-GIP for human GIPR by
performing binding experiments. Results show that N-acetyl-GIP
competed with radio-iodinated GIP to GIPR with ~2.5-fold lower
afﬁnity than that of GIP (Ki: 28.6 ± 4.3 nM for N-acetyl GIP versus
11.3 ± 3.1 nM for GIP, Supplemental Fig. 5A and Table 1). On the
other hand, N-acetyl-GIP stimulation of Flp-lnTM HEK-GIPR cells
resulted in a dose-dependent increase of cAMP levels, with a
maximal cAMP response close to that obtained with GIP, but a half-
maximal response (EC50) achieved with 14.8 ± 1.9 nM versus
1.1 ± 0.1 nM for GIP (Fig. 5B). Thus, N-acetyl-GIP behaved as a full
agonist of the GIPR to stimulate cAMP formation in HEK 293 cells
but was ~15-fold less potent that GIP.
Before use for internalization studies, AlexaF647-N-acetyl-GIP
was characterized pharmacologically. Binding experiments indi-
cated that AlexaF647-N-acetyl-GIP bound to GIPR with slightly
lower afﬁnity than that of unlabeled N-acetyl-GIP (Ki: 49.5 ± 5.8
versus 28.6 ± 4.3 nM, Supplemental Fig. 6S, A and Table 1, sup-
plemental data). Nevertheless, AlexaF647-N-acetyl-GIP stimulated
cAMP production with a 15.5-fold lower potency than that of
AlexaF647-GIP (EC50: 7.3 ± 0.9 nM for AlexaF647-N-acetyl-GIP
versus 0.47 ± 0.08 nM for AlexaF647-GIP, Supplemental Fig. 6S and
Table 1), supporting again that N-acetyl moiety is more important
for GIPR activation than for ligand binding.
Confocal microscopy studies of GIPR internalization following
stimulation with 1 mM AlexaF647-N-acetyl-GIP showed minor
internalization as compared with 0.1 mM AlexaF647-GIP which
provided similar cAMP production levels (Fig. 5C). In agreement
with this result, unlabeled N-acetyl-GIP did signiﬁcantly stimulate
internalization of GFP tagged GIPR transiently expressed in HEK
293Tcells, thus ruling out a possible role of AlexaF647moiety in the
inability of N-acetyl-GIP to trigger GIPR internalization (Fig. 5C).
Furthermore, using acid-washing procedure, we quantiﬁed inter-
nalization of GIPR in response to AlexaF647-N-acetyl-GIP in com-
parison to AlexaF647-GIP at times 5 and 30 min of stimulation. As
illustrated on Fig. 6, after 5 min and 30 min of stimulation, the
fraction of cell-associated AlexaF647-N-acetyl-GIP which remained
resistant to acid-washing was signiﬁcantly lower than that of
AlexaF647-GIP at the three concentrations tested. Despite no EC50
could be calculated because doseeresponse curves did not reach a
plateau, data from acid-washing experiments support that
AlexaF647-N-acetyl-GIP and AlexaF647-GIP stimulate differently
trapping and/or internalization of the GIPR. Strikingly, between ~54
and ~75% of cell-associated AlexaF647-N-acetyl-GIP were resistant
to acid-washing whereas only a minority of ﬂuorescence was
detected in the cell interior by confocal microscopy. This apparent
discrepancy suggests that binding of AlexaF647-N-acetyl-GIP to
GIPR was rapidly followed by its trapping (or sequestration) at the
plasma membrane but this was not pursued by its complete
internalization.
In light of the data showing distinct abilities of AlexaF647-N-
acetyl-GIP and AlexaF647-GIP to stimulate GIPR internalization, we
compared desensitization of cAMP responses stimulated with N-
acetyl-GIP or GIP. Indeed, phosphorylation by second messenger-
dependent protein kinases and G-protein-coupled receptor ki-
nases (GRK) followed by internalization are major cause of desen-
sitization of GPCR signaling (Marchese et al., 2008; Ferguson, 2001).
For desensitization experiments, Flp-lnTM HEK-GIPR cells were
pre-stimulated with N-acetyl-GIP or GIP for different periods of
time in order to cause desensitization of GIPR response. Then, cAMP
Fig. 4. Human GIP receptor internalization involves AP-2 complex and does not require b-arrestins. A: Flp-InTM HEK-GIPR cells or Flp-InTM HEK-CCK2R transfected with b-
arrestin2-GFP were stimulated with GIP or CCK (100 nM), respectively. Images show that b-arrestin2-GFP remains in the cytoplasm in stimulated Flp-InTM HEK-GIPR cells whereas
it was translocated to the plasma membrane (shown at time 5 min) in stimulated Flp-InTM HEK-CCK2R cells used as positive control of b-arrestin2 recruitment. Graphs of
recruitment assay represent measurement of cytosolic ﬂuorescence over the time after GIP or CCK stimulation. They show that cytosolic b-arrestin2-GFP concentration remains
unchanged in stimulated Flp-InTM HEK-GIPR cells whereas it rapidly decreases in stimulated Flp-InTM HEK-CCK2R cells. B: HEK293 T cells co-transfected with wild-type GIPR and
YFP tagged b2-subunit of AP-2 were stimulated with AlexaF647-GIP (100 nM). Confocal microscopy Images show co-localization of AlexaF647-GIP labeled GIPR with YFP tagged b2-
subunit of AP-2 on plasma membrane as well in endocytosis vesicles (shown at times 30 and 60 min).
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production in response to a second agonist challenge was
measured. As shown on Fig. 7, pre-stimulations with GIP dramati-
cally decreased the ability of GIPR to respond to a second agonist
challenge. Indeed, a 15-min pre-stimulation decreased by 63% the
cAMP response to GIP. In contrast, 15-min pre-stimulation of the
cells with N-acetyl-GIP did not signiﬁcantly affect cAMP responses;
Neither GIP, nor N-acetyl-GIP pre-stimulation affected the ability of
forskolin to increase cAMP level indicating that desensitization of
cAMP responses was related to GIPR and not to adenylyl cyclase
(not shown). Finally, PKA inhibitor, H89, which did not signiﬁcantly
affect internalization (Supplemental Fig. 7S) only partially reversed
down regulation by GIP and entirely reversed N-acetyl-GIP-
induced desensitization of cAMP response. In summary, N-acetyl-
GIP differs from GIP mostly in its potency to stimulate cAMP pro-
duction, as well as in its ability to desensitize GIPR-induced cAMP
production and to stimulate GIPR internalization.
3.6. N-acetyl-GIP efﬁciently stimulates insulin secretion from MIN-
6 cells
We next compared stimulatory effects of GIP and N-acetyl-GIP
on cultured b-cells. As shown on Fig. 8, both peptides dose-
dependently stimulated insulin secretion. Insulin secretion levels
with 1 and 10 nM as well as 0.1 mM N-acetyl-GIP were slightly (but
not signiﬁcantly) higher than that with GIP at equivalent concen-
trations. Unfortunately, the low number of GIPR receptors present
at the cell surface of MIN-6 as well as the low level of insulin
secretion did not allow us to investigate GIPR internalization and
desensitization.
4. Discussion
In the context of a renewed interest for the development of GIP
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Fig. 5. N-acetylation of GIP affects activity of the peptide on cAMP production and GIPR internalization in HEK cells. A: Inhibition of 125I-Phe1-GIP binding by GIP or N-acetyl
GIP to GIP receptor. Flp-InTM HEK-GIPR cells were incubated with 125I-Phe1-GIP (100 pM) alone or in the presence of increasing concentrations of GIP or N-acetyl-GIP for 30 min.
Bound radio-ligand was assayed and expressed as percent of speciﬁc binding. Results are mean ± SEM of 4 individual experiments. Inhibition constants, Ki, were: 11.3 ± 3.1 nM for
GIP and 28.6 ± 4.3 nM for N-acetyl-GIP. These were signiﬁcantly signiﬁcant, p<0.05. B: Dose-response curves of cAMP production in Flp-InTM HEK-GIPR stimulated with GIP or N-
acetyl-GIP. cAMP levels were measured by BRET as described in the section “Materials and methods”. cAMP levels with each concentration of agonist were expressed as percent of
cAMP level achieved with 10 mM GIP. Results are mean ± SD of 4 individual experiments. Concentration giving half-maximal responses were 1.1 ± 0.1 nM and 14.8 ± 1.9 nM,
respectively. These were signiﬁcantly signiﬁcant, p<0.001. C: Flp-InTM HEK-GIPR cells were stimulated by AlexaF647-GIP or AlexaF647-N-acetyl-GIP at 0.1 and 1 mM, respectively.
Images show absence of internalization of AlexaF647-N-acetyl-GIP labeled GIPR (middle panels). HEK293 T cells were transfected with GIPR-GFP and stimulated with N-acetyl-GIP.
Images (right panels) conﬁrm that GIPR-GFP remains at the cell surface. Positive control of internalization of GIPR-GFP following GIP stimulation is shown on Fig. 1. Each kinetic is
shown for the same microscope ﬁeld. Images are those from an experiment representative of at least two others.
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analogues therapeutic value, the aim of the current study was to
investigate internalization of the GIPR following pharmacological
stimulation by agonists, as well as the cellular and molecular un-
derlying mechanisms. This study was carried out in HEK cells, a
reference cell model for internalization studies.
By using two different means to trace GIPR internalization,
namely ﬂuorescent reversible labeling of the GIPR with AlexaF647-
GIP or covalent labeling with the GFP tag, we show rapid and
abundant internalization of the GIPR immediately after GIP stim-
ulation. Once internalized, GIPR poorly recycles to the cell surface
but rather co-localizes with LysoTracker labeled vesicles indicating
major targeting to late endosomes and lysosomes. Furthermore,
converging results obtained with chemical inhibitors (chlorprom-
azine or ﬁllipin) and GFP tagged proteins (Lca clathrin-eYFP or
caveolin1-GFP) of both clathrin-coated pits and caveolae clearly
support that internalization of the GIPR occurs mainly through
clathrin-coated pits, although we do not exclude that a minority of
GIP-stimulated GIPR could internalize through caveolae. GIPR
internalization was strongly diminished and delayed by a
dominant-negative and a chemical inhibitor of dynamin, thus
indicating involvement of this GTPase in the ﬁssion of GIPR-
containing endocytosis vesicles from the cell plasma membrane.
The molecular events linking GIPR activation and its subsequent
targeting to clathrin-coated pits were also investigated. Several
lines of evidence support that GIPR internalization does not require
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Fig. 6. Quantiﬁcation of uptake of AlexaF647-GIP or AlexaF647-N-acetyl-GIP by
HEK cells expressing GIP receptors. Flp-InTM HEK-GIPR cells were incubated at 37 !C
with AlexaF647-GIP or AlexaF647-N-acetyl-GIP at different concentrations. At time 5
and 30 min, cells were directly assayed for ﬂuorescence by FACS to measure amount of
both bound and internalized AlexaF647-GIP (panel A) or were acid-washed before
measuring cell-associated ﬂuorescence (panel B). Histograms A represent mean ± SEM
of total cell-associated ﬂuorescence from 3 separated experiments, and histograms B
represent the percent of cell-associated ﬂuorescence resistant to acid-washing. Percent
of cell-associated AlexaF647-N-acetyl-GIP resistant to acid washing was compared to
that of cell-associated AlexaF647-GIP resistant to acid washing. Signiﬁcance was as
follows: **0.001 < p < 0.01; ***p < 0.001.
Fig. 7. Differential desensitization of GIPR-dependant cAMP production by GIP and
N-acetyl-GIP. HEK 293T cells co-transfected with cDNA encoding GIPR and EPAC Bret
sensor were pre-stimulated with GIP (0.1 mM) or N-acetyl-GIP (1 mM) for indicated
times. Then, cells were washed and stimulated with GIP (0.1 mM) or N-acetyl-GIP
(1 mM) alone or in the presence PKA inhibitor, H89. cAMP production was determined
by BRET measurements as described in “Materials and methods” section. Signiﬁcance
for cAMP production of cells pre-stimulated with GIP and N-acetyl-GIP without H89 is
given in comparison with corresponding untreated cells. *0.01 < p < 0.05;
**0.001 < p < 0.01; Signiﬁcance is also shown for cAMP in the presence of H89 as
compared to cAMP in the absence of H89, ✹0.01 < p < 0.05; ✹✹0.001 < p < 0.01. Results
indicate that GIP-induced down regulation of cAMP production was more pronounced
and observed earlier than that with N-acetyl-GIP. Moreover, H89 only reversed a
fraction of GIP-induced desensitization of cAMP production whereas it fully reversed
N-acetyl-GIP-induced desensitization of cAMP production.
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Fig. 8. N-acetyl-GIP and GIP stimulations of insulin secretion from MIN-6-B1 cells.
Insulinoma cells (3.105cells/well) were grown in 24-wells plates for 48 h. After
washing, cells were incubated for 2 h at 37 !C in KRH buffer supplemented with
2.8 mM glucose. The incubation medium was discarded and replaced with 500 mL
buffer containing 11 mM glucose with or without human GIP or N-acetyl-GIP. Cells
were let to secrete insulin during 2 h. Insulin secreted in supernatants was assayed by
Elisa and results were expressed as -fold basal value obtained in the absence of pep-
tide. Results are the mean ± SEM of 4 individual experiments.
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b-arrestins. First, both confocal microscopy and BRET studies were
unable to show recruitment of b-arrestin 1 or 2 whereas parallel
experiments showed this recruitment to the CCK2R used as a
reference receptor recruiting b-arrestins (Magnan et al., 2011).
Moreover, elimination of phosphorylatable amino acids by trun-
cation of C-terminal region of GIPR did not affect internalization of
the GIPR, a result in agreement with previous reports by others
showing that, although probably phosphorylated on two serines,
the C-terminal tail of rodent GIPR was not essential for agonist-
induced internalization (Wheeler et al., 1999; Tseng and Zhang,
2000). Moreover, our results agree with those reported during
the preparation of this manuscript, indicating no signiﬁcant
recruitment b-arrestin2 by the GIPR in HEK293 cells (Al-Sabah
et al., 2014). On the other hand, confocal microscopy observations
strongly support participation of the AP-2 complex in GIPR inter-
nalization, a result in line with evidence showing that AP-2 is
essential, if not required, in clathrin-coat pit formation (Boucrot
et al., 1059; Motley et al., 2003). b-arrestins are adaptor proteins
classically recruited by phosphorylated G-protein coupled re-
ceptors, a biochemical event that is followed by binding of receptor-
arrestin dimer to both b2-subunit of the AP-2 complex and clathrin,
and subsequent targeting of the resulting cargo to clathrin-coated
pits. The fact that GIPR internalization does not require b-arrest-
ins whereas it involves AP-2 raises the question of the mechanism
by which activated GIPR is targeted to AP-2 complex before endo-
cytosis. In light of available data from the literature, several hy-
potheses can be proposed. First, activated GIPR might interact
directly via intracytosolic endocytosis motifs with a subunit of AP-2
complex. Consensus endocytosis motifs capable to be recognized
by AP-2 adaptor complex are YxxF tyrosine-based motifs where F
can be F, I, L, M or V as well as [ED]xxxL[LI] acidic dileucine motifs
(Traub, 2009). Several G-protein- coupled receptors, such as
protease-activated receptor 1 (PAR1), the chemokine CXCR2 and
CXCR4 receptors, and the b2-adrenergic receptor have been shown
to internalize by involving such sorting motifs (Paing et al., 2006)
(Fan et al., 2001; Orsini et al., 2000; Gabilondo et al., 1997). We have
performed an analysis of amino acid sequence of the GIPR and
found 3 potential consensus sorting motifs in the intracytosolic
region of the protein (bottom of transmembrane segments 2, 4 and
7). However, point-mutations within these motifs did not affect
signiﬁcantly GIPR internalization (unpublished data). Among other
likely hypotheses, involvement of GPCR kinases (GRKs) is plausible.
GRK are best known to phosphorylate intracellular domains of
active GPCRs resulting in receptor desensitization and internaliza-
tion and are also capable of regulating GPCR signaling and traf-
ﬁcking independently of phosphorylation (Pals-Rylaarsdam et al.,
1995; Moore et al., 2007; Shiina et al., 2001). GRK2 has been
shown to directly interact with clathrin through a clathrin box
(Pals-Rylaarsdam et al., 1995; Moore et al., 2007; Shiina et al.,
2001). However, contradictory results were reported about inter-
action of GRK2 with GIPR (Tseng and Zhang, 2000; Al-Sabah et al.,
2014). Indeed, recruitment assay using FRET could not detect any
binding of GRK2 to the GIPR whereas GRK2 over-expression caused
drops in GIPR-dependant cAMP production and insulin secretion
(Tseng and Zhang, 2000; Al-Sabah et al., 2014).
An additional important ﬁnding of the current work is the
identiﬁcation of new pharmacological properties of N-acetyl-GIP.
This peptide was previously shown to have an improved anti-
hyperglycemic activity and stimulatory action on insulin secretion
in vivo in ob/ob mice (O'Harte et al., 2002). The half-life of N-acetyl-
GIP to DPP IV degradation was estimated to be > 24 h in plasma
versus 6.2 h for natural GIP (Gault et al., 2003b). In the current
study, N-acetyl-GIP was found to be as potent and efﬁcient as GIP to
stimulate insulin secretion from MIN-6-B1 cells in spite of its 15-
fold lower potency to stimulate cAMP production. These ﬁndings
must be examined in light of results showing that N-acetyl-GIP
incompletely stimulates GIPR endocytosis and displays a decreased
ability to desensitize GIP-induced cAMP production. It is thus
plausible that N-acetylation of GIP improves insulinotropic action
of the peptide by decreasing its potency to stimulate desensitiza-
tion, internalization and lysosomal degradation of the GIPR. Addi-
tionally, like several other G-protein coupled receptors, GIPR might
stimulate cAMP production from plasma membrane and early
endocytosis vesicles as well and both cAMP pools would contribute
to insulin secretion (Calebiro et al., 2010). Related to this hypoth-
esis, it will be important to investigate precise early trafﬁcking of
GIPR stimulated both by GIP and N-acetyl-GIP, as well as possible
differential effects of the two peptides on GIPR recycling.
Thus, N-acetylation has a minor impact on afﬁnity of GIP for its
receptor but more strongly affects ability of GIP to activate GIPR.
These ﬁndings are compatible with converging data showing that
N-terminal part of GIP is crucial for activation of the GIPR, whereas
the C-terminal region of GIP is essentially involved in ligand
binding (Yaqub et al., 2010; Gault et al., 2003a; Hinke et al., 2001;
Hollenstein et al., 2014). Also, our previous studies dedicated to
mapping of the activation site of the GIPR showed that N-terminus
of receptor-bound GIP is in contact with aminoacids from trans-
membrane domains of the GIPR (Yaqub et al., 2010). Our results
showing distinct behaviors of N-acetyl-GIP relative to the full
agonist GIP led us to examine if this could be explained by different
binding poses of the two ligands in the binding site of the modeled
GIPR. We previously identiﬁed amino acid residues of the GIPR
binding site that are essential for GIPR activation by GIP using an
iterative approach involving homology modeling based on tem-
plates of Group A GPCRs and site-directed mutagenesis (Yaqub
et al., 2010). For the purpose of this study, we have validated the
data by reconstructing the GIPR homologymodel using the recently
published crystal structure of the human glucagon receptor
(GCGR), a Group B GPCR having a sequence identity of 58% with
GIPR. In the modeled GIPR. GIP complex represented in Fig. 9A and
B, the side chain of Tyr1 in GIP forms an H-bond with Q224 and a
cation-p interaction with R300 and the terminal ammonium moi-
ety of Tyr1 has an ionic interaction with E377 and a cation-p
interaction with F357. The side chain of Glu3 forms an ionic inter-
action with R183. The backbone of Gly4 forms an H-bond with
R190. The importance of R183, R190, Q224, R300 and F357 in GIPR
activation by GIP agrees with earlier site-directed mutagenesis re-
sults (Yaqub et al., 2010). Docking of N-acetyl-GIP in the binding site
of the GIPR indicates that N-acetyl-GIP maintains the most of
contacts apart from interactions with E377 and F357, acetylated
nitrogen being moved away from these residues (Fig. 9C). As a
consequence, N-acetyl-GIP has a less number of interactions with
helices 6 and 7 compared to GIP. These results, together with data
showing that helices 6 and 7 in G-protein coupled receptors are
essential for stabilization of the active conformation of receptors,
may explain atypical activity of N-acetyl-GIP analogue (Hollenstein
et al., 2014; Audet and Bouvier, 2012; Magnan et al., 2013). So, it is
plausible that the two agonists may stabilize different conforma-
tions of the GIPR, each of which having distinct ability to trigger
signals.
The understanding of the origin of incomplete internalization
and decreased desensitization of GIPR following stimulation by N-
acetyl-GIP will deserve additional investigations. Meanwhile, the
fact that the PKA inhibitor fully reverses desensitization by N-
acetyl-GIP whereas it partly reverses that by GIP supports the view
that distinct signaling pathways and mechanisms cause desensiti-
zation of GIPR response: weak desensitization following N-acetyl-
GIP exposure would mainly involve cAMP-dependent protein ki-
nase (PKA) whereas more intensive desensitization by GIP would
involve both PKA and other signaling pathways, including those
S. Ismail et al. / Molecular and Cellular Endocrinology 414 (2015) 202e215212
 81 
 
leading to internalization. Thus, it is plausible that N-acetyl-GIP
fails to activate a step of GIPR signaling involved in both desensi-
tization and internalization. Accordingly, N-acetyl-GIP is a biased
agonist candidate.
Our results on GIPR internalization in HEK cells differ from those
recently reported in transfected 3T3L1 adipocytes (Mohammad
et al., 2014). In the last study, it was shown that GIPR constitu-
tively internalizes and recycles to the cell surface and GIP regulates
down-regulation of plasma membrane GIPR by slowing GIPR
recycling without affecting kinetics of GIPR internalization
(Mohammad et al., 2014). We have no explanation for such
different ﬁndings excepted that GIPR, like other G-protein coupled
receptors, could behave differently according to the cell context
(Tobin et al., 2008). On the other hand, it is interesting to compare
behavior of the GIPR with that of the GLP1R. Indeed, although these
two receptors are highly homologous in structure and functions,
their insulinotropic responses are differently affected in diabetics.
Studies insulinoma and HEK cells both showed that GLP1 rapidly
internalizes in response to its natural agonist but also rapidly re-
cycles to the cell surface (Widmann et al., 1995; Roed et al., 2013).
Furthermore, GLP1 was shown to recruit GRK2 and b-arrestin2
upon activation (Al-Sabah et al., 2014). Thus, with respect to
recycling to the cell surface and molecular mechanisms involved in
internalization, GIPR seems to differ from GLP-1R (Al-Sabah et al.,
2014; Widmann et al., 1995; Roed et al., 2013).
5. Conclusion
In this study, internalization of the GIPR and subsequent intra-
cellular trafﬁcking has been characterized. GIP stimulated rapid
robust internalization of the GIPR, the major part being directed to
lysosomes. GIPR internalization involved clathrin-coated pits, AP-2
and dynamin. However, neither GIPR C-terminal region nor b-
arrestin1/2 was required. Thus, mechanisms of GIPR internalization
seems to differ from that reported for GLP1R. Finally, N-acetyl-GIP
recognized as a dipeptidyl-IV resistant analogue appeared to
weakly stimulate GIPR internalization and desensitization of cAMP
response. Molecular modeling of GIPR. N-acetyl-GIP complex
enabled to show that N-acetyl-GIP interact more slightly with
amino acids of helices 6 and 7 of the GIPR compared to GIP, sup-
porting that the two agonists may stabilize different conformations
of the GIPR, each of which having distinct ability to trigger signals.
We propose that incomplete or partial activity of N-acetyl-GIP on
signaling involved in GIPR desensitization and internalization
Fig. 9. Molecular models of GIP and N-acetyl-GIP binding at GIPR. A: Overall view of GIPR in the complex with GIP. B: Zoomed view of the GIP binding site. C: Zoomed view of the
acylGIP binding site. Unlike GIP, N-acetyl-GIP does not form an ionic interaction with E377 and a cation-p interaction with F357. Only the ﬁrst ﬁve residues of GIP and residues of the
helical bundle predicted to be important for GIPR activation based on previous site-directed mutagenesis are shown in stick-like representation. Hydrogen bonds and p-cation
interactions are in pink and dark green, respectively. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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contributes to the enhanced incretin activity of this peptide which
is a biased agonist candidate.
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Fig. 1S: Functional and binding characterization of cells expressing GIP receptors and fluorescent labeled GIP.  
Panel A, Flp-InTM HEK-GIPR stably expressing human GIPR were transfected with EPAC Bret sensor  or in 
panel B, HEK293T cells co-expressing transiently GIPR and EPAC Bret sensor were stimulated with GIP at 
indicated concentrations for 5 min. cAMP production was assayed by BRET as described in materials and methods. 
Concentration of GIP giving half-maximal stimulation of cAMP production were 0.53 ± 0.17 nM in 
Flp-InTM HEK-GIPR cells and 0.52 ± 0.06 nM in HEK293T-GIPR cells. Panel C, Flp-InTM HEK-GIPR were 
incubated with 125-I-Phe1-GIP in the presence of increasing concentrations of GIP or AlexaF647-GIP for 30 min. 
Results are mean ± SEM of 4 individual experiments. Analysis of inhibition curves provides the following 
Ki: 11.3 ± 3.1 nM for GIP and 25.5 ± 5.7 nM for AlexaF647-GIP. Panel D, HEK293T cells co-expressing 
transiently GIPR and EPAC Bret sensor were stimulated with AlexaF647-GIP at indicated concentrations for 5 min 
and cAMP production was assayed by BRET.  Results are mean ± SEM of 3 individual experiments. AlexaF647-GIP 
stimulated cAMP production with an EC50 of 0.47 ± 0.08 nM. 
 
Supplementary Data to article:Internalization and desensitization of the human glucose-dependent- 
insulinotropic receptor is affected by N-terminal acetylation of the agonist by Sadek Ismail et al. 
 85 
 
AlexaF647-GIP 
controle Acid-washed 
3’ 
Fig. 2S: Acid-washing of membrane-bound but not internalized AlexaF647-GIP.  
Flp-InTM HEK-GIPR were incubated with AlexaF647-GIP (100 nM) for 2-3 min. at 37°C. Then, cells were 
acid-washed (B) or not at 4°C for 5 min. Confocal microscopy images show efficiency 
of the elimination of membrane-bound fluorescent GIP and some remaining sequestered or internalized ligand.  
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B: AlexaF647-GIP 
+ Filipin 
1’ 
15’ 
60’ 
A: AlexaF647-GIP Cav1-GFP 
Merged 
Fig. 3S: GIP receptor does not significantly internalize through caveolae.  
Right panels: Flp-InTM HEK-GIPR cells were incubated with AlexaF647-GIP alone or in the presence of 
the caveola inhibitor, fillipin (50µM). Left panels: HEK 293T cells co-transfected with cDNA encoding GIPR 
and caveoline1-GFP were stimulated with AlexaF647-GIP for indicated times. Images show no significant 
change of internalization of GIPR in the presence of fillipin. AlexaF647-labeled GIPR strongly co-localizes 
with caveoline1-GFP at the plasma membrane and in some cases in endocytosic vesicles 
 (the white arrow shows an example). 
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Fig. 4S: Absence of β-arrestin1/2 recruitment to GIP receptor  
1) BRET assays showing absence of direct recruitment of β-arrestin2 to GIP receptor. 
Panel A: HEK293 T cells co-transfected with GIPR-RLuc and β-arrestin2-YFP were stimulated with GIP (100 nM). 
Panel B: HEK293 T cells co-transfected by CCK2R-RLuc and β-arrestin2-YFP were stimulated with CCK (100 nM). 
Results are those from one representative experiment of 3 others and are expressed as netBRET. 
2) Confocal microscopy images of Flp-InTM HEK-GIPR cells or Flp-InTM HEK-CCK2R transfected with 
β-arrestin2-GFP stimulated with GIP or CCK (100 nM), respectively. Images show that β-arrestin2-GFP  
remains in the cytoplasm in stimulated Flp-InTM HEK-GIPR cells whereas it was translocated to the plasma 
membrane in stimulated Flp-InTM HEK-CCK2R cells used as positive control of β-arrestin2 recruitment.  
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Fig. 5S: The C-terminal region of the GIP receptor is dispensable for internalization of GIP receptor.  
A: C-terminal truncated GIP receptors retain ability to stimulate adenylyl cyclase.  
HEK293 T cells co-transfected with EPAC BRET biosensor and with wild-type or truncated GIPR  
positions 414, 432 or 452 (termed TR414, TR432, TR452) were stimulated with increasing concentrations 
of GIP. BRET was measured 5 min. after addition of GIP. Almost identical maximal responses were observed 
with wild-type and truncated GIPR. Potencies to stimulate production of cAMP were as follow: 
EC50, Wild-type GIPR: 0.27 ± 0.21, TR414: 5.2 ± 0.1 nM, TR432: 5.8 ± 0.1 nM, TR452: 0.48 ± 0.25 nM. 
B: C-terminal truncated GIP receptors abundantly internalize upon stimulation with AlexaF647-GIP.  
HEK293 T cells transfected with wild-type GIPR or with TR414-, TR432-, TR452-GIPR were stimulated with 
AlexaF647-GIP (100 nM). Confocal microscopy images show that all truncated GIPR abundantly internalized 
upon GIP stimulation (shown at 45 min). 
C: Quantification of AlexaF647-GIP internalization indicates that the C-terminal region of the GIP receptor 
is dispensable for internalization of GIP receptor. Two batches of HEK293 T cells transfected with wild-type  
GIPR or with TR414-, TR432-, TR452-GIPR were stimulated with AlexaF647-GIP (100 nM) for 30 min. 
Uptake of ligand was stopped by cooling the cells on ice. After PBS washing at 4°C, one batch was acid-washed 
whereas the second batch was PBS-washed (4°C). Fluorescence remaining associated to cells was quantified by FACS. 
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Fig. 6S: Pharmacological properties of N-acetyl-GIP and AlexaF647-N-acetyl-GIP 
Panel A: Competition binding between 125I-Phe1-GIP and AlexaF647-N-acetyl-GIP. Flp-InTM HEK-GIPR 
were incubated with 125-I-Phe1-GIP (100 pM) in the presence of increasing concentrations of 
AlexaF647-N-acetyl-GIP for 30min. Results are mean ± SEM of 4 individual experiments. Inhibition constant 
of AlexaF647-N-acetyl-GIP was: 49.5 ± 5.8 nM. Panel B: Dose-response curve for stimulation of cAMP 
production by AlexaF647-N-acetyl-GIP. HEK293T cells co-expressing transiently GIPR and EPAC Bret 
sensor were stimulated with AlexaF647-N-acetyl-GIP at indicated concentrations, for 5 min, and cAMP production 
was assayed by BRET.  Results are mean ± SEM of 3 individual experiments and show that AlexaF647-N-acetyl-GIP 
stimulated cAMP production with an EC50 of 7.3 ± 0.9 nM. 
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Fig. 7S: Absence of effect of H89, a PKA inhibitor, on GIP-stimulated internalization of the GIP receptor. 
A: Flp-InTM HEK-GIPR cells were stimulated with AlexaF647-GIP (100 nM) in the absence or in the presence  
of H89. Confocal microscopy images show internalization of AlexaF647-GIP at 30 min). 
B: The absence of effect of H89 on GIP-induced GIPR internalization was confirmed by acid-washing experiment 
which indicated that the same amount of AlexaF647-GIP was resistant to acid washing when internalization  
proceeded in the absence or in the presence of H89. 
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Conclusions of Article I 
 
 
 
In this study we showed that upon GIP stimulation, GIPR is rapidly 
internalized and mainly directed to lysosomal degradation and exhibits a low 
recycling activity. Although a little contribution of caveolae, GIPR endocytosis seems 
to be mostly mediated by clathrin-coated pits where the dynamin GTPase step is 
essential for the vesicle closure at the cell membrane. 
 
We witnessed unusual events concerning the molecular process that leads the 
activated receptor to be driven to clathrin coated pits. Usually, for a large number of 
GPCRs, internalization  is mediated by the b-arrestins that bridges the C-terminal 
region of activated receptor to the AP-2 complex required in clatherin coated-pits 
formation. However, despite the strong implication of AP-2 subunit seen in our 
observations for GIPR internalization, we were not able to detect any b-arrestin 
recruitment neither by confocal microscopic observation nor by BRET. This result is 
in agreement with  another study that also shows no implication of b-arrestin2 in 
GIPR endocytosis. On the other hand, truncated GIPR receptors that we constructed 
lacking phosphorylation candidate residues behaved identically to the wild-type GIPR 
in term of internalization. This observation also correlates with a report by others 
showing that the C-terminal tail of GIPR is not essential for its internalization. 
 
In view of these results, among different hypotheses, we proposed two that 
could explain how GIPR activation is linked to endocytosis. First, a direct interaction 
between activated GIPR and AP-2 complex could be possible as other receptors, like 
CXCR2R and b2AR, present such mechanisms (Fan et al., 2001) (Gabilondo et al., 
1997). In a second hypothesis, GRK2 could be involved. Despite its essential role in 
GPCRs desensitization through phosphorylating intracellular residues of activated 
GPCRs, GRK2 was shown to be able to induce phosphorylation independent 
regulation of GPCR trafficking. In the literature, one study did not report a 
recruitment of GRK2 while another study showed an effect of GRK2 overexpression 
on GIP-mediated GIPR response(Al-Sabah et al., 2014) (Tseng and Zhang, 2000). In 
preliminary tests, which are not presented in this manuscript, we observed that over-
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expressing GRK2 but not GRK5 in HEK accelerated the rate of GIPR internalization. 
However, our attempts to detect a BRET signal accounting for interactions between 
GRK2 and GIPR were not successful. Therefore, the eventual role of GRK2 in GIPR 
regulation remains an open question. 
In the second part of our study we found that N-Acetyl-GIP, a GIP analogue 
recognized to be resistant to degradation by DPP-IV, fully stimulates insulin secretion 
in MIN-6-B1 b cell line in addition to having a full potential to induce cAMP 
production like GIP. However, GIP receptors stimulated by N-Acetyl-GIP were not 
able to internalize abundantly as under stimulation by GIP. These observations 
suggest that the modification of GIP in its N-terminal region which has been 
demonstrated to be responsible of the biological activity of the peptide, could have 
different conformational consequences on the activated GIPR compared to the natural 
peptide. Our modeling and docking assays are in favor of this hypothesis (Yaqub et 
al., 2010). 
 
Moreover, the fact that N-Acetyl-GIP weakly induces desensitization of GIPR 
as well as not stimulating its internalization reveals a possible biased behavior of the 
modified peptide towards GIPR, in which a signaling pathway different from that of 
GIP could be selectively triggered. 
 
Overall, these results improve our understanding of the mechanisms regulating 
GIPR internalization and thus opens new perspectives in the field (see general 
conclusion).. 
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Introduction to Article II 
 
Signaling via GPCRs plays an essential role in many physiological functions. 
An additional new aspect of subcellular signaling was identified a few years ago, in 
which several GPCRs were shown to signal via G proteins from intracellular sites 
after internalization. Remarkably, the newly identified signal was shown to present 
diverse functional consequences for many involved GPCRs. However, controversial 
opinions were given regarding this new concept. Moreover, the lack of an evidence 
directly proving the production of G protein-dependent signal from endosomes as 
well as the restricted number of receptors found to present such phenomenon, strongly 
convinced us to investigate this new concept on the GIP receptor. 
In the following work presented as an article submitted to Cellular Signaling 
journal, we investigate whether the GIPR internalization, studied in our first article, is 
accompanied by a G protein-dependent signaling phase producing cAMP. Thereby, 
our work strategy comprised three complementary approaches. 
 
First, we evaluated if the second messenger production following the GIPR 
stimulation by GIP is persistent in time after receptor internalization. Therefore, we 
adapted BRET technique so that we can measure in real time the amount of GIP-
induced cAMP accumulation. Moreover, to prove the dependency of the mechanism 
on internalization, we administered a powerful pharmacological inhibitor, dyngo-4a 
which prevents GIPR endocytosis. Furthermore, in the same context, we attempted to 
shortly stimulate cells then to remove residual ligands to exclude any signaling 
originating from the cell surface. In the latter assay, we switch to the FRET technique 
for experimental reasons regarding the procedure of ligand washout. 
 On the other hand, we tried to accumulate GIP-activated GIPRs in early 
internalized endosomes in an attempt to amplify the extent of any endosomal cAMP 
signal. For this purpose, we used functionally-inactive Rab7, a GTPase involved in 
the transfer of endosomes from early to later state.  
 
Our second approach consists in detecting the initiation of GIPR signaling in 
internalized compartments, as it is the case on the cell membrane, in a more direct 
manner. Therefore, we used genetically-encoded fluorescently-tagged nanobody, 
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GFP-Nb-37 which recognizes the active state of Gas, the molecular switch that 
initiates GIPR signaling following GIP binding. 
 
In the third approach we developed a strategy that allows us to directly detect 
the G protein-dependent signaling product of GIPR, cAMP released precisely from 
internalized compartments containing GIP-activated receptors. To apply our strategy, 
we designed the molecular biosensor of cAMP, EPAC in a particular way to make it 
specifically targeted to early endosomes.  The new construction is obtained by adding 
a FYVE sequence, derived from EEA1, to the EPAC which drive it to bind PtdIns(3)P 
located on the membrane of early endosomes. In comparison to BRET sensors, the 
constructed biosensor is a FRET probe that, in addition to its ability to detect cAMP, 
has the advantage of being viewable, thus localized in the cell by confocal 
microscopy imaging. 
 
Results from these approaches are presented and discussed in the following 
article entitled: “Internalized Receptor for Glucose-Dependent Insulinotropic 
Peptide Stimulates Adenylyl Cyclase on Early Endosomes”. 
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Dear Colleague,  
 
It is my pleasure to submit a manuscript entitled “Internalized Receptor for Glucose-
dependent Insulinotropic Peptide stimulates adenylyl cyclase on early endosomes” to Cell 
Research. 
Being a faithful reader of articles published in Cellular Signalling, I think that our timely 
study meets the scope of the journal and its readership as it is absolutely novel work, which 
provides breakthrough in the field of G-protein-coupled receptor signaling. Part of the work was 
presented as oral communications in international symposia. 
To summarize our achievement, until very recently, G-protein dependent signal of GPCRs 
was thought to originate exclusively from the plasma membrane and internalized GPCRs were 
considered silent. In the current work, we provide direct and unequivocal experimental 
demonstration that, once internalized and located in the membrane of early endosomes, the 
receptor for Glucose-dependent Insulinotropic receptor (GIPR) continues to trigger production of 
cAMP which accounts for sustained cAMP level observed in cells after GIP stimulation.  Hence, 
production of endosomal cAMP by internalized GIPR contributes to the spatio-temporal 
organization of cAMP signaling cascade downstream GIPR.  
This work has not been published or will not be considered for publication elsewhere and all 
co-authors agree with the content of the article and its submission to Cellular Signalling. 
However, I must mention that a previous manuscript which was similar to the current one, has 
been submitted to the journal. In the current manuscript, data from additional key experiments are 
inserted. We guess that this manuscript fulfills all criteria for acceptance.  
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With my thanks for considering our manuscript and best regards, 
 
May 18, 2016 
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Internalized G-protein coupled receptors were considered silent.>Glucose-dependent Insulinotropic 
receptor (GIPR) triggers production of cAMP in early endosomes.>Active form of Gαs was detected 
in early endosomes containing GIPR.>cAMP production was detected at the surface of endosomes 
containing GIPR.>Blockade of internalization causes reversibility of cAMP response.>Accumulation 
of GIPR in early endosomes prolonged and augmented cAMP production.  
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Until very recently, G-protein dependent signal of GPCRs was thought to originate exclusively from 
the plasma membrane and internalized GPCRs were considered silent. Here, we demonstrated that, 
once internalized and located in the membrane of early endosomes, glucose-dependent Insulinotropic 
receptor (GIPR) continues to trigger production of cAMP. Direct evidence is based on identification of 
the active form of Gαs in early endosomes containing GIPR using a genetically encoded GFP tagged 
nanobody, and on detection of a distinct FRET signal accounting for cAMP production at the surface 
of endosomes containing GIP, compared to endosomes without GIP. Furthermore, decrease of the 
sustained phase of cAMP kinetic as well as reversibility of cAMP production following GIP washout 
in cells treated with a pharmacological inhibitor of GIPR internalization, and continuous increase of 
cAMP level over time in the presence of dominant-negative Rab7, which causes accumulation of early 
endosomes in cells, were noticed. Hence the GIPR joins the few GPCRs which signal through G-
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Abstract 
Until very recently, G-protein dependent signal of GPCRs was thought to originate exclusively from 
the plasma membrane and internalized GPCRs were considered silent. Here, we demonstrated that, 
once internalized and located in the membrane of early endosomes, glucose-dependent Insulinotropic 
receptor (GIPR) continues to trigger production of cAMP. Direct evidence is based on identification of 
the active form of Gαs in early endosomes containing GIPR using a genetically encoded GFP tagged 
nanobody, and on detection of a distinct FRET signal accounting for cAMP production at the surface 
of endosomes containing GIP, compared to endosomes without GIP. Furthermore, decrease of the 
sustained phase of cAMP kinetic as well as reversibility of cAMP production following GIP washout 
in cells treated with a pharmacological inhibitor of GIPR internalization, and continuous increase of 
cAMP level over time in the presence of dominant-negative Rab7, which causes accumulation of early 
endosomes in cells, were noticed. Hence the GIPR joins the few GPCRs which signal through G-
proteins both at plasma membrane and on endosomes.  
 
Keywords: glucose-dependent-insulinotropic receptor, internalization, cAMP, BRET, FRET, early 
endosomes 
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Abbreviations: GIPR, glucose-dependent Insulinotropic Peptide Receptor; cAMP, 3',5'-cyclic 
adenosine monophosphate; BRET, Bioluminescence Resonance Energy Transfer; FRET, Fluorescence 
Resonance Energy Transfer  
1. Introduction 
 Seven-transmembrane receptors, also termed G-protein-coupled receptors (7 TMRs or GPCRs), 
form the largest class of cell surface membrane receptors, involving several hundred members in the 
human genome. Biological effects triggered by GPCRs result from activation of both G-protein-
dependent and G-protein-independent intracellular signalling pathways [1-3]. Until very recently, 
production of diffusible second messengers was thought to exclusively originate from the cell plasma 
membrane, where embedded GPCRs bound their cognate ligands and are subsequently activated to 
stimulate production of second messengers (3',5'-cyclic adenosine monophosphate, cAMP or inositol 
triphosphate, IP3) and downstream signalling cascade [3]. On the other hand, activation of membrane 
GPCRs is generally immediately followed by their Ser/Thr phosphorylation by second messenger-
dependent kinases and G-protein Receptor Kinases (termed GRKs) [1-4]. Phosphorylated GPCRs then 
recruit adaptor proteins such as β-arrestins which uncouple G-proteins from membrane receptors and 
promote GPCR endocytosis. Alternatively, activated and phosphorylated GPCRs can interact directly 
with components of the endocytic machinery which generally involves clathrin and the clathrin 
adaptor AP2. Coated-pits containing GPCRs are then separated from the plasma membrane by action 
of dynamin, leading to the formation of early endosomes. Finally, internalized GPCRs are sorted via 
the endocytic pathway to lysosomes or are recycled to the cell surface [1-4]. Thus, consensus holds 
that internalization disrupts G-protein-dependent signalling of GPCRs and consequently, internalized 
GPCRs become silent with respect to G-protein dependent production of diffusible second 
messengers. 
 Recently, the classical concept whereby G-protein-dependent signalling of GPCRs is restricted to 
plasma membrane has been challenged and refuted. Evidence of endosomal G-protein signalling of 
GPCRs was obtained with the parathyroid hormone receptor (PTHR) which induces sustained or 
persistent production of cAMP in response to PTH stimulation [5]. In kinetic studies, the sustained 
phase of cAMP production persisted after agonist removal. Concomitantly, sustained TSHR-
dependent production of cAMP, ascribed to internalized TSHR, was documented in native thyroid 
follicles isolated from transgenic mice expressing a FRET sensor of cAMP [6]. Dopamine 1 receptor 
and vasopressin receptors were subsequently shown to trigger cAMP production from endosomes [7, 
8]. Among the different experimental arguments provided in support of the concept of endosomal 
cAMP production, chemical and genetically encoded inhibitors of GPCR internalization such as 
dynasore and dynamin dominant-negative mutants, were shown to affect the sustained phase of cAMP 
production [5, 6]. Additional and more direct evidences were provided in studies with the β2-
adrenergic receptor in which conformational biosensors, consisting of nanobodies, enabled 
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identification, by confocal microscopy, of the active form of the β2-receptor, as well as the active Gαs 
subunit in early endosomes of living cells [9]. Interestingly, in agreement with the concept of 
compartimentalized cAMP signalling originally proposed in a study on cardiac myocytes, 
accumulating data support that cAMP produced from endosomes by activated GPCRs causes 
qualitatively different physiological effects compared to cAMP generated from the plasma membrane 
[5, 6, 10-12]. 
 However, despite reasonably convincing evidence that internalized GPCRs continue to trigger G-
protein dependent signals, this view has been refuted and still remains a subject of controversy[13, 
14]. Furthermore, G-protein-dependent production of diffusible second messengers by GPCRs in 
endosomes was only reported for a very restricted number of GPCRs (recently reviewed in [15]). 
Additionally, direct detection of cAMP production on endosomes resulting from activation of an 
internalized GPCR was not provided so far. This prompted us to investigate if the Glucose-dependent 
Insulinotropic Receptor (GIPR) which is a physiologically and pharmacologically important receptor 
regulating glucose and lipid homeostasis [16] and which is a universal GPCR overexpressed in 
neuroendocrine tumors [17], would also be endowed of capability to signal from early endosomes. 
GIPR which belongs to the subfamily-2 of GPCR, triggers Gs-mediated cAMP production and 
subsequent signalling cascades [16]. We have shown that GIPR undergoes rapid abundant 
internalization following stimulation by GIP and that internalized GIPR is mainly sorted to the 
lysosomal degradation pathway [18]. Interestingly, in contrast to most GPCRs, including the closely 
structurally and functionally related GLP1 receptor, GIPR is internalized independently of β-arrestin 
recruitment [18, 19]. 
 In the current study, by using an integrative approach comprised of live cell confocal microscopy, 
pharmacological and genetically encoded tools, BRET and FRET measurement of cAMP in whole 
cells, immune-detection of activated form of Gs and FRET cAMP measurements at the endosome 
surface, we unequivocally demonstrate that internalized GIPR remains active and triggers cAMP 
production at endosomes. Thus, GIPR joins the group of GPCRs which are activated at the plasma 
membrane and once, activated and internalized continue to stimulate production of their cognate 
diffusible second messenger. 
 
2. Materials and Methods 
2.1 Materials 
 Fragment 1-30 of human GIP (termed GIP) and DY647 labeled-GIP (termed DY647-GIP) were 
obtained as previously described [20].   The fluorescent probe was highly specific of GIPR (less than 
5% nonspecific labeling in the present of 100-fold excess of unlabeled peptide). Radio-labeled GIP 
was obtained by radio-iodination of Phe1-GIP(1-30) with 125I-Na (Perkin Elmer, France) in the 
presence of chloramine T and was HPLC purified on a C-18 column. 125I-Phe1-GIP bound to a single 
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class of GIPR binding sites from HEK 293T or Flp-InTMGIPR-293 cells with a dissociation constant, 
Kd of 75.7 ± 8.4 nM. Sequence encoding short variant of the human GIPR was derived from a plasmid 
kindly given by Professor Bernard Thorens (Lausanne, Switzerland) [21]. Chemicals were from the 
following sources: Dyngo-4a from Abcam, Foskolin from Sigma-Aldrich.  
Plasmids encoding DsRed tagged Rab5 (termed DsRed-Rab5), DsRed tagged Rab7-DN (termed 
DsRed-Rab7-DN), GFP tagged EEA1 (termed GFP-EEA1) were supplied by Addgene 
(www.addgene.org). Plasmid for BRET measurements of cAMP production, namely Rluc-Epac1-
citrine was kindly provided by Professor Marc Caron. 
 The cytosolic cAMP sensor Epac1-camps sequence [22] was used as a backbone to construct the 
EYFP-EPAC1-ECFP-FYVE sensor targeted to early endosomes. After removal of stop codon, the 
FYVE sequence was amplified by PCR using the primers AAG GAT CCA TGC CCT TGG TGG 
ATT TCT TCT GCT GGC AAT CTA GTC AAC GG and aaa ctc gag ttatccttgcaagtcattgaaaca, and 
inserted via BamHI and XhoI restriction sites into the Epac1-camps vector backbone. The resultant 
targeted sensor contained the full Epac1-camps sequences followed by a flexible linker 
GSMPLVDFFC and the FYVE sequence from WQSSQ on. Plasmid encoding the nanobody Nb-37 
recognizing activated form of Gs was generated according to [23]. Nb-37 specifically recognizes 
nucleotide-free form of α subunit of Gs[9].  
2.2 Cell lines and transfections 
 HEK 293 cells stably expressing the GIPR (Flp-lnTM HEK-GIPR) were obtained using the Flp-InTM 
system (Invitrogen). The cell lines was maintained in Dulbecco’s Modified Eagle’s medium 
supplemented with 10% of fetal bovine serum (FBS), in a humidified atmosphere at 95% air and 5% 
CO2. Transfections for BRET experiments were performed using polyethylenimine (PEI) transfection 
reagent (1mg/mL, pH 7.4) (Polyplus). Plasmids were diluted in DMEM without FBS (ratio DNA (μg) 
/ PEI (μL) 1:3). The mixture was mixed for 15 sec on a vortex, incubated for 15 min at room 
temperature and then deposited on the cells. For confocal experiments, transfections were performed 
using Lipofectamin 2000 (Invitrogen Life Technologies) following provider’s instructions (ratio DNA 
(μg) / LPF2000 (μL) 1:2). 
2.3 BRET assay of cAMP production 
 Flp-InTMGIPR-293 cells were plated onto 10-cm culture dishes and overnight grown afterward 
they were co-transfected with a total amount of 5 μg DNA plasmid of always comprising 4 μg of 
cAMP BRET biosensor RLuc-Epac-Citrine.  24 hours after transfection, cells were plated in 96-wells 
clear bottom plates (Corning) at a density of 100.000 cells per well in phenol red free DMEM 2% 
FBS. After an overnight incubation, the medium was removed and replaced by calcium and 
magnesium free PBS. BRET assay was initiated by adding 10 µl of coelenterazine h to the wells (final 
concentration 5 µM). After 10 min of incubation with coelenterazine h, stimulant of cAMP 
production, namely GIP or Forskolin was injected. Live-time mesurements were recorede at 37°C 
every 30 sec during 60 min.  Luminescence and fluorescence readings were performed on a Mithras 
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LB940 instrument (Berthold) that allows the sequential integration of signals at 465 to 505 nm and 
515 to 555 nm windows. MicroWin 2000 software was used for calculation.  
2.4 Live cell confocal fluorescence imaging 
 After an overnight transfection with 2 µg/well of pcDNA5/FRT containing cDNAs of interest, cells 
were transferred onto poly-L-lysine (Sigma-Aldrich) coated 4-wells Lab-Tek chambered coverglass 
(Nunc).  24 hours later, the culture medium was replaced by phenol red free medium (DMEM1X, 
4.5g/L D-glucose, L-Glutamine, 25mM HEPES, without sodium pyruvate, gibco Lifetechnologies). 
Cells were stimulated with appropriate ligand and were imaged at 37°C with a confocal Zeiss Laser 
Scanning Microscope LSM-780 equipped with 63×/1.4 NA oil immersion objective, a GaAsP detector 
with quantum yield of 45% and a parallel spectral detection attending 32 channels simultaneously in 
lambda (λ) mode. For multi-color imaging, the fluorophores were excited by the corresponding lasers 
and the fluorescence signals were collected in the corresponding emission spectra simultaneously. 
Images were processed using ImageJ software. 
2.5 Confocal microscopy image quantification of colocalisation 
 For co-localization determination both visual inspection and JACOP Image J plugin (Mander’s 
coefficient) were used. Briefly, for evaluating the co-localization of DY647-GIP with DsRed-Rab5 or 
GFP-EEA1, clearly observed DY647-GIP-containing vesicles were selected and counted. After 
merging the DY647 channel with DsRed or GFP channel using Image J, vesicles showing co-
localization were identified and counted. At the different times after stimulation, co-localization level 
representing co-localizing vesicles expressed as percent of total DY647-GIP-containing endocytic 
vesicles was determined. We found that Mander’s coefficients determined by JACOP ImageJ plugin 
matched well with the co-localization levels determined by visual inspection (Supplementary Fig. 2). 
3-5 cells were analyzed in 3-4 independent experiments. 
2.6 FRET assays of cAMP production 
cAMP production was determined by FRET on Flp-InTMGIPR-293 cells transfected with cytosolic 
cAMP sensor Epac1-camps plasmid [22]. FRET was monitored as the ratio between emission at 
535±20 nm (YFP) and emission at 480±615 nm (CFP), upon excitation at 436±10 nm using MetaFluor 
5.0 software (Molecular Devices). The imaging data were analyzed utilizing MetaMorph 5.0 
(Molecular Devices) and Prism (GraphPad Software) software, by correcting for spillover of CFP into 
the 535- nm channel and direct YFP-excitation, to give corrected YFP/CFP ratio data. Images were 
acquired every 5 s, with 5-ms illumination time, which resulted in negligible photobleaching for over 
30-min observation. To study GIP-induced changes and reversibility in cAMP, cells were 
continuously superfused with phenol red–free medium containing 1% BSA or the same plus GIP 
and/or internalization inhibitor, Dyngo-4a, with a custom apparatus. All experiments were performed 
at 25°C.  
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 FRET assay of cAMP from endosomes was carried out on a confocal Zeiss Laser Scanning 
Microscope LSM-780. FRET was monitored as the ratio between emission at 539±23 nm (YFP) and 
emission at 482±18 nm (CFP) upon excitation at 458 nm. The DY647-GIP emission at 655±40 nm 
was detected in sequential mode upon excitation at 633 nm. By using this setup and under our 
experiment conditions, GIP-DY647 fluorochrome did not influence signal of cAMP FRET biosensor 
(Figure 6S).  Images were analyzed using ImageJ. Threshold limited endosomes were outlined using 
“analyze particle” tool. Mean FRET value for each endosome is calculated on the FRET resulting 
image. Endosome state, namely internalized (containing DY647-GIP) or pre-existing (free of ligand), 
was visually determined on the merged image.  
2.7 Receptor binding assays 
 Flp-InTMGIPR-293 cells were grown onto 10-cm culture dishes for 24 h and then transferred to 24-
well plates. Approximately 24 h later, binding assays were performed using 125I-Phe1-GIP according to 
the protocol previously described in detail [24]. Non specific binding corresponded to residual binding 
of 125I-Phe1-GIP in the presence of 1µM GIP. IC50 (concentration inhibiting half of specific binding) 
was calculated using the non-linear curve fitting software GraphPad Prism (San Diego, CA).  
2.8 Statistics 
 All values are expressed as the mean +/- standard error of the mean (SEM). Statistical analyses of 
data using Student’s t-test were performed with GraphPad Prism software version 6.0. Significance 
degrees were given as following: * 0.01<p<0.05; ** 0.001<p<0.01; ***p<0.001. 
 
3. Results 
 
3.1 Inhibition of GIPR sorting to early endosomes affected the sustained phase of cAMP 
production 
 We investigated production of cAMP from early endosomes in HEK cells which has been proven 
to be an excellent and relevant cell model for the study of GPCR internalization and related signalling. 
HEK 293 cells stably expressing GIPR, (termed Flp-lnTM HEK-GIPR), bound GIP with a nanomolar 
affinity and dose-dependently responded to GIP by stimulating production of cAMP with an EC50 of 
1.1 ± 0.2 nM [18]. We traced GIPR at the cell surface or interior by using fluorescently tagged GIP 
(termed DY647-GIP) which bound to GIPR and stimulated cAMP production identically to 
unmodified GIP and, moreover, co-localized with GIPR for up to 2h during post-endocytic sorting to 
lysosomes [18]. As shown on Fig. 2A, confocal microscopy observations of Flp-lnTM HEK-GIPR cells 
revealed intense homogenous labeling of the plasma membrane immediately after addition of DY647-
GIP. Fluorescence was then rapidly relocated in membrane clusters and rapidly entered into the cells 
as punctuate vesicles which moved over the incubation time. Confocal microscopy imaging of cells 
expressing tagged functional proteins of early endosomes, namely DsRed-Rab5 or GFP-EEA1, 
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indicated that chronic stimulation of GIPR resulted in abundant localization of DY647-GIP-bound 
GIPR in vesicles positive for the markers of early endosomes (Fig. 2B, C, D). 
 In order to determine whether GIPR can signal from endosomes to produce cAMP, we first sought 
to assess the influence of internalization blockade on the kinetic and level of GIP-induced cAMP 
response measured in real-time by a cytosolic BRET biosensor. Internalization of GIPR occurs 
through clathrin-coated pits, with an involvement of dynamin that enables detachment of endocytic 
vesicles from the plasma membrane and formation of early endosomes containing GIPR [18](Fig. 1). 
In light of previous data showing that the chemical dynamin inhibitor Dynasore was not fully effective 
to arrest GIPR internalization, we tested Dyngo-4a which was reported to be ~6-fold more potent than 
dynasore to inhibit dynamin in intact cells [25].  However, confocal microscopy imaging experiments 
showed a dramatic decrease of Flp-lnTM HEK-GIPR cell labeling by DY647-GIP in the presence of 
Dyngo-4a (not shown). This result, which could not be due to an inhibitory action of Dyngo-4a on  
GIP binding to GIPR (see below), precluded the use of DY647-GIP to assess inhibitory effect of 
Dyngo-4a on GIPR internalization. Therefore, cells were transfected to express GFP-GIPR and then, 
were stimulated with 1µM GIP in the presence or absence of Dyngo-4a. Confocal microscopy imaging 
showed full blocking of GFP-GIPR internalization by Dyngo-4a (Supplementary Fig. 1). We therefore 
determined if Dyngo-4a affected kinetic and real-time levels of GIP-stimulated cAMP formation. As 
shown on Fig. 3, cAMP stimulated by 10nM GIP rapidly increased and remained sustained at its 
maximum level over time. In contrast, cAMP level continuously declined in the presence of Dyngo-4a 
to a value of ~27% of the maximum value at 60 min of stimulation, suggesting the existence of a 
relationship between cAMP production and GIPR internalisation. Profile of cAMP production 
stimulated by 100nM GIP was slightly different. It showed a rapid increase followed by a slight drop, 
likely due to strong desensitization of the initial cAMP response at this GIP concentration [18], until 
10 min of stimulation. Then, cAMP level remained constant to ~ 70% of the maximum value. 
 We further assessed that sustained phase of cAMP production truly result from internalized GIPR 
by studying reversibility of cAMP response after washout GIP from the cells. For this purpose, cAMP 
was measured by FRET using Epac1-Camps cytosolic sensor [22]on cells which were stimulated with 
10 nM GIP and then superfused with buffer to wash out GIP. Stimulation by GIP for 2 or 5 min 
caused rapid decreases of FRET ratio accounting for cAMP production and washout GIP did not result 
in significant FRET changes indicating irreversibility of cAMP response (Fig. 4A). In contrast, similar 
FRET measurements carried out on cells treated with Dyngo-4a to block GIPR internalization, 
revealed that after the decrease of FRET signal in response to GIP stimulation, washout GIP resulted 
in an important return of FRET signal accounting for reversibility of cAMP response (Fig. 4B). 
Quantitative analysis of the data indicates that cAMP response was reversible in cells having GIPR 
internalization blocked whereas cAMP response was only weakly reversible in control cells 
internalizing GIPR (Fig. 4C). 
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 We then verified that lost of cell labeling by DY647-GIP in the presence of Dyngo-4a was not due 
to an inhibition of GIP binding to GIPR thus explaining cAMP decline over time. We performed 
binding of radio-iodinated GIP in the presence or absence of Dyngo-4a. Results demonstrated that 
binding kinetic of radio-iodinated GIP and binding affinity of GIP for the GIPR were not affected in 
the presence of Dyngo-4a, clearly ruling out a possibility of interference of the dynamin inhibitor with 
GIP binding to GIPR (Supplementary Fig. 1B, C). Most likely, Dyngo-4a chemically reacts with 
DY647 and therefore quenched DY647 fluorescence. Furthermore, Dyngo-4a at concentration of 30 or 
60 µM did not affect production of cAMP resulting from direct stimulation of adenylyl cyclase by 
foskolin (Supplementary Fig. 1D, E). Collectively, this first set of results strongly supports the view 
that internalized GIPR contributes to the sustained phase and irreversibility of cAMP response in Flp-
lnTM HEK-GIPR cells. 
 
3.2 Accumulation of early endosomes containing GIPR enhanced the sustained phase of cAMP 
production 
 In order to further establish the relationship between the presence of GIPR in early endosomes and 
cAMP production profiles, we over-expressed a dominant negative of Rab7 in Flp-lnTM HEK-GIPR. 
Rab7 is a GTPase that, in addition to its regulatory role in cargo transport from late endosomes to 
lysosomes, is required for early sorting events (Fig. 1). Dominant negative of Rab7 (DN-Rab7), by 
inhibiting exchange between Rab5 and Rab7 in early endosomes leads to accumulation of early 
endosomes in cells [26]. Accordingly, stimulation of cells over-expressing DsRed-DN-Rab7 by 
DY647-GIP resulted in strong accumulation of DY647-GIP-bound GIPR in endocytic vesicles 
positive for GFP-EEA1 (Fig. 5A, B). As a quantitative proof of early endosome accumulation, image 
analysis and quantification indicated that 88 ± 3 % of endocytic vesicles containing DY647-GIP-
bound GIPR were positive for EEA1 in cells over-expressing DsRed-DN-Rab7 after 30 min of 
stimulation. This co-localization level was 73 ± 16 % in cells not expressing DsRed-DN-Rab7. After 
60 min of stimulation, 81 ± 3 % of endocytic vesicles containing DY647-GIP-bound GIPR were 
positive for EEA1 in cells over-expressing DsRed-DN-Rab7 whereas this co-localization level 
dropped to 24 ± 4 % in cells not expressing DsRed-DN-Rab7 (Fig. 5C). We then characterized the 
kinetic of cAMP production in Flp-lnTM HEK-GIPR cells transfected with plasmid encoding DsRed-
DN-Rab7 and which, according to fluorescence confocal microcopy observations, over-expressed the 
encoded protein. As shown on Fig. 5D, after a rapid rise, level of cAMP was stabilized (for 1 or 10 nM 
GIP stimulation) or slightly declined during few minutes (for 100 nM GIP stimulation) and then 
increased continuously. These profiles of enhanced cAMP production in cells over-expressing DsRed-
DN-Rab7 were observed for both physiological and pharmacological concentrations of GIP, namely 
from 1nM to 100 nM GIP. Control experiments showed no significant modification of forskolin-
stimulated cAMP levels in cells over-expressing DsRed-DN-Rab7 (supplementary Fig. 2). Therefore, 
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an accumulation of DY647-GIP-bound GIPR in early endosomes correlated with a continuous 
increase of cAMP level in Flp-lnTM HEK-GIPR cells. 
 
3.3 Identification of the active form of Gαs in early endosomes containing activated GIPR  
 At this step of the work, the view that internalized GIPR continues to stimulate cAMP production 
in early endosomes is based on data showing modulation of kinetic and level of cAMP by Dyngo-4a 
and Rab7 dominant negative acting respectively on internalization and accumulation of GIPR in early 
endosomes. Therefore, our next aim was to provide more direct evidence by detecting GIPR activation 
and signalling in early endosomes. We first used a conformational biosensor (termed GFP-Nb37) 
composed of a single-domain antibody (nanobody) tagged with GFP and recognizing Gs only in its 
active form. In the absence of GIPR stimulation, genetically expressed GFP-Nb37 localized 
exclusively in the cytoplasm of cells (Fig. 6A). Immediately after stimulation by GIP, GFP-Nb37 was 
recruited to the plasma membrane. This recruitment of GFP-Nb37 to the plasma membrane lasted 
during the chronic stimulation by GIP (Fig. 6A). Strikingly, many endocytic vesicles containing 
DY647-GIP were also labeled by GFP-Nb37, demonstrating presence of active Gαs together with 
DY647-GIP-bound GIPR in these vesicles (Fig. 6A, lower images). Furthermore, vesicles positive for 
GFP-Nb37 also expressed DsRed-Rab5 or GFP-EEA1, two markers of early endosomes. This co-
localization was illustrated by line scan analysis of confocal microscopy images of an endocytic 
vesicle (Fig. 6C). Quantification of co-localization indicated that 76.0 ± 7.0 % of endocytic vesicles 
containing DY647-GIP-bound GIPR were labeled with GFP-Nb37 at time 30 min. This proportion 
decreased to 48.9 ± 7.9% at 60 min. In cells over-expressing DsRed-DN-Rab7, the proportion of 
endocytic vesicles labeled with Nb-37-GFP remained high, 82.8 ± 4.1 % and 78.5 ± 4.7% at times 30 
and 60 min, respectively (Fig. 6D, E). From these different experiments, it appears that active Gαs is 
present together with activated GIPR in early endocytic vesicles and over-expression of Rab7 
dominant negative prolongs this co-localization. 
 
3.4 Direct identification of cAMP production on early endosomes containing internalized GIPR
 To further demonstrate production of cAMP by internalized GIPR, we performed detection of 
cAMP in endosomes. For this purpose, we took advantage of the fact that PtdIns(3)P is the most 
abundant phosphoinositide in the membrane of early endosomes to target expression of a FRET cAMP 
probe at the external surface of early endosomes using FYVE domain of EEA1. The FYVE domain is 
a protein motif that allows the interaction of cytosolic proteins, such as EEA1, with membranes 
containing the lipid phosphatidylinositol 3-phosphate [27]. The probe for cAMP detection was thus a 
FRET probe consisting in EYFP-Epac1 (binding domain)-ECFP-EAE1 (FYVE domain). This probe 
(termed FYVE-EPAC) was efficiently targeted to the membrane of endosomes in the majority of cells. 
In order to determine if internalized GIPR continued to stimulate production of cAMP, we compared 
FRET ratio in early endosomes containing DY647-GIP-bound GIPR which therefore contained 
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activated GIPR, with FRET ratio in pre-existing endosomes lacking DY647-GIP from the same cell. 
As an example, on Fig. 7, are outlined images of 4 endosomes from a single cell stimulated with 
DY647-GIP showing that FRET ratios were 2.60 and 2.67 at the surface of the two endosomes 
containing DY647-GIP-bound GIPR whereas FRET ratios were 2.91 and 3.00 at the surface of the two 
endosomes lacking DY647-GIP-bound GIPR. The lower FRET ratio at the surface of endosomes 
containing DY647-GIP-bound GIPR most likely reflected endosomal production of cAMP. Indeed, 
the 4 endosomes were equally distant to the cell surface and were equally subject to diffusible cAMP 
produced at the plasma membrane. Furthermore, analysis of a large population of endosomes from 13 
individual cells stimulated with DY647-GIP indicated that in each cell (represented by an empty circle 
linked by a dotted line to an empty square), FRET ratio at the membrane surface of early endosomes 
containing activated GIPR was lower than FRET ratio in early endosomes lacking activated GIPR. 
Averaged FRET ratios were 2.56 ± 0.03 versus 2.83 ± 0.04, p˂0.001 at time 30 min of stimulation. 
These data unequivocally establish the existence of production of cAMP at the surface of endosomes 
containing both GIPR and its ligand. Control experiments measuring total cAMP using cytosolic 
FRET sensor showed rapid decreased of FRET after stimulation by GIP followed by stabilization 
(Supplementary Fig. 4) in agreement with BRET kinetics that accounted for persistent stimulation of 
total cAMP in cells (Fig. 3).  
4. Discussion 
 The current work provides a series of experimental data demonstrating that, once internalized and 
located in the membrane of early endosomes, GIPR continues to be activated and to trigger production 
of cAMP. Direct evidence for the activity of internalized GIPR is based on identification of the active 
form of Gαs in early endosomes containing GIP using a genetically encoded GFP tagged nanobody, 
and on detection of a distinct FRET signal accounting for cAMP production at the surface of 
endosomes containing GIP compared to endosomes without GIP. Furthermore, strong indirect 
experimental proofs were obtained on cells treated with a pharmacological inhibitor of GIPR 
internalization, such as decrease of the sustained phase of cAMP kinetic and reversibility of cAMP 
response following GIP washout. Furthermore a continuous increase of cAMP levels over time was 
observed in cells expressing genetically encoded dominant-negative of Rab7 which causes 
accumulation of early endosomes. 
 In fact, direct identification of active Gα and cAMP production at the surface of endosomes was 
made possible by the combinational use of three major biological tools: the fluorescent agonist of the 
GIPR, DY647-GIP, the fluorescent nanobody recognizing active Gαs and FYVE-EPAC-based FRET 
sensor for local endosomal cAMP production. DY647-GIP, which retains biological activity of native 
GIP and which fully co-localizes with GIPR for at least the first 2 hours of post-endocytic trafficking 
[18], enabled to distinguish endosomes containing activated GIPR from endosomes devoid of 
fluorescent GIP and therefore, not containing activated GIPR. The second crucial tool was the GFP-
 112 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 
11 
 
tagged nanobody, GFP-Nb37. It specifically recognizes the guanine-nucleotide-free form of Gαs 
representing the catalytic intermediate of Gαs activation[9]. The third biological tool, especially 
developed for this study, was FYVE-EPAC FRET sensor for cAMP which was specifically targeted to 
early endosomes by insertion of FYVE sequence. Indeed, FYVE sequence, derived from EEA1, 
provided binding of the FRET sensor to PtdIns(3)P contained in the membrane of early endosomes 
[27]. 
 Our findings contradict the classical concept whereby G-protein dependent signalling of GPCRs 
occurs exclusively at the plasma membrane and that internalized GPCRs are silent with respect to this 
signalling pathway. On the other hand, based on these findings, the GIPR joins the group of GPCRs 
for which endosomal G-protein coupled signalling have been suggested or demonstrated. So far, this 
group of GPCRs includes Parthyroid Hormone receptor, Tyroid-Stimulating Hormone receptor, 
Vasopressin 2 receptor, dopamine D1 receptor, Sphingosine-1-phosphate receptor, β2-adrenergic 
receptor, Pituitary Adenylate Cyclase 1 receptor and Glucagon-like peptide 1 receptor [5-9, 11, 28, 
29]. 
 How internalized GIPR triggers G-dependent signalling in endosomes and how this spatio-
temporal signalling can be reconciled with sequential events governing GIPR activation-
desensitization (inactivation) cycle at the plasma membrane are important and timely issues which are 
not elucidated yet. In the canonical cycle of Gs-coupled GPCR activation and desensitization, the 
agonist ligand binds to an active form of the receptor and stabilizes it, permitting coupling to cognate 
heterotrimeric GDP-bound G proteins. The active receptor-G-protein complex catalyzes GDP-GTP 
exchange causing dissociation of the Gα subunit and βγ dimer from the receptor. Next, GTP-bound Gα 
binds to and activates adenylate cyclase that converts ATP into cAMP. After G-protein 
coupling/decoupling, the receptor is phosphorylated by GRK and by second messenger-dependent 
kinases (such as PKA), an event, which most often causes recruitment of the adaptator proteins β-
arrestins. β-arrestins terminate G-protein-dependent  signal and permit the targeting of the receptor to 
clathrin-coated pits for endocytosis. At this step, the receptor is associated with a set of proteins of 
internalization and trafficking cell machineries.  
 Studies with β2-adrenergic receptor support the view that, after dissociation of Gαs from the 
membrane receptor and recruitment of β-arrestins, Gαs is activated in endosomes containing β2-
adrenergic receptor presumably free of β-arrestins [9]. A different mechanism has been elucidated for 
the PTH and vasopressin 2 receptors in which agonist-activated receptors form a ternary complex that 
include arrestins and Gβγ dimer which accelerate rate of Gαs activation and increase levels of 
activated Gαs, leading to persistent production of cAMP. In this later example, arrestins play the role 
of scaffold protein for maintaining activated Gαs associated with the receptors [8, 30]. In the current 
case of GIPR, it is unlikely that β-arrestins could play a role in activation of Gαs. Indeed, the GIPR 
does not recruit β-arrestins upon activation [18, 19] and GFP tagged β-arrestin-1 or -2 were never 
identified in endosomes containing GIPR [18]. Another difference between GIPR and PTHR concerns 
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the influence of endosome acidification for the termination of endosomal cAMP production. Indeed, 
we did not observe any significant effect of bafilomycin, an inhibitor of v-ATPase, on the sustained 
phase of cAMP production (Supplementary Fig. 5), whereas, for the PTH receptor, based on results 
with this inhibitor, it has been proposed that endosomal cAMP production is turned off by endosome 
acidification which dissociates PTH from its receptor. On the other hand, as for GIPR in the current 
study, TSHR was shown to bind TSH and be activated in acidic conditions [6]. 
 In line with presence of active Gαs in endosomes containing activated GPCRs, a recent study 
shows that presence of Gαs in endosomes has a function which is not restricted to stimulation of 
diffusible second messengers. Indeed, endosomal Gαs was found to contribute to the endocytic sorting 
of several GPCRs to lysosomes. This occurs through binding to GPCR-associated binding protein-1 
(GASP1) and dysbindin, two key proteins of the endosomal sorting of GPCRs in intra-luminal vesicles 
of multivesicular bodies [31]. Interestingly, this function of Gαs in lysosomal degradation of GPCRs 
does not require its activation, supporting a scaffolding rather a signalling function. In light of these 
findings, it is plausible that during post-endocytic sorting of GPCRs, Gαs successively plays a role in 
their endosomal signalling in early endosomes and then, in their trafficking to lysosomes.  
 Results from the current study on HEK cells represent a real milestone and call future works on 
cells naturally expressing GIPR. Indeed, a major issue raised by endosomal production of cAMP lies 
in its functional relevance. In fact, the novelty of the discovery that GPCRs continue to stimulate 
cAMP formation on endosomes is enhanced by accumulating data demonstrating that cAMP is 
compartimentalized in cells to enable discrete pathways of localized signalling and related 
physiological responses to occur [32]. In this regard, it can be hypothesized that endosomal cAMP 
production mediated by internalized GPCRs contributes to the spatio-temporal organization of cAMP 
signalling cascade involving PKAs, EPACs, AKAPs, PDEs, etc....  
 As an example supporting this concept, it was reported that internalization of the TSH receptor is 
required to ensure normal actin rearrangement in thyroid follicles and phosphorylation of vasodilator-
stimulated phosphoprotein (VASP) [6]. As another example, the duration of PTH-induced calcemic 
and phosphate responses in mice which are dependent of PTH ligands, was related to the duration of 
cAMP responses in correspondence with the ability of the ligands to stimulate cAMP from 
internalized PTH receptors [5]. The divergent antinatriuretic and antidiuretic actions of vasopressin 
and oxytocin, both acting on V2 vasopressin receptor, were also explained by different profiles of 
cAMP responses to the two hormones, with vasopressin causing an endosomal sustained cAMP 
production and oxytocin causing a short cAMP production, limited to the plasma membrane [8]. 
Moreover, a relationship between expression of cAMP-dependent genes and endosomal cAMP 
production triggered by internalized β-adrenergic receptor was recently reported [12].  In this study, 
inhibitors of β-adrenergic receptor internalization reduced PKA phosphorylation of CREB and 
expression of several cAMP-regulated genes, including the gene encoding the phosphoenolpyruvate 
carboxykinase 1. In light to these data, our forthcoming investigations should address the question of 
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how endosomal GIP-induced cAMP signalling is required for full physiological functions of GIP. 
Such a challenging question requires development of new relevant biological tools.  
5. Conclusion 
 We have demonstrated that, once internalized and located in the membrane of early endosomes, the 
receptor for Glucose-dependent Insulinotropic receptor (GIPR) continues to trigger production of 
cAMP which accounts for sustained cAMP production.  Hence, production of endosomal cAMP by 
internalized presumably contributes to the spatio-temporal organization of cAMP signalling cascade 
downstream GIPR.  
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8.  Figure legends 
 
Fig. 1: Schematic representation of GIP receptor internalization and post-endocytic trafficking 
and tools used to identify endosomal production of cAMP 
GIP-bound-GIPR was identified using DY647-GIP. Total cAMP production was measured using 
cytosolic Bret sensor RLuc-Epac1-citrine or Fret sensor EYFP-Epac1-ECFP. Early endosomes were 
labeled with DsRed-Rab5 or GFP-EEA1. Dyngo4-a, an inhibitor of dynamin, served to inhibit GIPR 
internalization whereas DsRed-DN-Rab7 caused accumulation of early endosomes. Activity of GIPR 
in early endosomes was detected using a nanobody specific of active form of Gαs subunit and an 
endosomal FRET sensor genetically targeted to early endosomes thanks to FYVE sequence 
recognizing PI(3)P.    
Fig. 2: Internalization and localization of GIP receptor in early endosomes 
HEK cells expressing the human GIP receptor (Flp-InTMGIPR-293 cells) transfected with plamids 
encoding fluorescence tagged proteins of the early endosomes, DsRed-Rab5 or GFP-EEA1, were 
stimulated with 10 nM DY647-GIP at 37°C. Fluorescence confocal microscopy images were acquired 
over the time using identical instrument settings. Panel A corresponds to a representative microscopy 
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field showing two cells, over-expressing or not DsRed-Rab5 (displayed in green). DY647-GIP-labeled 
GIPR (displayed in red) is seen at the cell surface at time 3 min of incubation, then, in endocytic 
vesicles close to the membrane (5 min) and scattered within the cells (20, 30 min). DY647-GIP-
labeled GIPR co-localizes with DsRed-Rab5 (79 ± 9 % at 30 min, Pearson’s correlation coefficient -
PCC- is indicated on image of time 30 min). Panel B shows co-localization of DY647-GIP-labeled 
GIPR with GFP-EEA1 at times 20 and 60 min of stimulation (values of co-localization were 73 ± 
17%, PCC: 0.64 ± 0.07 and 24 ± 4%, PCC: 0.50 ± 0.06, respectively). Panel C shows a zoom of an 
endosome containing both DY647-GIP and DsRed-Rab5, and panel D shows its line scan.  
Fig. 3: Inhibition of GIP receptor internalization affected the sustained phase of GIP-stimulated 
cAMP production 
 HEK cells expressing the human GIP receptor (Flp-InTMGIPR-293 cells) transfected with plamids 
encoding BRET biosensor, Rluc-Epac1-citrine, were stimulated with GIP (10 or 100 nM) for BRET 
measurement of cAMP, as described in “Materials and Methods” section. Blue records (control) 
correspond to 1/BRET signal from experiments performed in the absence of inhibitor of 
internalization, and Red records correspond to 1/BRET signals in the presence of inhibitor of 
internalization (Dyngo4-a, 60 µM). 1/BRET values expressed as percent of maximum in control assay 
are the mean ± SEM of 3 individual experiments. They account for a decrease of the sustained and late 
phase of cAMP production in the presence of Dyngo-4a.   
 
Fig. 4: Inhibition of GIPR internalization abolished irreversibility of GIP-induced cAMP 
production 
Stable Flp-InTMGIPR-293 cells were transfected with plamid encoding cytosolic biosensor Epac1-
camps. 24 h post-transfection, cells were washed and then incubated with medium (A, control) or with 
medium containing 30µM Dyngo-4a (B, Dyngo-4a). Next, cells were superfused with 10nM GIP for 2 
or 5 min with subsequent washout. All experiments were performed at 25°C. During these 
experiments, FRET was recorded as described in “Materials and Methods” section. Four 
representative records are shown. Values of YFP/CFP FRET ratios are expressed relative to initial 
FRET ratio which was normalized to 1.00. For analysis of reversibility of cAMP response after GIP 
washout, (C, reversibility), signal reversibility calculated by setting the minimum FRET ratio value 
equal and the initial FRET value before GIP stimulation to 100%. Values are the mean±SEM of 8-10 
records (noticed on figure). The data indicate that cAMP response was reversible in cells having GIPR 
internalization blocked whereas cAMP response was only weakly reversible in control cells 
internalizing GIPR. 
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Fig. 5: Accumulation of activated internalized GIP receptors in early endosomes enhanced the 
sustained phase of cAMP production 
Confocal microscopy images captured after 60 min of stimulation with 100 nM DY647-GIP of HEK 
cells expressing the human GIP receptor (Flp-InTMGIPR-293 cells) co-transfected with plamid 
encoding GFP-EEA1 (displayed in green) plus plasmid encoding DsRed tagged dominant negative of 
Rab7 (DsRed-DN-Rab7, displayed in blue, panel A), or with plamid encoding GFP-EEA1 plus empty 
plasmid pcDNA5 (control, panel B). Pearson’s correlation coefficients –PCC- are indicated on 
images. Presence of DY647-GIP-labeld GIPR in early endosomes was quantified by analyzing co-
localization of DY647-GIP and GFP-EEA1. Results at times 30 and 60 min, reported in panel C, 
show persistent co-localization at time 60 min in cells overexpressing DsRed-DN-Rab7, whereas a 
dramatic decrease is seen in control cells not transfected with DsRed-DN-Rab7 (p˂0.001). In panel D, 
Flp-InTMGIPR-293 cells were co-transfected with plamid encoding BRET biosensor (Rluc-Epac1-
citrine) plus plasmid encoding DsRed-DN-Rab7 or empty plasmid PcDNA5 as control. Cells were 
stimulated with GIP (10 or 100 nM) for BRET measurement of cAMP, as described in “Materials and 
Methods” section. Blue records correspond to 1/BRET signal ratio from control cells and Red records 
correspond to 1/BRET signal ratio from cells over-expressing DsRed-DN-Rab7. 1/BRET values 
expressed as percent of maximum in control assay are the mean ± SEM of 3 individual experiments. 
They account for an increased of the sustained and late phase of cAMP production in the presence of 
DN-Rab7.   
Fig. 6: Immunological detection of active Gαs in endosomes containing activated GIP receptor 
HEK cells expressing the human GIP receptor (Flp-InTMGIPR-293 cells) transfected with plasmid 
encoding the GFP-tagged nanobody specifically recognizing the active form of Gs (termed GFP-
NB37, displayed in green) were stimulated with DY647-GIP. Fluorescence confocal microscopy 
images were captured at various time of stimulation. Images in panel A show co-localization of 
DY647-GIP, DsRed-Rab5 and GFP-Nb37 in endocytic vesicles. The white arrow on GFP-Nb37 
images shows membrane recruitment of GFP-Nb37. A merge image of DY647-GIP and GFP-Nb37 
colors is shown for the time 30 min of stimulation with DY647-GIP. It can be appreciated from an 
image zoom of the cell that many endosomes labeled by DY647-GIP are also labeled by the antibody 
against active Gαs, GFP-Nb37 (displayed by white arrows). In panel B and C are shown an image 
zoom of an endosome and the line scan, respectively. Panel D, confocal microscopy images of Flp-
InTMGIPR-293 cells co-transfected with plasmid encoding GFP-NB37, (displayed in green) and 
DsRed-DN-Rab7 (displayed in blue) at time 60 min of stimulation with 100 nM DY647-GIP. Upper 
images correspond to cells co-transfected with plasmids encoding GFP-NB37 and DsRed-DN-Rab7 
whereas lower images correspond to control cells co-transfected with plasmids encoding GFP-NB37 
and pcDNA5. Panel E reports quantification of co-localization indicating that 76.0 ± 7.0 % of 
endocytic vesicles containing DY647-GIP-bound GIPR were labeled with GFP-Nb37 at time 30 min. 
This ratio decreased to 48.9 ± 7.9% at 60 min. In cells over-expressing DsRed-DN-Rab7, the ratio of 
 118 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 
17 
 
endocytic vesicles labeled with Nb-37-GFP was high, 82.8 ± 4.1 % and 78.5 ± 4.7% at times 30 and 
60 min, respectively. Co-localization ratios at 60 min were significantly different in control cells and 
in cells over-expressing DsRed-DN-Rab7, p˂0.002. 
 Fig. 7: Direct detection of cAMP production by FRET in endosomes containing activated GIP 
receptors  
Flp-InTMGIPR-293 cells co-transfected with plasmid encoding DsRed-DN-Rab7 and plasmid encoding 
FRET sensor of cAMP targeted to early endosomes thanks to FYVE sequence, (termed CFP-EPAC-
YFP-FYVE), were stimulated with 100 nM DY647-GIP for 30 min. Panel A shows representative 
confocal microscopy images of cells presenting endocytic vesicles. Panel B shows a confocal 
microscopy image on which only red fluorescence of DY647-GIP and green fluorescence of cAMP 
FRET sensor are displayed for convenience. Two vesicles containing DY647-GIP-bound GIPR 
presenting FRET ratio of 2.60 and 2.67 and two vesicles devoid of DY647-GIP presenting a FRET 
ratio of 2.91 and 3.00 are pointed to illustrate how measurement of cAMP production on the surface of 
endosomes containing or not DY647-GIP-activated GIPR was performed. Panel C is the 
representation of average FRET values on endosomes lacking DY647-GIP (empty circles) or on 
endosomes containing DY647-GIP-bound GIPR (empty squares). Endosomes taken in 13 cells from 3 
independent experiments and corresponding to a total of 66 and 53 vesicles were analyzed. Each 
couple of symbols (circle or square) linked by a dotted line corresponds to a single cell. From this 
representation it is evident that in each cell, FRET ratio is lower in endosomes containing DY647-
GIP-bound GIPR than in endosomes lacking DY647-GIP-bound GIPR. 
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Supplementary Fig. 1: Dyngo4-a efficiently inhibited GIPR internalization and did not affect GIP binding and 
foskolin-stimulated cAMP production  
HEK T cells transiently expressing the GFP-tagged GIPR (termed GFP-GIPR) were stimulated with 1µM GIP at 37° C with or 
without 30 µM Dyngo-4a, an inhibitor of dynamin-dependent internalization. Confocal microscopy images were recorded 
at various times of stimulation. Panel A corresponds to images of representative microscopy field at times 15 and 60 min 
of stimulation, illustrating kinetic of GIP-stimulated internalization of GFP-GIPR (upper images) which is inhibited by  
Dyngo-4a (lower images). In panels B and C, Flp-InTMGIPR-293 cells were incubated with 125I-Phe1-GIP with or without 
1µM GIP (for non specific binding determination) in the presence or absence of 30µM Dyngo -4a. Specific 125I-Phe1-GIP binding  
was determined at various times of incubation (panel B) or Specific 125I-Phe1-GIP binding at 30 min of incubation was inhibited 
by increasing concentrations of GIP (panel C). Results are expressed as percent of maximum specific binding and values are 
mean ± SEM of 3 individual determinations. They indicate that Dyngo-4a did not significantly influence kinetic and affinity 
of GIP binding. Panel D and E show representative experiments of cAMP measurement by BRET carried out on 
Flp-InTMGIPR-293 cells transfected with plasmid encoding Rluc-Epac1-Citrine and stimulated by Foskolin (10µM) in the 
presence or the absence of Dyngo-4a (30 or 60µM). Values of 1/BRET were expressed as percent of maximum. 
 
Supplementary data to article: Internalized Receptor for Glucose-dependent Insulinotropic Peptide 
stimulates adenylyl cyclase on early endosomes by Ismail et al. 
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Supplementary Fig. 2: Over-expression of dominant negative of Rab7 does not modify forskolin-induced  
production of cAMP 
Flp-InTMGIPR-293 cells co-transfected with plasmid encoding Rluc-Epac1-Citrine and DsRed-DN-Rab7 or 
pcDNA5 (control) were stimulated with 10µM foskolin. BRET determination of cAMP was performed as 
described in the “Materials and Methods” section. Values of 1/BRET were expressed as percent of maximum. 
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Supplementary Fig. 3: Determination of DY647-GIP and GFP-EEA1 co-localization using Mander’s coefficient. 
Flp-InTMGIPR-293 cells co-transfected with plasmid encoding GFP-EEA1 and DsRed-DN-Rab7 or pcDNA5 
(control) were stimulated with 100 nM DY647-GIP. Co-localization was determined by ACOP ImageJ plugin 
on images captured at 60 min of stimulation with DY647-GIP. 3-5 cells were analyzed in 3-5 independent  
experiments. Results matched well with the co-localization levels determined by visual inspection as shown on Fig. 4C. 
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Supplementary Fig. 4: FRET detection of total cAMP production in response to GIP receptor stimulation  
Flp-InTMGIPR-293 cells transfected with plasmid encoding CFP-EPAC1-YFP cytosolic FRET sensor were stimulated 
with 100 nM GIP. FRET corresponding to illumination of cytosolic FRET sensor was calculated on ROI 
(Region Of Interest) corresponding to the whole cell interior at the different times after GIP stimulation. 
Results are the mean ± SEM of 3 determinations. 
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Supplementary Fig. 5: Inhibition of V-ATPase of endosomes does not affect sustained level of cAMP  
Flp-InTMGIPR-293 cells transfected with plasmid encoding Rluc-Epac1-Citrine were incubated with 
or without 30 nM bafilomycin for 15 min and then stimulated with 100 nM GIP for BRET determination of cAMP 
as described in the “Materials and Methods” section. Values of 1/BRET were expressed as percent of maximum. 
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Supplementary Fig.6: Absence of DY647-GIP emission signal upon excitation of FRET sensor   
A spectral acquisition (λ mode) under the FRET experimental conditions was lunched. Emission signals  
every 3 nm between 599 and 700 nm were recuperated.  Acquisitions were performed before addition of  
DY647-GIP (deep blue curve) upon excitation at 458 nm or after ligand addition upon excitation  
at 458 nm or 633 nm (clear blue and red curves, respectively). No emission signal in the DY647 emission 
spectra could be detected upon excitation at 458 nm, neither before nor after DY647-GIP addition. 
DY647 emission signal was detected only upon excitation at 633 nm.  
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Conclusions of Article II 
 
In this current study, we successfully applied our strategy of three approaches 
to prove that GIPR signaling is not restricted to cell membrane, rather it exceeds the 
cell surface limit and can be active in intracellular compartments attained by the 
internalization of the receptor. 
   
The first approach showed that GIP-induced GIPR signaling is maintained 
after receptor endocytosis. Our first set of experimental results, administrating a 
pharmacological inhibitor of GIPR endocytosis, shows a weakening or a reversibility 
of sustained cAMP production phase following continuous or interrupted GIP 
stimulation respectively. Moreover, amplifying the reservoir of early endosomes 
containing activated-GIPR by overexpressing dominant-negative Rab7, shifted the 
cAMP production slope to increase.  Altogether, relying on indirect proofs of concept, 
these results prove that GIPR exhibits a sustained GIP-induced cAMP producing 
phase of signaling that is tightly related to receptor internalization. 
 
Our second approach presented a more direct evidence for the concept of 
GIPR signaling from endosomes. By the use of GFP-Nb37, results show an activation 
of Gas on the  membrane of early endosomes containing activated-GIPR as well as 
on the cell surface. 
 
In The third approach, the use of a specific endosome-targeted cAMP FRET-
sensor allowed us to witness a considerable increase in cAMP production level 
originating from early endosomes containing activated-GIPR. 
  To our knowledge, this experiment constitutes the first and only evidence that 
directly proves clear emission of a G protein-dependent signal from an internalized 
activated GPCR located in endosomes. 
 
Overall, the results of our study support the uprising concept of G protein-
dependent GPCR signaling from endosomes and thereby adds the GIPR to the list of 
involved ones. 
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Contrarily to PTHR and knowing that GIPR internalization do not involve b-
arrestins, the mechanism underlying the persistence of GIPR signal could be closer to 
that of the b2AR one, where receptor-associated-Gas undergoes a second round of 
activation at the level of early endosomes, after dissociation of adaptors of the 
endocytosis ( b-arrestins in the case of b2AR). 
Furthermore, GIPR endosomal signal termination does not seem to be caused 
by the acidification of endosomes, as it is the case for the PTHR. Indeed, our 
supplementary results showed that the sustained phase of GIP-induced cAMP 
production is unaffected by the use of bafilomycin, an inhibitor of the endosome-
acidifying pump v-ATPase. 
 
Finally, this new aspect in GIPR signaling added a twist to the global 
regulation of GIPR signal and its functional consequences; it opens many perspectives 
in the pharmacological regulation of GPCRs signaling in general. 
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The current research works were conducted in the INSERM team named 
“Receptors and therapeutic targeting of cancers”. In this team, projects are developed 
with the aim to take advantage of over-expression of GPCRs in certain cancers to 
eradicate tumor cells. The strategy used does not consist in blocking GPCR with 
antagonists but wants to use membrane GPCR as a target for killing agents, namely 
magnetic nanoparticles grafted with GPCR ligands.  The strategy is based on the 
ability of magnetic nanoparticles to move under a magnetic field of low frequency or 
to heat under an alternating magnetic field of high frequency. GPCR internalization 
represents the physiological process able to direct magnetic nanoparticles to the tumor 
cell interior. Thus, the main motivation for the development of this research axis on 
GIPR was not only related to the potential therapeutic interest of this peculiar GPCRs 
in diabetology. It was also directly linked to the potentiality of GIPR as a target in 
cancers. 
Indeed, abundant data reported expression and even over-expression of GPCR 
in cancers and it is now clear that neuroendocrine tumors are characterized by an 
over-expression of several GPCRs. Our team recently contributed to the discovery, in 
collaboration with JC Reubi (Bern) that almost all endocrine human tumors over-
expressed the Glucose Insulinotropic Polypeptide Receptor (GIPR) making GIPR the 
most universal receptor target for endocrine tumor detection(Waser et al., 2012). Of 
particular interest, over-expression of GIPR in pancreatic endocrine tumors contrasts 
with down-regulation of GIPR in the pancreas of diabetes 2 patients. 
Our data clearly establish that GIPR, like other GPCRs, is rapidly and 
abundantly internalized following stimulation by its natural agonist ligand. This 
finding was obtained in HEK cells but it was confirmed in endocrine tumor cells 
transplanted in mice (Gourni et al., 2014). Hence, internalization of GIPR over-
expressed in endocrine tumors could be used to accumulate killing agents in tumor 
cells.  
Data also indicate that a minor part of internalized GIPR is recycled to the cell 
surface whereas ~90% are directed to the degradation pathways, in the lysosomes. 
Whether this fact might contribute to the decrease of GIPR incretin response reported 
in diabetic situation remained to be established. To address this important question, it 
would be interesting to investigate GIPR internalization on insulin-producing cells 
from diabetic models.  
 
 136 
Regarding the underlying mechanisms of GIPR internalization, in contrast to 
another GPCR, the CCK2R, abundantly studied in our team, GIPR internalization 
does not involve recruitment of β-arrestins. Unfortunately, despite our efforts to 
understand how GIPRs is directed to AP2 complex and clathrin coated-pits for its 
endocytosis, we are not able to propose any demonstrated mechanism. 
In the course of our studies on internalization of GIPR we identified the first 
potential GIPR biaised agonist, N-acetyl-GIP. This agonist is a GIP peptide modified 
at its N-terminal end that was shown by several groups, including us, as being crucial 
for receptor activation. The biaised agonist fully stimulated Gs-dependent production 
of cAMP but was much less efficient on GIPR desensitization, internalization and 
related signaling pathways. 
 These findings are important for the following reasons: 
- firstly, this biased agonist could be used to target tumoral cells over-
expressing GIPR while maintaining it at or near the cell surface. Hence, N-Acetyl GIP 
could be useful to direct magnetic nanoparticles to the plasma membrane of tumor 
cells over-expressing the GIPR enabling their eradication by application of a magnetic 
field. 
- Secondly, the biased agonist should be an excellent tool to delineate 
desensitization mechanism of GIPR, a timely topic in the field of diabetes research; 
- thirdly, it could be an excellent pharmacological tool to differentiate GIPR 
signaling coming from internalized GIPR (in early endosomes) from that coming 
from cell surface GIPR. 
- Fourthly, we anticipate that performing the same chemical modification on 
other peptides in the same family (GLP1, glucagon, VIP, PACAP…) should produce 
biaised agonists too. This statement is based on the fact that members of group B1 of 
G protein coupled receptors share features in the mechanism whereby agonists 
activate their cognate receptors. Hence, our discovery of the first potential biaised 
agonist of the GIPR and further understanding of the mechanism at the origin of 
the biaised activity should have an impact in drug design applied to ligands of 
group B1 of GPCRs. 
 
We believe that identification of cAMP signal coming from activated GIPR in 
early endocomes reported in the second article represents an important piece of work 
since, for the first time, we succeed in direct detection of cAMP around early 
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endosomes containing GIP-activated GIPR. This finding was made possible thanks to 
combination of several methodological approaches and development of powerful 
molecular tools such as fluorescent GIP and early endosome-targeted FRET sensor of 
cAMP. Moreover, manipulation of trafficking of internalized GIPR using Rab7 
mutant which causes accumulation of internalized material in early endosomes 
represents an additional original and demonstrative approach. 
Although our results clearly demonstrate that internalized GIPR stimulates 
cAMP production, we did not evaluate to which extent it quantitatively contributes to 
GIP-induced cAMP production in the whole cell. Perhaps, the design of a plasma 
membrane-targeted FRET probe and calibration of the probes, would be necessary to 
measure in real time cAMP production in the different sub-cellular compartments. 
Moreover, short-time stimulations with more physiological concentrations of GIP on 
cells more relevant to physiological situations, would help to better appreciate 
desensitization of the membrane phase of cAMP production and understand the whole 
spatio-temporal production of cAMP. However, methodological and equipment 
limitations or signal detection limits exists.  
Another important question, regarding cAMP signal caused by internalized 
GIPR remain without answer: is cAMP signal produced from early endosomes 
qualitatively, if not quantitatively, physiologically important for the biology of 
endocrine cells? Although data from the literature established the physiological 
importance of cAMP in early endosomes, this question calls further investigations in 
appropriate biological models in the case of GIP 
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Methods of study of GPCRs and Resonance energy transfer 
techniques 
 
Although the first studies of GPCRs, based on biochemical studies and cDNA 
determination, elucidated the interactions of the components of the GPCR signaling 
machinery, they essentially lacked visualization. Two recent technologies have now 
contributed such visualization to the field. The first is the elucidation of the structure 
of many GPCRs in their inactive, as in their active forms, and also the structure of 
their downstream G protein (see previous section: G protein dependent signal 
transduction). The second is the visualization of the receptors themselves as well as 
their signaling cascades by optical methods; these methods are based on the genetic or 
chemical labeling of GPCRs and their downstream signaling proteins and allow the 
monitoring of both their cellular localization and their activity. Additionally, attaching 
two different labels each to a specific site, allows the study of the interactions of these 
two labels by resonance energy transfer techniques. The most used techniques are 
Fluorescence resonance energy transfer (FRET) and Bioluminescence resonance 
energy transfer (BRET). Fluorescent labels are required for FRET and BRET studies, 
but labels also include fluorescent proteins and light-emitting enzymes (which are 
needed for BRET).  
FRET is a radiationless energy transfer between two fluorophores that depends 
on three parameters (see Figure 14): 1) spectral overlap (the donor emission and the 
acceptor excitation spectra need to overlap), 2) distance between the fluorophores 
(FRET generally occurs at <100 Å), and 3) relative orientation of their dipole 
moments toward each other (highest FRET for parallel dipole orientation)(Förster, 
1948; Jares-Erijman and Jovin, 2003; Jares-Erijman and Jovin, 2006; Miyawaki, 
2011). 
FRET can be measured in several ways (Jares-Erijman and Jovin, 2003; 
Miyawaki, 2011) . The most frequently used approaches are 1) acceptor 
photobleaching (emission of donor increases after bleaching of the acceptor with 
bright light; increase corresponds to FRET efficiency), 2) sensitized emission 
(acceptor emits when excited by a donor via FRET), or 3) fluorescent lifetime-
imaging (the lifetime of the donor fluorescence decays more rapidly after excitation 
with a pulsed laser; increase in decay speed depends on FRET efficiency). FRET is 
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most commonly measured as intermolecular FRET to study the association of two 
proteins, each one carrying a label (Figure 14 A). Alternatively, it can be used as 
intramolecular FRET to study conformational changes in a protein that carries two 
labels that move relative to each other when the conformation of the protein changes 
(Figure 14 B). In the second case, equal concentrations of the two labels are 
automatically assured; in the first case, equal levels should be determined 
experimentally to avoid artifacts. Particularly when sensitized emission is measured a 
number of further controls are needed to assure that changes in acceptor emission are 
indeed due to FRET (and not, for example, fluorescence quenching of either the donor 
or the acceptor (Jares-Erijman and Jovin, 2003).  
In practice, first, a suitable pair of donor and acceptor fluorophores with good 
spectral overlap is chosen and then used to label suitable positions in the protein(s) of 
interest. Among the fluorescent proteins, CFP/YFP is the most popular pair, along 
with its improved variants (Miyawaki, 2011). Despite their great usefulness, these 
fluorescent proteins consist of 230 amino acids and thus are rather large proteins (27 
kDa) that are attached to the protein(s) of interest. Hence, it is important to test that 
the integrity of the protein under investigation was not altered as a result of the 
incorporation of a GFP variant (Hoffmann et al., 2005). Another important issue is the 
dimerization tendency of the original fluorescent protein variant containing an A206K 
mutation which exhibits a lower propensity to dimerize (Shaner et al., 2005). 
BRET is an alternative to FRET in which a light-emitting enzyme is used 
instead of the donor. The basic principles of FRET or BRET are very similar, as one 
needs a donor and an acceptor for the resonance energy transfer in both cases. In the 
case of BRET, the major donor class is based on Renilla reniformis luciferase (Rluc) 
or its different variations, whereas the acceptor fluorophore is a variant of GFP (Xu et 
al., 1999). The light source for the donor in BRET is a chemical substance that is 
converted by Rluc, and the energy is transferred to GFP, applying the same rules as 
for FRET. The major advantage of this technique is the lack of illumination by a 
conventional light source. This prevents disturbance of the autofluorescence effects in 
the sample (Pfleger and Eidne, 2006). Optimization of the technique have led to 
different generations of the BRET system. The originally described system (Xu et al., 
1999) is now referred to as BRET1  and uses the conventional enhanced GFP in 
combination with Rluc; benzyl-coelenterazine (coelenterazine h ) is used in the 
oxidative reaction to generate light with an emission peak at 480 nm and its signal 
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allows detection of BRET for up to 1 h. The next generation used a different GFP 
variant called GFP2 , which emits light like the normal GFP but is excited at ~400 nm. 
Hence, the novel GFP2 variant is characterized by a large Stokes shift; it requires a 
different substrate, called DeepBlueC (commercialized as Coelenterazine 400A; 
Biotium, Inc., Hayward, CA), for excitation. This system is referred to as BRET2 . 
BRET2  suffers from a much more rapid signal decay and exhibits a >100-fold lower 
quantum yield compared with coelenterazine h (Hamdan et al., 2005).  
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Figure	14 
Principle	of	inter-	(A)	and	intramolecular	(B)	FRET	
Shown	are	proteins	(gray)	labeled	with	the	fluorophores	CFP	(cyan)	and	YFP	(yellow).	If	
the	fluorophores	are	close	to	each	other	(_10	nm),	the	excited	CFP	transfers	energy	to	
YFP	and	yellow	emission	results.	A	small	change	in	the	distance	between	CFP	and	YFP	
may	 result	 from	 the	 approximation	 of	 the	 two	 proteins	 in	 A	 or	 a	 conformational	
change	of	the	protein	in	B	and	result	in	marked	changes	in	FRET	(Lohse	et	al.,	2012).	
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